<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>regeneron_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">

<P align=center><FONT face=serif size=2>UNITED STATES <BR></FONT><FONT face=serif size=2>SECURITIES AND EXCHANGE COMMISSION <BR>Washington, D.C.
20549</FONT></P>
<P align=center><B><FONT face=serif size=2>Form 10-Q</FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>(Mark
      One)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>(X)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>EXCHANGE ACT OF 1934</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=left width="58%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>For the quarterly
      period ended</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><FONT size=2>September 30, 2009</FONT></TD>
    <TD noWrap align=left width="38%">&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=left width="38%"></TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="98%" colSpan=4><FONT face=serif size=2>OR</FONT>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="98%" colSpan=4>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>(&nbsp;&nbsp;
      )</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
      SECURITIES</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>EXCHANGE ACT OF 1934</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=left width="58%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>For
      the transition period from ______________</FONT><FONT face=serif size=2>to
      ______________</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>Commission File Number
<U>0-19034</U></FONT></P>
<P align=center><U><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.</FONT></U> <FONT face=serif size=2><BR>(Exact name of registrant as
specified in its charter)</FONT></P>
<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>New
      York</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><U><FONT face=serif size=2>13-3444607</FONT></U>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>(State or
      other jurisdiction of</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>(I.R.S.
      Employer Identification No.)</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>incorporation
      or organization)</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%">&nbsp;</TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>777 Old Saw
      Mill River Road</FONT>&nbsp;</TD>
    <TD noWrap align=left width="49%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>Tarrytown,
      New York</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><U><FONT face=serif size=2>10591-6707</FONT></U>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>(Address of
      principal executive offices)</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>(Zip
      Code)</FONT>&nbsp;</TD></TR></TABLE>
<P align=center><U><FONT face=serif size=2>(914) 347-7000</FONT></U> <FONT face=serif size=2><BR></FONT><FONT face=serif size=2>(Registrant&#146;s telephone
number, including area code)</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90
days.</FONT></P>
<P align=center><FONT face=serif size=2>Yes</FONT> <U><FONT face=serif size=2>X</FONT></U><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No __</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit
and post such files).</FONT></P>
<P align=center><FONT face=serif size=2>Yes
__&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No __</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See definitions of &#147;large accelerated
filer&#148;, &#147;accelerated filer&#148;, and &#147;smaller reporting company&#148; in Rule 12b-2 of
the Exchange Act.</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>Large accelerated
      filer</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><FONT face=serif size=2><FONT size=3>&nbsp;</FONT>
    X</FONT>&nbsp;</TD>
    <TD noWrap align=left width="50%">&nbsp;</TD>
    <TD noWrap align=left width="46%"><FONT face=serif size=2>Accelerated
      filer</FONT>&nbsp; __</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>Non-accelerated
      filer</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="50%"><FONT face=serif size=2>&nbsp;(Do not
      check if a smaller reporting company)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="46%"><FONT face=serif size=2>Smaller
      reporting company</FONT>&nbsp; __</TD></TR></TABLE>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).</FONT></P>
<P align=center><FONT face=serif size=2>Yes
__&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No</FONT> <U><FONT face=serif size=2>X</FONT></U><FONT face=serif size=2></FONT></P>
<P align=justify><FONT face=serif size=2>Number of shares outstanding of each of
the registrant&#146;s classes of common stock as of&nbsp;October 15, 2009:</FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>Class of
      Common Stock</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2><U>Number of
      Shares</U></FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>Class A Stock,
      $0.001 par value</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>&nbsp;2,246,698</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>Common Stock,
      $0.001 par value</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>78,247,674</FONT>&nbsp;</TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=center><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR></FONT></B><B><FONT face=serif size=2>Table of Contents <BR>September 30,
2009 </FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp; </TD>
    <TD noWrap align=center width="3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=2><B><FONT face=serif size=2>Page Numbers</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><B><FONT face=serif size=2>PART I</FONT></B>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=left width="87%" bgColor=#c0c0c0><B><FONT face=serif size=2>FINANCIAL INFORMATION</FONT></B>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1</FONT></U>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Financial Statements</FONT></U>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed balance sheets (unaudited) at September 30, 2009 and
      December 31, 2008</FONT>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT size=2>3</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp; </TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statements of operations (unaudited) for the
      three</FONT>&nbsp;<FONT size=2>and nine months ended September 30, 2009
      and 2008</FONT> </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT size=2>4</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%">&nbsp; </TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp; </TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statement of stockholders&#146; equity (unaudited) for the
      nine months ended September 30, 2009</FONT>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT size=2>5</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%">&nbsp; </TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp; </TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statements of cash flows (unaudited) for the nine months
      ended September 30, 2009 and 2008</FONT>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT size=2>6</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%">&nbsp; </TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp; </TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Notes
      to condensed financial statements (unaudited)</FONT>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>7-17</FONT>&nbsp; </TD></TR>
  <TR>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item
      2</FONT></U>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Management's Discussion and Analysis of Financial Condition and
      Results of Operations</FONT></U>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT size=2>18-42</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%">&nbsp; </TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp; </TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item
      3</FONT></U>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Quantitative and Qualitative Disclosures About Market
      Risk</FONT></U>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>43</FONT>&nbsp; </TD></TR>
  <TR>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item
      4</FONT></U>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Controls and Procedures</FONT></U>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>43</FONT>&nbsp; </TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><B><FONT face=serif size=2>PART II</FONT></B>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><B><FONT face=serif size=2>OTHER INFORMATION</FONT></B>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1</FONT></U>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Legal Proceedings</FONT></U>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>43</FONT>&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1A</FONT></U>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Risk
      Factors</FONT></U>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>44-59</FONT>&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="87%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 6</FONT></U>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Exhibits</FONT></U>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>59</FONT>&nbsp; </TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=3><B><FONT face=serif size=2>SIGNATURE PAGE</FONT></B>&nbsp; </TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>60</FONT>&nbsp; </TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>PART I. FINANCIAL INFORMATION
<BR>ITEM 1. FINANCIAL STATEMENTS</FONT></B></P>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face=serif size=2>CONDENSED BALANCE SHEETS AT
SEPTEMBER 30, 2009 AND DECEMBER 31, 2008 (Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(In thousands, except share data)</FONT></I></B></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="84%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=2>September 30,</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD noWrap align=center width="7%" colSpan=3>&nbsp; <B><FONT face=serif size=2>December 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=center width="84%"><B><FONT face=serif size=2></FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="7%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="7%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B> &nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=center width="7%" colSpan=3><I><FONT face=serif size=2>(Revised
      -</FONT></I> </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=center width="7%" colSpan=3><I><FONT face=serif size=2>see Note
      9)</FONT></I> </TD></TR>
  <TR>
    <TD align=center width="84%" bgColor=#c0c0c0><FONT face=serif size=2><STRONG>ASSETS</STRONG></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=center width="7%" bgColor=#c0c0c0 colSpan=3></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"><FONT face=serif size=2>Current
assets</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%">&nbsp;</TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash
      equivalents</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>250,321</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>247,796</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Marketable securities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>129,475</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>226,954</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Accounts receivable from the sanofi-aventis Group</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>63,953</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>33,302</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Accounts receivable - other</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>3,813</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>1,910</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Prepaid expenses and other current assets</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>14,032</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>11,480</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total current assets</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>461,594</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>521,442</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted cash</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,600</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,650</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"><FONT face=serif size=2>Marketable
      securities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>57,200</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>51,061</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0><FONT face=serif size=2>Property, plant, and equipment, at cost, net of
    accumulated</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>depreciation and amortization</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>215,169</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>142,035</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"><FONT face=serif size=2>Other
      assets</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>6,629</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>8,032</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total assets</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>742,192</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>724,220</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR>
    <TD align=center width="84%" bgColor=#c0c0c0><FONT face=serif size=2><STRONG>LIABILITIES and STOCKHOLDERS' EQUITY</STRONG></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"><FONT face=serif size=2>Current
      liabilities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Accounts payable and accrued expenses</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>55,291</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>36,168</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Deferred revenue from sanofi-aventis, current
      portion</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>21,580</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>21,390</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Deferred revenue - other, current portion</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>37,294</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>26,114</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total current liabilities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>114,165</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>83,672</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0><FONT face=serif size=2>Deferred revenue from sanofi-aventis</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>90,251</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>105,586</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"><FONT face=serif size=2>Deferred revenue -
      other</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>49,421</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>56,835</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0><FONT face=serif size=2>Facility lease obligation</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>62,571</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>54,182</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%"><FONT face=serif size=2>Other long-term
      liabilities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>3,341</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>2,431</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total liabilities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>319,749</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>302,706</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0><FONT face=serif size=2>Commitments and contingencies</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0><FONT face=serif size=2>Stockholders' equity</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Preferred stock, $.01 par value; 30,000,000 shares
      authorized; issued and</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>outstanding-none</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Class A Stock, convertible, $.001 par value; 40,000,000 shares
      authorized;</FONT>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>shares issued and outstanding - 2,246,698 in 2009
      and 2,248,698 in 2008</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Common Stock, $.001 par value; 160,000,000 shares
      authorized;</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>shares issued and outstanding - 78,243,286 in 2009
      and 77,642,203 in 2008</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>78</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>78</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Additional paid-in capital</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,323,432</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,294,813</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Accumulated deficit</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>(904,606</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>(873,265</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Accumulated other comprehensive income (loss)</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>3,537</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(114</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total stockholders' equity</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>422,443</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>421,514</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="84%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total liabilities and stockholders'
    equity</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>742,192</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>724,220</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>3 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(In thousands, except
per share data) </FONT></I></B></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="69%"></TD>
    <TD noWrap align=center width="15%" colSpan=7><B><FONT face=serif size=2>Three months ended September 30,</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="15%" colSpan=7><B><FONT face=serif size=2>Nine months ended September 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3>&nbsp; <B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3>&nbsp; <B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><I><FONT face=serif size=2>(Revised -</FONT></I></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><I><FONT face=serif size=2>(Revised -</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><I><FONT face=serif size=2>see Note 9)</FONT></I></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><I><FONT face=serif size=2>see Note 9)</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Revenues</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%">&nbsp; &nbsp; &nbsp; &nbsp;<FONT face=serif size=2>Contract research and development from sanofi-aventis</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%"><FONT face=serif size=2>68,536</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%"><FONT face=serif size=2>42,006</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%"><FONT face=serif size=2>178,928</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%"><FONT face=serif size=2>116,346</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0>&nbsp; &nbsp; &nbsp;
      &nbsp;<FONT face=serif size=2>Other contract research and
      development</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>13,946</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>10,872</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>40,176</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>33,568</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%">&nbsp; &nbsp; &nbsp; &nbsp;<FONT face=serif size=2>Research progress payments</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>20,000</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>20,000</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0>&nbsp; &nbsp; &nbsp;
      &nbsp;<FONT face=serif size=2>Technology licensing</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>10,000</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>10,000</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>30,000</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>30,000</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%">&nbsp; &nbsp; &nbsp; &nbsp;<FONT face=serif size=2>Net product sales</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>4,973</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>2,706</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>13,364</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>2,706</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>117,455</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>65,584</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>282,468</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>182,620</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Expenses</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%">&nbsp; &nbsp; &nbsp; &nbsp;<FONT face=serif size=2>Research and development</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>105,434</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>72,089</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>279,972</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>200,335</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0>&nbsp; &nbsp; &nbsp;
      &nbsp;<FONT face=serif size=2>Selling, general, and
    administrative</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>12,840</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>11,103</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>35,892</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>35,652</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%">&nbsp; &nbsp; &nbsp; &nbsp;<FONT face=serif size=2>Cost of goods sold</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>472</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>292</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>1,299</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>292</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>118,746</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>83,484</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>317,163</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>236,279</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Loss
      from operations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(1,291</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(17,900</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(34,695</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(53,659</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Other
      income (expense)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%">&nbsp; &nbsp; &nbsp; &nbsp;<FONT face=serif size=2>Investment income</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>857</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>3,674</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>3,935</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>15,513</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0>&nbsp; &nbsp; &nbsp;
      &nbsp;<FONT face=serif size=2>Interest expense</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(581</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(1,772</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(581</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(7,457</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%">&nbsp; &nbsp; &nbsp; &nbsp;<FONT face=serif size=2>Loss on early extinguishment of debt</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>(7</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>(938</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>276</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,895</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>3,354</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>7,118</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss before income tax expense</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(1,015</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(16,005</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(31,341</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(46,541</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Income
      tax expense</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>3,079</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>3,079</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(1,015</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(19,084</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(31,341</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(49,620</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss per share, basic and diluted</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(0.01</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(0.24</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(0.39</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(0.63</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted average shares outstanding, basic and diluted</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>79,866</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>78,937</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>79,663</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>78,706</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>4&nbsp;</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) <BR>For the nine
months ended September 30, 2009<BR><EM>(In thousands)</EM></FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="45%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="2%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="2%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="3%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="3%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="4%" colSpan=2></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%" colSpan=3></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="8%" colSpan=3><B><FONT face=serif size=1>Accumulated</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="5%" colSpan=3></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%" colSpan=3></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="2%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="2%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="3%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="3%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="4%" colSpan=2><B><FONT face=serif size=1>Additional</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%" colSpan=3></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="8%" colSpan=3><B><FONT face=serif size=1>Other</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="5%" colSpan=3><B><FONT face=serif size=1>Total</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%" colSpan=3></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=6><B><FONT face=serif size=1>Class A Stock</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=4><B><FONT face=serif size=1>Common Stock</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="4%" colSpan=2><B><FONT face=serif size=1>Paid-in</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%" colSpan=3><B><FONT face=serif size=1>Accumulated</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="8%" colSpan=3><B><FONT face=serif size=1>Comprehensive</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="5%" colSpan=3><B><FONT face=serif size=1>Stockholders'</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%" colSpan=3><B><FONT face=serif size=1>Comprehensive</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"></TD>
    <TD align=right width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="4%" colSpan=3><B><FONT face=serif size=1>Shares</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=1>Amount</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%"><B><FONT face=serif size=1>Shares</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="4%" colSpan=2><B><FONT face=serif size=1>Amount</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="4%" colSpan=2><B><FONT face=serif size=1>Capital</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="7%" colSpan=3><B><FONT face=serif size=1>Deficit</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=3><B><FONT face=serif size=1>Income (Loss)</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="5%" colSpan=3><B><FONT face=serif size=1>Equity</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="7%" colSpan=3><B><FONT face=serif size=1>Loss</FONT></B></TD></TR>
  <TR>
    <TD align=left width="45%"  bgColor=#c0c0c0><STRONG><FONT size=1>Balance, December 31, 2008 </FONT></STRONG></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="2%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="2%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="3%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="3%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="3%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="5%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="6%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=right width="3%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD align=left width="5%"  bgColor=#c0c0c0></TD>
    <TD align=left width="1%"  bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <STRONG><EM>(Revised - see
      Note 9)</EM></STRONG></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=1>2,249</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=1>2</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>77,642</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>78</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>1,294,813</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=1>(873,265</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>(114</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>421,514</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"><FONT face=serif size=1>Issuance of Common
      Stock in </FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR>
    <TD align=left width="45%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; connection with exercise of
      </FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR>
    <TD align=left width="45%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stock options, net of shares
      </FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tendered</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=1>518</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=1>4,626</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=1>4,626</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=1>Issuance of Common Stock in </FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD align=left width="45%" bgColor=#c0c0c0><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; connection with Company
      401(k)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Savings Plan
      contribution</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>81</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>1,391</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>1,391</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD align=left width="45%"><FONT size=1>Conversion of Class A Stock to
      </FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stock</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=1>(2</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=1>2</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=1>Stock-based compensation expense</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>22,602</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>22,602</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"><FONT face=serif size=1>Net loss</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=1>(31,341</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=1>(31,341</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="5%"><FONT face=serif size=1>(31,341</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=1>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=1>Change
      in net unrealized gain </FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (loss) on marketable
      securities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>3,651</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>3,651</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=1>3,651</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="45%"><B><FONT face=serif size=1>Balance, September
      30, 2009</FONT></B></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT face=serif size=1>2,247</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT face=serif size=1>2</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=1>78,243</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=1>78</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=1>1,323,432</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%"><FONT face=serif size=1>(904,606</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%"><FONT face=serif size=1>3,537</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=1>422,443</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%"><FONT face=serif size=1>(27,690</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" align=left width="1%"><FONT face=serif size=1>)</FONT></TD></TR></TABLE>
<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>5</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(In
thousands)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=center width="17%" colSpan=7><B><FONT face=serif size=2>Nine months ended September 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD align=left width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><I><FONT face=serif size=2>(Revised -</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD align=left width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><I><FONT face=serif size=2>see Note 9)</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Cash
      flows from operating activities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net loss</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>(31,341</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>(49,620</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjustments to reconcile net
      loss to net cash used in</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif>operating activities</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Depreciation and amortization</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>9,312</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>8,661</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Non-cash compensation expense</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>22,602</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>24,716</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Loss on early extinguishment of debt</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>938</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Net realized (gain) loss on marketable securities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(56</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>1,166</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Changes in assets and liabilities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Increase in accounts receivable</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(32,554</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(23,886</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#ffffff><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Increase in prepaid expenses and other assets</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=right width="6%" bgColor=#ffffff><FONT face=serif size=2>(370</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=right width="6%" bgColor=#ffffff><FONT face=serif size=2>(5,279</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Decrease in deferred revenue</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(11,379</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(10,076</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Increase in accounts payable, accrued expenses,</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      and other liabilities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>17,960</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>134</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Total adjustments</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>5,515</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(3,626</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Net cash used in operating activities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>(25,826</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>(53,246</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Cash
      flows from investing activities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchases of marketable
      securities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>(190,666</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>(478,276</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sales or maturities of
      marketable securities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>284,934</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>443,587</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capital expenditures</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>(75,002</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>(19,117</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease (increase) in
      restricted cash</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>50</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(50</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Net cash provided by (used in) investing activities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>19,316</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>(53,856</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Cash
      flows from financing activities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extinguishment of long-term
      debt</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>(83,304</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceeds in connection with
      facility lease obligation</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>5,182</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Payments in connection with
      facility lease obligation</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>(773</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="6%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net proceeds from the issuance
      of Common Stock</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>4,626</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>6,165</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Net cash provided by (used in) financing activities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>9,035</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT face=serif size=2>(77,139</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      increase (decrease) in cash and cash equivalents</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>2,525</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(184,241</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Cash
      and cash equivalents at beginning of period</FONT>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>247,796</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>498,925</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Cash
      and cash equivalents at end of period</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>250,321</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>314,684</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE>
<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>6</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>1.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Interim Financial
Statements </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
interim Condensed Financial Statements of Regeneron Pharmaceuticals, Inc.
(&#147;Regeneron&#148; or the &#147;Company&#148;) have been prepared in accordance with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all information and disclosures necessary for a presentation of the
Company&#146;s financial position, results of operations, and cash flows in
conformity with accounting principles generally accepted in the United States of
America. In the opinion of management, these financial statements reflect all
adjustments, consisting only of normal recurring accruals, necessary for a fair
presentation of the Company&#146;s financial position, results of operations, and
cash flows for such periods. The results of operations for any interim periods
are not necessarily indicative of the results for the full year. The December
31, 2008 Condensed Balance Sheet data were derived from audited financial
statements, but do not include all disclosures required by accounting principles
generally accepted in the United States of America. These financial statements
should be read in conjunction with the financial statements and notes thereto
contained in the Company&#146;s Annual Report on Form 10-K for the year ended
December 31, 2008. In addition, the previously issued balance sheet of the
Company at December 31, 2008 contained in the Company&#146;s Annual Report on Form
10-K for the year ended December 31, 2008, and the previously issued condensed
statement of operations for the three and nine months ended September 30, 2008
and condensed statement of cash flows for the nine months ended September 30,
2008, contained in the Company&#146;s Quarterly Report on Form 10-Q for the period
ended September 30, 2008, have been revised in this Quarterly Report on Form
10-Q with respect to the Company&#146;s December 2006 lease of office and laboratory
facilities in Tarrytown, New York by applying authoritative guidance issued by
the Financial Accounting Standards Board (FASB). See Note 9b below. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in research and development expenses is the Company&#146;s share of VEGF Trap-Eye
development expenses incurred by Bayer HealthCare LLC, including the Company&#146;s
share of Bayer HealthCare&#146;s estimated VEGF Trap-Eye development expenses for the
most recent interim fiscal quarter. The Bayer HealthCare estimate each quarter
is adjusted to agree with actual expenses for such quarter in the subsequent
interim fiscal quarter.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Effective
in the first quarter of 2009, the estimated useful lives of laboratory and other
equipment, which is a component of property, plant, and equipment, has been
extended from 3 &#150; 5 years to 3 &#150; 10 years. The effect of this change in estimate
was to lower depreciation expense by $0.2 million and $0.7 million for the three
and nine months ended September 30, 2009. The impact on the net loss per share
as a result of this change in estimate was not material. </FONT></P>
<P align=justify><B><FONT face=serif size=2>2.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP></FONT></B><B><FONT face=serif size=2> (rilonacept)
Product Revenue</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
February 2008, the Company received marketing approval from the U.S. Food and
Drug Administration (&#147;FDA&#148;) for ARCALYST<SUP>&#174;</SUP> (rilonacept) Injection for Subcutaneous Use for the treatment of
Cryopyrin-Associated Periodic Syndromes (&#147;CAPS&#148;). The Company recognizes
ARCALYST net product sales as revenue when the right of return no longer exists
and rebates can be reasonably estimated. ARCALYST net product sales revenue
totaled $5.0 million and $13.4 million for the three and nine months ended
September 30, 2009, respectively, and $2.7 million for both the three and nine
months ended September 30, 2008. At September 30, 2009 and 2008, deferred
revenue related to ARCALYST net product sales totaled $5.0 million and $3.8
million, respectively.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Cost of
goods sold related to ARCALYST sales, which consisted primarily of royalties,
totaled $0.5 million and $1.3 million for the three and nine months ended
September 30, 2009, respectively, and $0.3 million for both the three and nine
months ended September 30, 2008. To date, ARCALYST shipments to the Company&#146;s
customers have consisted of supplies of inventory manufactured and expensed
prior to FDA approval of ARCALYST; therefore, the costs of these supplies were
not included in costs of goods sold. At September 30, 2009, the Company had $0.4
million of inventoried work-in-process costs related to ARCALYST, which is
included in prepaid expenses and other current assets. There were no capitalized
inventory costs at December 31, 2008.</FONT></P>
<P align=center><FONT face=serif size=2>7&nbsp;</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify><FONT face=serif size=2><B>3. Per Share Data </B></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company&#146;s basic and diluted net loss per share amounts have been computed by
dividing net loss by the weighted average number of shares of Common Stock and
Class A Stock outstanding. Net loss per share is presented on a combined basis,
inclusive of Common Stock and Class A Stock outstanding, as each class of stock
has equivalent economic rights. For the three and nine months ended September
30, 2009 and 2008, the Company reported net losses; therefore, no common stock
equivalents were included in the computation of diluted net loss per share for
these periods, since such inclusion would have been antidilutive. The
calculations of basic and diluted net loss per share are as follows:</FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=7><FONT face=serif size=2>Three Months Ended September
    30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=3><FONT face=serif size=2>2008</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss (Numerator)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(1,015</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(19,084</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="82%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted-average shares, in thousands (Denominator)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>79,866</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>78,937</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD align=left width="82%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Basic
      and diluted net loss per share</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(0.01</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(0.24</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="82%">&nbsp;</TD>
    <TD align=center width="17%" colSpan=7></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="17%" colSpan=7><FONT face=serif size=2>Nine Months Ended September
  30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=3><FONT face=serif size=2>2009</FONT> </TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=3><FONT face=serif size=2>2008</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss (Numerator)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(31,341</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(49,620</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="82%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted-average shares, in thousands (Denominator)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>79,663</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>78,706</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD align=left width="82%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Basic
      and diluted net loss per share</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(0.39</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(0.63</FONT> </TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Shares
issuable upon the exercise of stock options, vesting of restricted stock awards,
and conversion of convertible debt, which have been excluded from the September
30, 2009 and 2008 diluted per share amounts because their effect would have been
antidilutive, include the following: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="86%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="13%" colSpan=5><FONT face=serif size=2>Three months ended September
    30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="6%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="6%" colSpan=2><FONT face=serif size=2>2008</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Stock
      Options:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Weighted average number, in thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>19,860</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>17,454</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Weighted average exercise price</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>17.65</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>17.31</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted Stock:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Weighted average number, in thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>500</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>500</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Convertible Debt:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Weighted average number, in thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>3,890</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Conversion price</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>30.25</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="13%" colSpan=5><FONT size=+0><FONT face=serif size=2>Nine months ended
      September 30,</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="6%" colSpan=2><FONT size=+0><FONT face=serif size=2>2009</FONT></FONT></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="6%" colSpan=2><FONT size=+0><FONT face=serif size=2>2008</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Stock
      Options:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Weighted average number, in thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>20,059</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>17,572</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Weighted average exercise price</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>17.59</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>17.24</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted Stock:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Weighted average number, in thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>500</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>500</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Convertible Debt:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Weighted average number, in thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>5,450</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="86%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Conversion price</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>30.25</FONT></TD></TR></TABLE>
</DIV><BR>
<P align=center><FONT face=serif size=2>8&nbsp;</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>4.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Statement of Cash
Flows </FONT></B></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Supplemental disclosure of noncash
investing and financing activities: </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in accounts payable and accrued expenses at September 30, 2009 and December 31,
2008 were $10.5 million and $7.0 million, respectively, of accrued capital
expenditures. Included in accounts payable and accrued expenses at September 30,
2008 and December 31, 2007 were $5.1 million and $1.7 million, respectively, of
accrued capital expenditures. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the application of FASB authoritative guidance to the Company&#146;s
lease of office and laboratory facilities in Tarrytown, New York (see Note 9b),
the Company recognized a facility lease obligation of $4.0 million and $23.0
million for the nine months ended September 30, 2009 and 2008, respectively, in
connection with capitalizing, on the Company&#146;s books, the landlord&#146;s costs of
constructing new facilities that the Company has leased.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in accounts payable and accrued expenses at December 31, 2008 and 2007 were $1.5
million and $1.1 million, respectively, of accrued Company 401(k) Savings Plan
contribution expense. In the first quarter of 2009 and 2008, the Company
contributed 81,086 and 58,575 shares, respectively, of Common Stock to the
401(k) Savings Plan in satisfaction of these obligations. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in marketable securities at September 30, 2009 and December 31, 2008 were $1.0
million and $1.7 million, respectively, of accrued interest income. Included in
marketable securities at both September 30, 2008 and December 31, 2007 was $2.2
million of accrued interest income. </FONT></P>
<P align=justify><B><FONT face=serif size=2>5.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Marketable
Securities </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Marketable securities at September 30, 2009 and December 31, 2008
consisted of debt securities, as detailed below, and equity securities, the
aggregate fair value of which was $7.1 million and $3.7 million at September 30,
2009 and December 31, 2008, respectively, and the aggregate cost basis of which
was $4.0 million and $4.1 million at September 30, 2009 and December 31, 2008.
The following tables summarize the amortized cost basis of debt securities
included in marketable securities, the aggregate fair value of those securities,
and gross unrealized gains and losses on those securities at September 30, 2009
and December 31, 2008. The Company classifies its debt securities, other than
mortgage-backed and other asset-backed securities, based on their contractual
maturity dates. Maturities of mortgage-backed and other asset-backed securities
have been estimated based primarily on repayment characteristics and experience
of the senior tranches that the Company holds.</FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2></TD>
    <TD align=left width="3%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT size=+0><FONT face=serif size=2>Amortized</FONT></FONT></TD>
    <TD align=center width="2%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD align=center width="6%" colSpan=2><FONT size=+0>&nbsp;<FONT face=serif size=2>Fair</FONT></FONT></TD>
    <TD align=center width="2%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="21%" colSpan=10><FONT size=+0><FONT face=serif size=2>Unrealized</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><FONT face=serif size=2>At September 30, 2009</FONT></TD>
    <TD align=left width="58%">&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT size=+0><FONT face=serif size=2>Cost
Basis</FONT></FONT></TD>
    <TD align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="6%" colSpan=2><FONT size=+0><FONT face=serif size=2>Value</FONT></FONT></TD>
    <TD align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="5%" colSpan=2><FONT size=+0><FONT face=serif size=2>Gains</FONT></FONT></TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="7%" colSpan=3><FONT size=+0><FONT face=serif size=2>(Losses)</FONT></FONT></TD>
    <TD align=center width="1%"><FONT size=3></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="7%" colSpan=3><FONT size=+0><FONT face=serif size=2>Net</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities within one year</FONT></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="4%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="5%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="4%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="5%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="5%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>U.S. government obligations</FONT></TD>
    <TD align=right width="3%"></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>105,253</FONT></FONT></TD>
    <TD align=right width="2%"></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>105,353</FONT></FONT></TD>
    <TD align=right width="2%"></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>100</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>100</FONT></FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>15,819</FONT></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>16,109</FONT></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>290</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>290</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Mortgage-backed securities</FONT></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>3,417</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>3,211</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>(206</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>(206</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>U.S. government guaranteed</FONT></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>collateralized mortgage obligations</FONT></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>4,717</FONT></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>4,802</FONT></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>85</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>85</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2>&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%"><FONT size=+0><FONT face=serif size=2>129,206</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>129,475</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%"><FONT size=+0><FONT face=serif size=2>475</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>(206</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>269</FONT></FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities between one and three years</FONT></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>U.S. government guaranteed corporate </FONT><FONT face=serif size=2>bonds</FONT></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>48,608</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>49,086</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>478</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>478</FONT></FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Mortgage-backed securities</FONT></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>1,278</FONT></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>999</FONT></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="4%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(279</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(279</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2>&nbsp;</TD>
    <TD align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%"><FONT size=+0><FONT face=serif size=2>49,886</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>50,085</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%"><FONT size=+0><FONT face=serif size=2>478</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>(279</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>199</FONT></FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD align=right width="3%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>179,092</FONT></FONT></TD>
    <TD align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>179,560</FONT></FONT></TD>
    <TD align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>953</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(485</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>468</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2></TD>
    <TD noWrap align=center width="3%" colSpan=2><FONT face=serif size=2>Amortized</FONT></TD>
    <TD align=center width="1%"><FONT size=+0></FONT></TD>
    <TD align=center width="4%" colSpan=2><FONT face=serif size=2>Fair</FONT></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="21%" colSpan=10><FONT face=serif size=2>Unrealized</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"><FONT face=serif size=2>At December 31, 2008</FONT></TD>
    <TD noWrap align=left width="65%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><FONT face=serif size=2>Cost Basis</FONT></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="4%" colSpan=2><FONT face=serif size=2>Value</FONT></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="4%" colSpan=2><FONT face=serif size=2>Gains</FONT></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="9%" colSpan=3><FONT face=serif size=2>(Losses)</FONT></TD>
    <TD align=center width="2%"><FONT size=3></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="5%" colSpan=3><FONT face=serif size=2>Net</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities within one year</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>U.S. government obligations</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="2%"><FONT face=serif size=2>170,993</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="2%"><FONT face=serif size=2>172,253</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="2%"><FONT face=serif size=2>1,260</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="2%"><FONT face=serif size=2>1,260</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>26,894</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>26,662</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>25</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(257</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(232</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Mortgage-backed securities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>9,098</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>8,420</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>(678</FONT></TD>
    <TD align=left width="2%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>(678</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Other asset-backed securities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>7,842</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>7,829</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(13</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(13</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>U.S. government guaranteed</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>collateralized mortgage obligations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>11,742</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>11,792</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>50</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>50</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>226,569</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>226,956</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>1,335</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(948</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>387</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="99%" colSpan=18>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities between one and three years</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>U.S. government guaranteed corporate </FONT><FONT face=serif size=2>bonds</FONT>&nbsp; </TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>29,853</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>29,811</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>82</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>(124</FONT></TD>
    <TD align=left width="2%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>(42</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>10,446</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>10,414</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>77</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(109</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(32</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Mortgage-backed securities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>1,821</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>1,556</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>(265</FONT></TD>
    <TD align=left width="2%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>(265</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>U.S. government guaranteed</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>collateralized mortgage obligations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>5,297</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>5,570</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>273</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>273</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>47,417</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>47,351</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>432</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT face=serif size=2>(498</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 1pt solid" align=left width="2%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>(66</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 1pt solid" align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=18>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="69%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>273,986</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>274,307</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>1,767</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(1,446</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>321</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At
September 30, 2009 and December 31, 2008, marketable securities included an
additional unrealized gain of $3.1 million and an additional unrealized loss of
$0.4 million, respectively, related to one equity security in the Company&#146;s
marketable securities portfolio.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
following table shows the fair value of the Company&#146;s marketable securities that
have unrealized losses and that are deemed to be only temporarily impaired,
aggregated by investment category and length of time that the individual
securities have been in a continuous unrealized loss position, at September 30,
2009 and December 31, 2008. The debt securities listed at September 30, 2009
mature at various dates through December 2011. </FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="13%" colSpan=6><FONT size=+0><FONT face=serif size=2>Less than 12
      Months</FONT></FONT></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="12%" colSpan=6><FONT size=+0><FONT face=serif size=2>12 Months or
      Greater</FONT></FONT></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="12%" colSpan=6><FONT size=+0><FONT face=serif size=2>Total</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="5%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="6%" colSpan=3><FONT size=+0><FONT face=serif size=2>Unrealized</FONT></FONT></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="5%"></TD>
    <TD align=center width="1%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=center width="5%" colSpan=3><FONT size=+0><FONT face=serif size=2>Unrealized</FONT></FONT></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="4%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="6%" colSpan=3><FONT size=+0><FONT face=serif size=2>Unrealized</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><FONT face=serif size=2>At September 30, 2009</FONT></TD>
    <TD align=left width="55%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=2><FONT size=+0><FONT face=serif size=2>Fair
Value</FONT></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT size=+0><FONT face=serif size=2>Loss</FONT></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=2><FONT size=+0><FONT face=serif size=2>Fair
Value</FONT></FONT></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="5%" colSpan=3><FONT size=+0><FONT face=serif size=2>Loss</FONT></FONT></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT size=+0><FONT face=serif size=2>Fair
Value</FONT></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT size=+0><FONT size=2>Loss</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="60%" bgColor=#c0c0c0 colSpan=2>&nbsp;<FONT face=serif size=2>Mortgage-backed
      securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="5%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="4%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>4,210</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(485</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>4,210</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(485</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=22>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%"><FONT face=serif size=2>At December 31, 2008</FONT></TD>
    <TD align=left width="55%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>15,559</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(287</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>2,933</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(79</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>18,492</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(366</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2><FONT face=serif size=2>Government
      guaranteed</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corporate
bonds</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>11,300</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>(124</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>11,300</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>(124</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Mortgage-backed securities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>871</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(74</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>9,104</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(869</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>9,975</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(943</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2><FONT face=serif size=2>Other
      asset-backed securities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>7,829</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>(13</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>7,829</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="4%"><FONT size=+0><FONT face=serif size=2>(13</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Equity securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>3,608</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(436</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>3,608</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(436</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="60%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%"><FONT size=+0><FONT face=serif size=2>39,167</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%"><FONT size=+0><FONT face=serif size=2>(934</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%"><FONT size=+0><FONT face=serif size=2>12,037</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT size=+0><FONT face=serif size=2>(948</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%"><FONT size=+0><FONT face=serif size=2>51,204</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%"><FONT size=+0><FONT face=serif size=2>(1,882</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR></TABLE>
<BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Realized
gains and losses are included as a component of investment income. For both the
three and nine months ended September 30, 2009, realized gains on sales of
marketable securities totaled $0.2 million and realized losses on sales of
marketable securities were not significant. For the three and nine months ended
September 30, 2008, realized gains on sales of marketable securities totaled
$1.0 million and $1.1 million, respectively, and realized losses on sales of
marketable securities were not significant. In computing realized gains and
losses, the Company computes the cost of its investments on a specific
identification basis. Such cost includes the direct costs to acquire the
security, adjusted for the amortization of any discount or premium.</FONT></P>
<P align=center><FONT face=serif size=2>10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company&#146;s assets that are measured at fair value on a recurring
basis</FONT><I><FONT face=serif size=2>,</FONT></I><FONT face=serif size=2> at
September 30, 2009 and December 31, 2008, were as follows: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2></TD>
    <TD align=left width="2%"></TD>
    <TD align=center width="6%"></TD>
    <TD align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="27%" colSpan=8><FONT face=serif size=2>Fair Value Measurements at Reporting
      Date Using</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Quoted Prices in</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="8%" colSpan=2>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Active Markets</FONT></TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>Significant Other</FONT></TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>Significant</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2></TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>Fair
      Value at</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>for
      Identical</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>Observable</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>Unobservable</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2></TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>September 30,</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Assets</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"><FONT face=serif size=2>Description</FONT></TD>
    <TD align=left width="62%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>(Level 1)</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>(Level 2)</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=2><FONT face=serif size=2>(Level 3)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Available-for-sale marketable securities</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0><FONT size=+0></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>U.S. government obligations</FONT></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="6%"><FONT face=serif size=2>105,353</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"><FONT size=+0></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="6%"><FONT face=serif size=2>105,353</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>U.S. government guaranteed corporate</FONT>&nbsp;<FONT face=serif size=2>bonds</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>49,086</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0><FONT size=+0></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>49,086</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>16,109</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"><FONT size=+0></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>16,109</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Mortgage-backed securities</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>4,210</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0><FONT size=+0></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>4,210</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>U.S. government guaranteed</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="6%"><FONT size=+0></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"><FONT size=+0></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="6%"><FONT size=+0></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>collateralized mortgage obligations</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>4,802</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"><FONT size=+0></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>4,802</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Equity securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>7,115</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>7,115</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="6%" bgColor=#c0c0c0><FONT size=+0></FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="63%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%"><FONT face=serif size=2>186,675</FONT></TD>
    <TD align=right width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%"><FONT face=serif size=2>7,115</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%"><FONT face=serif size=2>179,560</FONT></TD>
    <TD align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%"><FONT size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=center width="6%"></TD></TR></TABLE><BR>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2></TD>
    <TD align=left width="1%"></TD>
    <TD align=center width="6%"></TD>
    <TD align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="23%" colSpan=8><FONT face=serif size=2>Fair Value Measurements at Reporting
      Date Using</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Quoted Prices in</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="5%" colSpan=2>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Active Markets</FONT></TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Significant Other</FONT></TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Significant</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Fair
      Value at</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>for
      Identical</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Observable</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Unobservable</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>December 31,</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Assets</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"><FONT face=serif size=2>Description</FONT></TD>
    <TD align=left width="66%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>2008</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>(Level 1)</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=2><FONT face=serif size=2>(Level 2)</FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>(Level 3)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Available-for-sale marketable securities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>U.S. government obligations</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="6%"><FONT face=serif size=2>172,253</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=right width="2%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="6%"><FONT face=serif size=2>172,253</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>U.S. government guaranteed corporate </FONT><FONT face=serif size=2>bonds</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>29,811</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>29,811</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>37,076</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>37,076</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Mortgage-backed securities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>9,976</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>9,976</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Other asset backed securities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>7,829</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="6%"><FONT face=serif size=2>7,829</FONT></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>U.S. government guaranteed</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="6%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>collateralized mortgage obligations</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>17,362</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>17,362</FONT></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Equity securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="6%"><FONT size=+0><FONT face=serif size=2>3,708</FONT></FONT></TD>
    <TD align=right width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="2%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>3,608</FONT></FONT></TD>
    <TD align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="6%"></TD>
    <TD align=right width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="4%"><FONT size=+0><FONT face=serif size=2>100</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="67%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>278,015</FONT></FONT></TD>
    <TD align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="2%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>3,608</FONT></FONT></TD>
    <TD align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>274,307</FONT></FONT></TD>
    <TD align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>100</FONT></FONT></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Marketable securities included in Level 2 were valued using a market
approach utilizing prices and other relevant information, such as interest
rates, yield curves, prepayment speeds, loss severities, credit risks and
default rates, generated by market transactions involving identical or
comparable assets. The Company considers market liquidity in determining the
best price for these securities. During the three and nine months ended
September 30, 2009, the Company did not record any charges for
other-than-temporary impairment of its Level 2 marketable securities. During the
third quarter of 2008, deterioration in the credit quality of a marketable
security from one issuer subjected the Company to the risk of not being able to
recover the security&#146;s $2.0 million carrying value. As a result, the Company
recognized a $1.7 million charge related to this Level 2 marketable security,
which the Company considered to be other than temporarily impaired.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Marketable securities included in Level 3 were valued using information
provided by the Company&#146;s investment advisors, including quoted bid prices which
take into consideration the securities&#146; current lack of liquidity. During the
nine months ended September 30, 2009 and 2008, deterioration in the credit
quality of a marketable security included in Level 3 subjected the Company to
the risk of not being able to recover the carrying value of the investment. As such, the
Company recorded charges for other-than-temporary impairment of this Level 3
marketable security totaling $0.1 million for both the three and nine months
ended September 30, 2009, and $0.5 million for the nine months ended September
30, 2008.</FONT></P>
<P align=center><FONT face=serif size=2>11</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There
were no unrealized gains or losses related to the Company&#146;s Level 3 marketable
securities for the three or nine months ended September 30, 2009 and 2008. In
addition, there were no purchases, sales, or maturities of Level 3 marketable
securities, and no transfers of marketable securities between the Level 2 and
Level 3 classifications, during the three and nine months ended September 30,
2009 and 2008. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Changes
in marketable securities included in Level 3 during the three months ended
September 30, 2009 and 2008 were as follows: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="13%" colSpan=7><FONT face=serif size=2>Level 3 marketable
  securities</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Balance, July 1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>4,995</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Settlements</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(5,665</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Realized gain</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>940</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Impairments</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(100</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Balance, September 30</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>270</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Changes
in marketable securities included in Level 3 during the nine months ended
September 30, 2009 and 2008 were as follows: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="13%" colSpan=7><FONT face=serif size=2>Level 3 marketable
  securities</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Balance, January 1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>7,950</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Settlements</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(8,090</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Realized gain</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>940</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Impairments</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(100</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(530</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Balance, September 30</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>270</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>On a
quarterly basis, the Company reviews its portfolio of marketable securities,
using both quantitative and qualitative factors, to determine if declines in
fair value below cost are other-than-temporary. With respect to debt securities,
this review process also includes an evaluation of the Company&#146;s (a) intent to
sell an individual debt security or (b) need to sell the debt security before
its anticipated recovery or maturity. With respect to equity securities, this
review process includes an evaluation of the Company&#146;s ability and intent to
hold the securities until their full value can be recovered.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
current economic environment, the deterioration in the credit quality of some of
the issuers of securities that the Company holds, and the recent volatility of
securities markets increase the risk that there could be further declines in the
market value of marketable securities in the Company&#146;s investment portfolio and
that such declines could result in charges against income in future periods for
other-than-temporary impairments, and such amounts could be material.
</FONT></P>
<P align=center><FONT face=serif size=2>12</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>6.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Accounts Payable
and Accrued Expenses </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Accounts
payable and accrued expenses as of September 30, 2009 and December 31, 2008
consist of the following: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="89%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>September 30,</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>December 31,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Accounts payable</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>13,855</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>6,268</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%"><FONT face=serif size=2>Payable to Bayer
      HealthCare</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>2,753</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>9,799</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Accrued payroll and related costs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>15,706</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,948</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%"><FONT face=serif size=2>Accrued clinical
      trial expense</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>11,637</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>4,273</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Accrued property, plant, and equipment expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,838</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,994</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%"><FONT face=serif size=2>Accrued
      expenses, other</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>5,502</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>3,886</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>55,291</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>36,168</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face=serif size=2>7.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Research Progress
Payment from Bayer HealthCare LLC </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the Company&#146;s license and collaboration agreement with Bayer
HealthCare LLC to globally develop and commercialize outside the United States
the Company&#146;s VEGF Trap-Eye for the treatment of eye disease by local
administration, the Company received a $20.0 million substantive milestone
payment in July 2009 in connection with the dosing of the first patient in a
Phase 3 trial of VEGF Trap-Eye in Central Retinal Vein Occlusion (&#147;CRVO&#148;). The
$20.0 million payment was recognized in revenues as a research progress payment
for the three and nine months ended September 30, 2009. </FONT><B><FONT face=serif size=2></FONT></B></P>
<P align=justify><B><FONT face=serif size=2>8.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Comprehensive Loss
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Comprehensive loss of the Company includes net loss adjusted for the
change in net unrealized gain (loss) on marketable securities. For the three and
nine months ended September 30, 2009 and 2008, the components of comprehensive
loss are: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="21%" colSpan=7><FONT face=serif size=2>Three months ended September
    30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(1,015</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(19,084</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"><FONT face=serif size=2>Change in net
      unrealized gain (loss) on marketable securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="8%"><FONT face=serif size=2>2,523</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="8%"><FONT face=serif size=2>(3,645</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total comprehensive income
      (loss)</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>1,508</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(22,729</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="21%" colSpan=7><FONT face=serif size=2>Nine months ended September
  30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(31,341</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(49,620</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"><FONT face=serif size=2>Change in net
      unrealized gain (loss) on marketable securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="8%"><FONT face=serif size=2>3,651</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="8%"><FONT face=serif size=2>(4,130</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total comprehensive
    loss</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(27,690</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(53,750</FONT> </TD>
    <TD style="PADDING-BOTTOM: 2px" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face=serif size=2>9.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Lease &#150; Tarrytown,
New York Facilities</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>a. Lease Amendment
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company leases laboratory and office facilities in Tarrytown, New York. In
December 2006, the Company entered into an agreement (which was amended in
October 2007 and September 2008) to lease laboratory and office space at the
Company&#146;s Tarrytown location, including newly constructed space that was
completed during the third quarter of 2009 (the &#147;new facilities&#148;). The term of
the lease commenced effective June 2008 and will expire in June 2024. In April
2009, the Company amended the lease agreement to increase the amount of space
the Company will lease. As amended, the lease contains early termination options
for the portion of the space that excludes the new facilities. Other terms and
conditions, as previously described in the Company&#146;s Annual Report on Form 10-K
for the year ended December 31, 2008, remain unchanged. In connection with the
lease amendment, in April 2009, the Company terminated an April 2008 sublease
for space in Tarrytown, New York.</FONT></P>
<P align=center><FONT face=serif size=2>13</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the April 2009 lease amendment, the Company&#146;s total estimated
future minimum noncancelable lease commitments, previously disclosed in the
Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2008, will
increase to $9.4 million, $14.5 million, $14.7 million, $13.7 million, and $15.1
million for the years ended December 31, 2009, 2010, 2011, 2012, and 2013,
respectively, and increase to an aggregate amount of $182.5 million for the
eleven-year period commencing on January 1, 2014.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>b. Revisions of Previously Issued
Financial Statements </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
application of FASB authoritative guidance, under certain conditions, can result
in the capitalization on a lessee&#146;s books of a lessor&#146;s costs of constructing
facilities to be leased to the lessee. In mid-2009, the Company became aware
that certain of these conditions were applicable to its December 2006 lease, as
amended, of new laboratory and office facilities in Tarrytown, New York. As a
result, the Company is deemed, in substance, to be the owner of the landlord&#146;s
buildings, and the landlord&#146;s costs of constructing these new facilities were
required to be capitalized on the Company&#146;s books as a non-cash transaction,
offset by a corresponding lease obligation on the Company&#146;s balance sheet. In
addition, the land element of the lease should have been accounted for as an
operating lease; therefore, adjustments to non-cash rent expense previously
recognized in connection with these new facilities were also required. Lease
payments on these facilities commenced in August 2009. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company revised its previously issued financial statements to capitalize the
landlord&#146;s costs of constructing the new Tarrytown facilities which the Company
is leasing and to adjust the Company&#146;s previously recognized rent expense in
connection with these facilities, as described above. These revisions primarily
resulted in an increase to property, plant, and equipment and a corresponding
increase in facility lease obligation (a long-term liability) at each balance
sheet date. The Company also revised its statements of operations and statements
of cash flows to reflect rent expense in connection with only the land element
of its lease, with a corresponding adjustment to other long-term liabilities. In
addition, the Company&#146;s statement of cash flows for the quarter ended March 31,
2009 was revised to reclassify, from an operating activity to a financing
activity, a $5.2 million reimbursement received from the Company&#146;s landlord for
tenant improvement costs that the Company incurred. Under FASB authoritative
guidance, such payments that the Company receives from its landlord are deemed
to be a financing obligation.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
previously disclosed, the above described revisions consisted entirely of
non-cash adjustments. They had no impact on the Company&#146;s business operations,
existing capital resources, or the Company&#146;s ability to fund its operating
needs, including the preclinical and clinical development of its product
candidates. The revisions also had no impact on the Company&#146;s previously
reported net increases or decreases in cash and cash equivalents in any period
and, except for the quarter ended March 31, 2009 (as described above), had no
impact on the Company&#146;s previously reported net cash flows from operating
activities, investing activities, and financing activities. In addition, these
revisions had no impact on the Company&#146;s previously reported current assets,
current liabilities, and operating revenues. We have not amended previously
issued financial statements because, after considering both qualitative and
quantitative factors, the Company determined that the judgment of a reasonable
person relying on the Company&#146;s previously issued financial statements would not
have been changed or influenced by these revisions.</FONT></P>
<P align=center><FONT face=serif size=2>14</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<P align=justify><STRONG><FONT size=2>Balance Sheet Impact at December 31, 2007
and 2008, and March 31, 2009<BR><EM>(in millions)</EM></FONT></STRONG></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to the
Company&#146;s balance sheets as of the dates set forth below is as follows:
</FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"></TD>
    <TD noWrap align=center width="10%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="10%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><B><FONT face=serif size=2>2007</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><B><U><FONT face=serif size=2>As originally reported</FONT></U></B></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="8%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="8%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"><FONT face=serif size=2>Property, plant,
      and equipment, net</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>58.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>87.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>109.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Total assets</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Other long-term liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="8%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>5.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>13.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"><FONT face=serif size=2>Total
      liabilities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>476.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>251.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>271.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(793.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(875.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(893.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"><FONT face=serif size=2>Total
      stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>460.3</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>418.8</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>410.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities and stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><B><U><FONT face=serif size=2>As revised</FONT></U></B></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="8%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="8%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"><FONT face=serif size=2>Property, plant,
      and equipment, net</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>79.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>142.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>164.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Total assets</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Facility lease obligation</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>21.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>54.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>60.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"><FONT face=serif size=2>Other long-term
      liabilities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>0.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>2.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>3.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>498.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>302.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>321.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(794.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(873.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(888.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%"><FONT face=serif size=2>Total
      stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>459.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>421.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>415.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="70%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities and stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE></DIV>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to the
Company&#146;s statements of operations and statement of cash flows for the period(s)
set forth below is as follows: </FONT></P>
<P align=justify><B><FONT face=serif size=2>Statements of Operations Impact for
the three, six, and nine month periods ended March 31, June 30, and September
30, 2008, the years ended December 31, 2007 and 2008, and the three months ended
March 31, 2009<BR><EM>(in millions, except per share data)</EM></FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"></TD>
    <TD noWrap align=center width="9%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>June 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>September 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=7><B><FONT face=serif size=2>December 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2007</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%" bgColor=#c0c0c0><B><U><FONT face=serif size=2>As originally reported</FONT></U></B></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="7%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"><FONT face=serif size=2>Research and
      development expenses</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="7%"><FONT face=serif size=2>61.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>127.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>201.7</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>201.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>278.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>82.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%" bgColor=#c0c0c0><FONT size=2>Selling,
      general, and <FONT face=serif>administrative expenses</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="7%" bgColor=#c0c0c0><FONT face=serif size=2>11.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>24.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>35.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>37.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>49.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>11.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"><FONT face=serif size=2>Total
      expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="7%"><FONT face=serif size=2>72.3</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>152.3</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>237.9</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>239.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>328.3</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>94.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="7%" bgColor=#c0c0c0><FONT face=serif size=2>(11.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(30.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(51.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(105.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(82.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(17.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"><FONT size=2>Net loss per share, basic
      <FONT face=serif>and diluted</FONT></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="7%"><FONT face=serif size=2>(0.15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(0.38</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(0.65</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(1.59</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(1.05</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(0.22</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=24>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%" bgColor=#c0c0c0><B><U><FONT face=serif size=2>As revised</FONT></U></B></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="7%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"><FONT size=2>Research and development
      <FONT face=serif>expenses</FONT></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="7%"><FONT face=serif size=2>61.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>128.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>200.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>202.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>274.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>80.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%" bgColor=#c0c0c0><FONT size=2>Selling,
      general, and <FONT face=serif>administrative expenses</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="7%" bgColor=#c0c0c0><FONT face=serif size=2>11.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>24.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>35.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>37.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>48.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>11.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"><FONT face=serif size=2>Total
      expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="7%"><FONT face=serif size=2>72.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>152.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>236.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>240.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>324.7</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>92.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="7%" bgColor=#c0c0c0><FONT face=serif size=2>(11.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(30.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(49.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(106.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(79.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(15.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="45%"><FONT face=serif size=2>Net loss per
      share, basic and diluted</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="7%"><FONT face=serif size=2>(0.15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(0.39</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(0.63</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(1.61</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(1.00</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(0.19</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR></TABLE><BR>

<P align=center><FONT face=serif size=2>15</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><STRONG><FONT size=2>Statement of Cash Flows Impact for the
three months ended March 31, 2009</FONT></STRONG><BR><STRONG><EM><FONT size=2>(in millions)</FONT></EM></STRONG></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"></TD>
    <TD noWrap align=center width="10%" colSpan=3><B><FONT face=serif size=2>As Originally</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><B><FONT face=serif size=2>Reported</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=2>As Revised</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Net cash used in operating activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(10.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>(15.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"><FONT face=serif size=2>Net cash used in
      investing activities</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>(39.5</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=2>(39.5</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Net cash provided by financing activities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>1.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=2>6.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net decrease in cash and cash
      equivalents</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="8%"><FONT face=serif size=2>(48.7</FONT> </TD>
    <TD style="PADDING-BOTTOM: 2px" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="6%"><FONT face=serif size=2>(48.7</FONT> </TD>
    <TD style="PADDING-BOTTOM: 2px" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>These
revised amounts, as applicable, are reflected in the Company&#146;s financial
statements included in this Quarterly Report on Form 10-Q for the period ended
September 30, 2009, and will be reflected in the Company&#146;s financial statements
included in the Company&#146;s Annual Report on Form 10-K for the year ended
December 31, 2009 and the Company&#146;s Quarterly Report on Form 10-Q for the period ended
March 31, 2010.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>c. Facility Lease Obligation
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
described above in Note 9b, in connection with the application of FASB
authoritative guidance to the Company&#146;s lease of office and laboratory
facilities constructed in Tarrytown, New York by the Company&#146;s landlord, the
Company capitalized the landlord&#146;s costs of constructing the new facilities,
which totaled $58.2 million as of September 30, 2009, and recognized a
corresponding facility lease obligation of $58.2 million. The Company also
recognized, as an additional facility lease obligation, a $5.2 million
reimbursement received from the Company&#146;s landlord for tenant improvement costs
that the Company incurred since, under FASB authoritative guidance, such
payments that the Company receives from its landlord are deemed to be a
financing obligation. Monthly lease payments on these facilities are allocated
between the land element of the lease (which is accounted for as an operating
lease) and the facility lease obligation, based on the estimated relative fair
values of the land and buildings. The imputed interest rate applicable to the
facility lease obligation is approximately 11%. The new facilities were placed
in service by the Company in September 2009. For the three and nine months ended
September 30, 2009, the Company recognized $0.6 million of interest expense in
connection with the facility lease obligation in the Company&#146;s statement of
operations. At September 30, 2009, the facility lease obligation balance was
$62.6 million.</FONT></P>
<P align=justify><B><FONT face=serif size=2>10.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Royalty Agreements
with Novartis Pharma AG </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In June
2009, the Company entered into two royalty agreements with Novartis Pharma AG
(&#147;Novartis&#148;) that replaced a previous collaboration and license agreement. Under
the first royalty agreement, the Company is entitled to receive royalties on
worldwide sales of Novartis&#146; canakinumab (ACZ885), a fully human
anti-interleukin-IL1&#223; antibody approved to treat CAPS and in development for a
number of other inflammatory diseases. On the basis of the same agreement, the
Company waived its rights to opt-in to the development and commercialization of
canakinumab. Under the second royalty agreement, Novartis is entitled to receive
royalties on worldwide sales of a second-generation interleukin-1 Trap, should
the Company decide to proceed in the development of, and ultimately
commercialize, this Trap. The financial terms of both agreements are identical
in relation to stepped royalties to be paid on the basis of future sales, which
start at 4% and reach 15% when annual sales exceed $1.5 billion. The agreements
do not provide for any upfront or milestone payments or any sharing of
development expenses. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
royalty agreements replace a 2003 collaboration and license agreement under
which the Company had the right to opt in to the development and
commercialization of Novartis&#146; interleukin-1 antibody and Novartis had the right
to opt in to the development and commercialization of the Company&#146;s
second-generation interleukin-1 Trap. That collaboration and license agreement
has been terminated. </FONT></P>
<P align=justify><B><FONT face=serif size=2>11.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Legal Matters
</FONT></B><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From time
to time, the Company is a party to legal proceedings in the course of its
business. The Company does not expect any such current legal proceedings to have
a material adverse effect on the Company&#146;s business or financial condition.
</FONT></P>
<P align=center><FONT face=serif size=2>16</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>12.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Future Impact of
Recently Issued Accounting Standards </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
October 2009, the FASB amended its authoritative guidance on
multiple-deliverable revenue arrangements. The amended guidance provides greater
ability to separate and allocate arrangement consideration in a multiple element
revenue arrangement by requiring the use of estimated selling price to allocate
arrangement consideration, thereby eliminating the use of the residual method of
allocation. The amended guidance also requires expanded qualitative and
quantitative disclosures surrounding multiple deliverable revenue arrangements.
This guidance may be applied retrospectively or prospectively for new or
materially modified arrangements. The Company will be required to adopt this
amended guidance effective for the fiscal year beginning January 1, 2011,
although earlier adoption is permitted. Management is currently evaluating the
impact that this guidance will have on the Company&#146;s financial statements.
</FONT></P>
<P align=justify><B><FONT face=serif size=2>13.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Subsequent Events
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company has evaluated subsequent events through November 3, 2009, the date on
which the financial statements were issued, and has determined that there are no
subsequent events that require adjustments to the financial statements for the
quarter ended September 30, 2009.</FONT></P>
<P align=center><FONT face=serif size=2>17</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>ITEM 2. MANAGEMENT&#146;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT face=serif size=2>The
discussion below contains forward-looking statements that involve risks and
uncertainties relating to future events and the future financial performance of
Regeneron Pharmaceuticals, Inc., and actual events or results may differ
materially. These statements concern, among other things, the possible success
and therapeutic applications of our product candidates and research programs,
anticipated sales of our marketed product, the timing and nature of the clinical
and research programs now underway or planned, and the future sources and uses
of capital and our financial needs. These statements are made by us based on
management's current beliefs and judgment. In evaluating such statements,
stockholders and potential investors should specifically consider the various
factors identified under the caption &#147;Risk Factors&#148; which could cause actual
results to differ materially from those indicated by such forward-looking
statements. We do not undertake any obligation to update publicly any
forward-looking statement, whether as a result of new information, future
events, or otherwise, except as required by law.</FONT></I></P>
<P align=justify><B><FONT face=serif size=2>Overview </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron
Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops,
and commercializes pharmaceutical products for the treatment of serious medical
conditions. We currently have one marketed product: ARCALYST<SUP>&#174;</SUP>
(rilonacept) Injection for Subcutaneous Use, which is available for prescription
in the United States for the treatment of Cryopyrin-Associated Periodic
Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and
Muckle-Wells Syndrome (MWS) in adults and children 12 and older.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We also
have six product candidates currently in clinical development, including three
in late-stage clinical development. Our late stage programs are aflibercept
(VEGF Trap), which is being developed in oncology in collaboration with the
sanofi-aventis Group, VEGF Trap-Eye, which is being developed in eye diseases
using intraocular delivery in collaboration with Bayer HealthCare LLC, and
ARCALYST, which is being developed for the treatment of gout. Our earlier stage
clinical programs are REGN88, an antibody to the interleukin-6 receptor (IL-6R),
which is being developed in rheumatoid arthritis, REGN421, an antibody to
Delta-like ligand-4 (Dll4), which is being developed in oncology, and REGN475,
an antibody to Nerve Growth Factor (NGF), which is being developed for the
treatment of pain. All three of these antibodies are being developed in
collaboration with sanofi-aventis. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
that our next generation of product candidates will be based on our proprietary
technologies for developing human monoclonal antibodies. Our antibody program is
being conducted primarily in collaboration with sanofi-aventis. Our preclinical
research programs are in the areas of oncology and angiogenesis, ophthalmology,
metabolic and related diseases, muscle diseases and disorders, inflammation and
immune diseases, bone and cartilage, pain, cardiovascular diseases, and
infectious diseases. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our core
business strategy is to maintain a strong foundation in basic scientific
research and discovery-enabling technology and combine that foundation with our
clinical development and manufacturing capabilities to build a successful,
integrated biopharmaceutical company. However, developing and commercializing
new medicines entails significant risk and expense. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
believe that our ability to develop product candidates is enhanced by the
application of our <EM>VelociSuite</EM><SUP>TM</SUP> technology platforms. Our
discovery platforms are designed to identify specific genes of therapeutic
interest for a particular disease or cell type and validate targets through
high-throughput production of mammalian models. Our human monoclonal antibody
technology (</FONT><I><FONT face=serif size=2>VelocImmune<STRONG><SUP>&#174;</SUP></STRONG></FONT></I><FONT face=serif size=2>) and cell line expression technologies (</FONT><I><FONT face=serif size=2>VelociMab<SUP>TM</SUP></FONT></I><I><FONT face=serif size=2>)
</FONT></I><FONT face=serif size=2>may then be utilized to design and produce
new product candidates directed against the disease target. Our first three
antibody product candidates currently in clinical trials were developed using
</FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2>. Over the course of the next several years, we plan to advance an
average of two to three new antibody product candidates into clinical
development each year. We continue to invest in the development of enabling
technologies to assist in our efforts to identify, develop, and commercialize
new product candidates. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>18</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><U><FONT face=serif size=2>Commercial
Product:</FONT></U></B><B><FONT face=serif size=2> </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>ARCALYST<SUP>&#174;
</SUP></FONT></I></B><B><I><FONT face=serif size=2>(rilonacept) &#150;
Cryopyrin-Associated Periodic Syndromes (CAPS) </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
February 2008, we received marketing approval from the U.S. Food and Drug
Administration (FDA) for ARCALYST<SUP><FONT face=Arial>&#174;
</FONT></SUP></FONT><FONT face=serif size=2>(rilonacept) Injection for
Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes
(CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and
Muckle-Wells Syndrome (MWS) in adults and children 12 and older. We shipped $5.3
million and $15.0 million of ARCALYST to our distributors during the third
quarter and first nine months of 2009, respectively, compared to $4.3 million
and $6.7 million in the same periods of 2008. We expect to ship approximately
$20 million of ARCALYST to our U.S. distributors in 2009, compared to $10.7
million in 2008.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
October 2009, rilonacept was approved under exceptional circumstances by the
European Medicines Agency (EMEA) for the treatment of CAPS with severe symptoms
in adults and children aged 12 years and older. Such authorizations are
permissible for products for which a company can demonstrate that comprehensive
data cannot be provided, for example, because of the rarity of the
condition</FONT><FONT face=serif size=2>. </FONT><FONT face=serif size=2>Each
year, we will need to provide for review by the EMEA any new or follow-up
information that may become available. We own worldwide rights to ARCALYST (rilonacept).
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>ARCALYST
is a protein-based product designed to bind the interleukin-1 (called IL-1)
cytokine and prevent its interaction with cell surface receptors. ARCALYST is
approved in the United States for patients with CAPS, a group of rare,
inherited, auto-inflammatory conditions characterized by life-long, recurrent
symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue.
Intermittent, disruptive exacerbations or flares can be triggered at any time by
exposure to cooling temperatures, stress, exercise, or other unknown stimuli.
CAPS is caused by a range of mutations in the gene NLRP3</FONT><I><FONT face=serif size=2> </FONT></I><FONT face=serif size=2>(formerly known as
</FONT><I><FONT face=serif size=2>CIAS1</FONT></I><FONT face=serif size=2>)
which encodes a protein named cryopyrin. In addition to FCAS and MWS, CAPS
includes Neonatal Onset Multisystem Inflammatory Disease (NOMID). ARCALYST has
not been studied for the treatment of NOMID.</FONT></P>
<P align=justify><B><U><FONT face=serif size=2>Clinical
Programs:</FONT></U></B><B><FONT face=serif size=2> </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>1. Aflibercept (VEGF Trap) &#150;
Oncology </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is a protein-based product candidate designed to bind all
forms of Vascular Endothelial Growth Factor-A (called VEGF-A, also known as
Vascular Permeability Factor or VPF), VEGF-B and the related Placental Growth
Factor (called PlGF), and prevent their interaction with cell surface receptors.
VEGF-A (and to a less validated degree, VEGF-B and PlGF) is required for the
growth of new blood vessels (a process known as angiogenesis) that are needed
for tumors to grow and is a potent regulator of vascular permeability and
leakage.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is being developed globally in cancer indications in
collaboration with sanofi-aventis. We and sanofi-aventis are enrolling patients
in three Phase 3 trials that are evaluating combinations of aflibercept with
standard chemotherapy regimens for the treatment of cancer. One trial (called VELOUR) is
evaluating aflibercept as a 2<SUP>nd </SUP></FONT><FONT face=serif size=2>line
treatment for metastatic colorectal cancer in combination with
FOLFIRI (folinic acid (leucovorin), 5-fluorouracil, and irinotecan). A second
trial (VITAL) is evaluating aflibercept as a 2<SUP>nd </SUP></FONT><FONT face=serif size=2>line treatment for metastatic non-small cell lung cancer in combination
with docetaxel. The third trial (VENICE) is evaluating aflibercept as a 1<SUP>st
</SUP></FONT><FONT face=serif size=2>line treatment for metastatic
androgen-independent prostate cancer in combination with docetaxel/prednisone. All three trials are studying the current standard of chemotherapy
care for the cancer being studied with and without aflibercept. At the end of
the third quarter of 2009, each of these trials was more than 80% enrolled.
Analyses of the data from these studies will be conducted when a prespecified
number of events have occurred in each trial. Based on current enrollment and
event rates, an interim analysis of the Phase 3 study in colorectal cancer is
expected to be conducted by an Independent Data Monitoring Committee (IDMC) in
the second half of 2010. Complete results from this study in colorectal cancer
and from the study in non-small cell lung cancer are anticipated in the first
half of 2011. Based on current enrollment and event rates, an interim analysis
of the prostate study is expected to be conducted by an IDMC in mid-2011, with
complete results anticipated in 2012. In addition, we and sanofi-aventis are
conducting a Phase 2 study (called AFFIRM) of aflibercept in 1<SUP>st</SUP> line
metastatic colorectal cancer in combination with folinic acid (leucovorin),
5-fluorouracil, and oxaliplatin. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>19</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
September 2009, as previously reported, a fourth Phase 3 trial (VANILLA) that
was evaluating aflibercept as a 1<SUP>st </SUP></FONT><FONT face=serif size=2>line treatment for metastatic pancreatic cancer in combination with
gemcitabine was discontinued at the recommendation of an IDMC. As part of a
planned interim efficacy analysis, the IDMC determined that the addition of
aflibercept to gemcitabine would be unable to demonstrate a statistically
significant improvement in the primary endpoint of overall survival compared to
placebo plus gemcitabine in this study. The types and frequencies of adverse
events reported on the combination arm with aflibercept were generally as
anticipated. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, multiple exploratory studies are being conducted in conjunction with
the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)
evaluating aflibercept as a single agent or in combination with chemotherapy
regimens in a variety of cancer indications. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Aflibercept Collaboration with the
sanofi-aventis Group </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
sanofi-aventis U.S. (successor to Aventis Pharmaceuticals, Inc.) collaborate on
the development and commercialization of aflibercept globally. Under the terms
of our September 2003 collaboration agreement, as amended, we and sanofi-aventis
will share co-promotion rights and profits on sales, if any, of aflibercept
outside of Japan for disease indications included in our collaboration. In
Japan, we are entitled to a royalty of approximately 35% on annual sales of
aflibercept, subject to certain potential adjustments. We may also receive up to
$400 million in milestone payments upon receipt of specified marketing
approvals, including up to $360 million in milestone payments related to receipt
of marketing approvals for up to eight aflibercept oncology and other
indications in the United States or the European Union and up to $40 million
related to receipt of marketing approvals for up to five oncology indications in
Japan. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Under the
aflibercept collaboration agreement, as amended, agreed upon worldwide
development expenses incurred by both companies during the term of the agreement
will be funded by sanofi-aventis. If the collaboration becomes profitable, we
will be obligated to reimburse sanofi-aventis for 50% of aflibercept development
expenses in accordance with a formula based on the amount of development
expenses and our share of the collaboration profits and Japan royalties, or at a
faster rate at our option.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>2. VEGF Trap-Eye &#150; Ophthalmologic
Diseases </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>VEGF
Trap-Eye is a specially purified and formulated form of VEGF Trap for use in
intraocular applications. We and Bayer HealthCare are testing VEGF Trap-Eye in a
Phase 3 program in patients with the neovascular form of age-related macular
degeneration (wet AMD). We and Bayer HealthCare also are conducting a Phase 2
study of VEGF Trap-Eye in patients with diabetic macular edema (DME). Wet AMD
and diabetic retinopathy (which includes DME) are two of the leading causes of
adult blindness in the developed world. In both conditions, severe visual loss
is caused by a combination of retinal edema and neovascular proliferation. We
and Bayer HealthCare also initiated a Phase 3 program in Central Retinal Vein
Occlusion (CRVO) in July 2009. In connection with the dosing of the first
patient in a Phase 3 study in CRVO, we received a $20.0 million milestone
payment from Bayer HealthCare.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The Phase
3 trials in wet AMD, known as VIEW 1 and VIEW 2 (</FONT><U><FONT face=serif size=2>V</FONT></U><FONT face=serif size=2>EGF Trap: </FONT><U><FONT face=serif size=2>I</FONT></U><FONT face=serif size=2>nvestigation of </FONT><U><FONT face=serif size=2>E</FONT></U><FONT face=serif size=2>fficacy and Safety in
</FONT><U><FONT face=serif size=2>W</FONT></U><FONT face=serif size=2>et
age-related macular degeneration), are comparing VEGF Trap-Eye and
Lucentis<SUP>&#174; </SUP>(ranibizumab injection),
marketed by Genentech, Inc., an anti-angiogenic agent approved for use in wet
AMD. VIEW 1 is being conducted in North America and VIEW 2 is being conducted in
Europe, Asia Pacific, Japan, and Latin America. The VIEW 1 and VIEW 2 trials are
both evaluating VEGF Trap-Eye doses of 0.5 milligrams (mg) and 2.0 mg at dosing
intervals of four weeks and 2.0 mg at a dosing interval of eight weeks (after
three monthly doses) compared with Lucentis dosed according to its U.S. label,
which specifies doses of 0.5 mg administered every four weeks over the first
year. As-needed dosing (PRN) with both agents will be evaluated in the second
year of the studies. VIEW 1 and VIEW 2 are now fully enrolled, and initial data
are expected in late 2010. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
Bayer HealthCare have conducted a Phase 2 study in wet AMD which demonstrated
that patients treated with VEGF Trap-Eye achieved durable improvements in visual
acuity and retinal thickness for up to one year. These one-year study results
were reported at the 2008 annual meeting of the Retina Society. In this
double-masked Phase 2 trial, known as CLEAR-IT 2, 157 patients were initially
treated for three months with VEGF Trap-Eye: two groups received monthly doses
of 0.5 or 2.0 mg (at weeks 0, 4, 8, and 12) and three groups received quarterly
doses of 0.5, 2.0, or 4.0 mg (at baseline and week 12). Following the initial
three-month fixed-dosing phase, patients continued to receive VEGF Trap-Eye at
the same dose on a PRN dosing schedule through one year, based upon the
physician assessment of the need for re-treatment in accordance with
pre-specified criteria.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>20</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Patients
receiving monthly doses of VEGF Trap-Eye of either 2.0 or 0.5 mg for 12 weeks
followed by PRN dosing achieved mean improvements in visual acuity versus
baseline of 9.0 letters (p&lt;0.0001 versus baseline) and 5.4 letters
(p&lt;0.085 versus baseline), respectively, at the end of one year. The
proportion of patients with vision of 20/40 or better (part of the legal minimum
requirement for an unrestricted driver's license in the U.S.) increased from 23%
at baseline to 45% at week 52 in patients initially treated with 2.0 mg monthly
and from 16% at baseline to 47% at week 52 in patients initially treated with
0.5 mg monthly. Patients receiving monthly doses of VEGF Trap-Eye of either 2.0
or 0.5 mg also achieved mean decreases in retinal thickness versus baseline of
143 microns (p&lt;0.0001 versus baseline) and 125 microns (p&lt;0.0001 versus
baseline) at week 52, respectively. After week 12 to week 52 in the PRN dosing
period, patients initially dosed on a 2.0 mg monthly schedule received, on
average, only 1.6 additional injections and those initially dosed on a 0.5 mg
monthly schedule received, on average, 2.5 additional injections.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>While PRN
dosing following a fixed quarterly dosing regimen (with dosing at baseline and
week 12) also yielded improvements in visual acuity and retinal thickness versus
baseline at week 52, the results generally were not as robust as those obtained
with initial fixed monthly dosing.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>All
patients who completed the one year CLEAR-IT 2 study were eligible to
participate in an extension stage of the study. Twenty-four-month results of the
extension stage were presented in October 2009 at the 2009 American Academy of
Ophthalmology meeting. After receiving VEGF Trap-Eye for one year, the 117
patients who elected to enter the extension stage were dosed on a 2.0 mg PRN
basis, irrespective of the dose at which they were treated earlier in the study.
On a combined basis, for these 117 patients, the mean gain in visual acuity was
7.3 letters (</FONT><I><FONT face=serif size=2>p</FONT></I><FONT face=serif size=2>&lt;0.0001 versus baseline) at the three-month primary endpoint of the
original Phase 2 study, 8.4 letters (</FONT><I><FONT face=serif size=2>p</FONT></I><FONT face=serif size=2>&lt;0.0001 versus baseline) at one
year, and 6.1 letters (</FONT><I><FONT face=serif size=2>p</FONT></I><FONT face=serif size=2>&lt;0.0001 versus baseline) at month 12 of the extension
stage. Thus, after 24 months of dosing with VEGF Trap-Eye in the Phase 2 study,
patients continued to maintain a highly significant improvement in visual acuity
versus baseline, while receiving, on average, only 4.6 injections over the
21-month PRN dosing phase that extended from month three to month 24. The most
common adverse events were those typically associated with intravitreal
injections and included conjunctival hemorrhage at the injection site and
transient increased intraocular pressure following an injection.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The DME
study, known as the DA VINCI study, is a double-masked, randomized, controlled
trial that is evaluating four different VEGF Trap-Eye regimens versus laser
treatment. The study began in December 2008 and completed enrollment of
approximately 200 patients in the U.S., Canada, European Union, and Australia in
July 2009. The patients in the study will be treated for 52 weeks followed by
six additional months of safety evaluation. The primary efficacy endpoint is the
change in best corrected visual acuity (BCVA) from baseline to week 24. These
data are expected to be reported during the first half of 2010.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>VEGF
Trap-Eye is also in Phase 3 development for the treatment of Central Retinal
Vein Occlusion (CRVO), another cause of blindness. The COPERNICUS (COntrolled
Phase 3 Evaluation of Repeated iNtravitreal administration of VEGF Trap-Eye In
Central retinal vein occlusion: Utility and Safety) study is being led by
Regeneron and the GALILEO (General Assessment Limiting Infitration of Exudates
in central retinal vein Occlusion with VEGF Trap-Eye) study is being led by
Bayer HealthCare. Patients in both studies will receive six monthly intravitreal
injections of either VEGF Trap-Eye at a dose of 2 mg or sham control injections.
The primary endpoint of both studies is improvement in visual acuity versus
baseline after six months of treatment. At the end of the initial six months,
patients will be dosed on a PRN basis for another six months. All
patients will be eligible for rescue laser treatment. Enrollment in the
COPERNICUS study began during the third quarter of 2009, and enrollment in the
GALILEO study began in October 2009. Initial data are anticipated in early 2011.
</FONT></P>
<P align=justify><B><FONT face=serif size=2>Collaboration with Bayer HealthCare
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
October 2006, we entered into a collaboration agreement with Bayer HealthCare
for the global development and commercialization outside the United States of
VEGF Trap-Eye. Under the agreement, we and Bayer HealthCare will collaborate on,
and share the costs of, the development of VEGF Trap-Eye through an integrated
global plan that encompasses wet AMD, DME, and CRVO. Bayer HealthCare will
market VEGF Trap-Eye outside the United States, where the companies will share
equally in profits from any future sales of VEGF Trap-Eye. If VEGF Trap-Eye is
granted marketing authorization in a major market country outside the United
States, we will be obligated to reimburse Bayer HealthCare for 50% of the
development costs that it has incurred under the agreement from our share of the
collaboration profits. Within the United States, we retain exclusive
commercialization rights to VEGF Trap-Eye and are entitled to all profits from
any such sales. We received an up-front payment of $75.0 million from Bayer
HealthCare. In 2007, we received a $20.0 million milestone payment from Bayer
HealthCare following dosing of the first patient in a Phase 3 study of VEGF
Trap-Eye in wet AMD. In July 2009, we received a $20.0 million milestone payment
from Bayer HealthCare following dosing of the first patient in a Phase 3 study
of VEGF Trap-Eye in CRVO. We can earn up to $70 million in additional
development and regulatory milestones related to the development of VEGF
Trap-Eye and marketing approvals in major market countries outside the United
States. We can also earn up to $135 million in sales milestones if total annual
sales of VEGF Trap-Eye outside the United States achieve certain specified
levels starting at $200 million.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>21</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>3. ARCALYST<SUP>&#174;
</SUP></FONT></I></B><B><I><FONT face=serif size=2>(rilonacept) &#150; Inflammatory
Diseases</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
evaluating ARCALYST in gout, a disease in which, as in CAPS, IL-1 may play an
important role in pain and inflammation. In September 2008, we announced the
results of a Phase 2 study which evaluated the efficacy and safety of ARCALYST
versus placebo in the prevention of gout flares induced by the initiation of
urate-lowering drug therapy that is used to control gout. In this 83-patient,
double-blind, placebo-controlled study, the mean number of flares per patient
over the first 12 weeks of urate-lowering therapy was 0.79 with placebo and 0.15
with ARCALYST (p=0.0011), an 81% reduction. This was the primary endpoint of the
study. All secondary endpoints also were met with statistical significance. In
the first 12 weeks of treatment, 45.2% of patients treated with placebo
experienced a gout flare and, of those, 47.4% had more than one flare. Among
patients treated with ARCALYST, only 14.6% experienced a gout flare (p=0.0037
versus placebo) and none had more than one flare. Injection-site reaction was
the most commonly reported adverse event with ARCALYST and no serious
drug-related adverse events were reported.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Results
from this study after the first 16 weeks of urate-lowering therapy were reported
at the annual meeting of the European League Against Rheumatism (EULAR) in June
2009. Through 16 weeks, the mean number of flares per patient was 0.93 with
placebo and 0.22 with ARCALYST (p=0.0036). In the first 16 weeks of treatment,
47.6% of patients treated with placebo experienced a gout flare and, of those,
55.0% had more than one flare. Among patients treated with ARCALYST, 22.0%
experienced a gout flare (p=0.0209 versus placebo) and none had more than one
flare. Adverse events after 16 weeks of treatment were similar to those reported
after 12 weeks with the most frequently reported categories being infection and
musculoskeletal complaints. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Gout is
characterized by high blood levels of uric acid, a bodily waste product normally
excreted by the kidneys. The uric acid can form crystals in the joints of the
toes, ankles, knees, wrists, fingers, and elbows. Chronic treatment with uric
acid-lowering medicines, such as allopurinol, is prescribed to eliminate the
uric acid crystals and prevent reformation. During the first months of
allopurinol therapy, while uric acid blood levels are being reduced, the break
up of the uric acid crystals can result in stimulation of inflammatory
mediators, including IL-1, resulting in acute flares of joint pain and
inflammation. These painful flares generally persist for at least five days.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the first quarter of 2009, we initiated a Phase 3 clinical development program
with ARCALYST for the treatment of gout. The program includes four clinical
trials, all of which are currently enrolling patients. Two Phase 3 clinical
trials (called PRE-SURGE 1 and PRE-SURGE 2) are evaluating ARCALYST versus
placebo for the prevention of gout flares in patients initiating urate-lowering
drug therapy. A third Phase 3 trial in acute gout (SURGE) is evaluating
treatment with ARCALYST alone versus ARCALYST in combination with a
non-steroidal anti-inflammatory drug (NSAID) versus an NSAID alone. The fourth
Phase 3 trial is a placebo-controlled safety study (RE-SURGE). We expect to
report initial data from the Phase 3 program during the first half of 2010.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In June
2009, we announced that we had entered into two royalty agreements with Novartis
Pharma AG that replaced a previous collaboration and license agreement. Under
the first royalty agreement, we are entitled to receive royalties on worldwide
sales of Novartis&#146; canakinumab (ACZ885), a fully human anti-interleukin-IL1&#223;
antibody. Under this agreement, we also waived our rights to opt-in to the
development and commercialization of canakinumab. Canakinumab is approved to
treat Cryopyrin-Associated Periodic Syndrome (CAPS) and is in development for
chronic gout and a number of other inflammatory diseases. On October 20, 2009,
Novartis announced positive Phase 2 results showing that canakinumab is
significantly more effective than an injectable corticosteroid at reducing pain
and preventing recurrent attacks or &#147;flares&#148; in patients with hard-to-treat
gout. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>22</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Under the
second royalty agreement, Novartis is entitled to receive royalties on worldwide
sales of a second-generation interleukin-1 Trap, should we decide to proceed in
the development of this Trap. The financial terms of both agreements are
identical in relation to stepped royalties, to be paid on the basis of future
sales, which start at 4%
and reach 15%, when annual sales exceed $1.5 billion. The agreements do not
provide for any upfront or milestone payments or any sharing of development
expenses. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
royalty agreements replace a 2003 collaboration and license agreement under
which we had the right to opt in to the development and commercialization of
Novartis&#146; interleukin-1 antibody and Novartis had the right to opt in to the
development and commercialization of our second-generation interleukin-1 Trap.
That collaboration and license agreement has been terminated. </FONT></P>
<P align=left><B><I><FONT face=serif size=2>4. Monoclonal Antibodies
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
sanofi-aventis are collaborating on the discovery, development, and
commercialization of fully human monoclonal antibodies generated using our
<I>VelocImmune<SUP>&#174;</SUP></I> technology. The first therapeutic antibody
product candidates to enter clinical development under the collaboration are
REGN88, REGN475, and REGN421. During the third quarter of 2009, REGN475, an
antibody to Nerve Growth Factor (NGF), a novel target for pain, began a dose
ranging study in osteoarthritis of the knee. Trial results are expected during
the first half of 2010. A Phase 1 study of REGN475 in healthy volunteers is also
continuing, and Phase 1 studies are in progress with REGN88, an antibody to the
interleukin-6 receptor (IL-6R) that is being evaluated in rheumatoid arthritis,
and REGN421, an antibody to Delta-like ligand-4 (Dll4) that is being studied in
patients with advanced malignancies. We and sanofi-aventis expect to enter two
more human monoclonal antibodies into clinical development this year and to
advance an average of two to three into clinical development each year
thereafter over the course of the next several years. </FONT></P>
<P align=left><B><U><FONT face=serif size=2>Research and Development
Technologies:</FONT></U></B><B><FONT face=serif size=2> </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>One way
that a cell communicates with other cells is by releasing specific signaling
proteins, either locally or into the bloodstream. These proteins have distinct
functions, and are classified into different &#147;families&#148; of molecules, such as
peptide hormones, growth factors, and cytokines. All of these secreted (or
signaling) proteins travel to and are recognized by another set of proteins,
called &#147;receptors,&#148; which reside on the surface of responding cells. These
secreted proteins impact many critical cellular and biological processes,
causing diverse effects ranging from the regulation of growth of particular cell
types, to inflammation mediated by white blood cells. Secreted proteins can at
times be overactive and thus result in a variety of diseases. In these disease
settings, blocking the action of specific secreted proteins can have clinical
benefit.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2> Our
scientists have developed two different technologies to design protein
therapeutics to block the action of specific secreted proteins. The first
technology, termed the &#147;Trap&#148; technology, was used to generate our first
approved product, ARCALYST<SUP>&#174;</SUP> (rilonacept), as well as aflibercept and
VEGF Trap-Eye, all of which are in Phase 3 clinical trials. These novel &#147;Traps&#148;
are composed of fusions between two distinct receptor components and the
constant region of an antibody molecule called the &#147;Fc region&#148;, resulting in
high affinity product candidates. </FONT><I><FONT face=serif size=2>VelociSuite</FONT></I><FONT face=serif size=2> is our second technology
platform and it is used for discovering, developing, and producing fully human
monoclonal antibodies.</FONT></P>
<P align=left><B><FONT face=serif size=2><EM>VelociSuite<SUP>TM</SUP></EM><B><FONT face=serif size=2>
</FONT></B></FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT face=serif size=2>VelociSuite</FONT></I><FONT face=serif size=2> consists of
</FONT><I><FONT face=serif size=2>VelocImmune<SUP>&#174;</SUP></FONT></I><I><FONT face=serif size=2>, VelociGene<SUP>&#174;</SUP></FONT></I><I><FONT face=serif size=2>, VelociMouse<SUP>&#174;</SUP></FONT></I><I><FONT face=serif size=2>, and
VelociMab<SUP>TM</SUP></FONT></I><I><FONT face=serif size=2>.</FONT></I><FONT face=serif size=2> The </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> mouse platform is utilized
to produce fully human monoclonal antibodies. </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> was generated by
exploiting our </FONT><I><FONT face=serif size=2>VelociGene</FONT></I><FONT face=serif size=2> technology (see below), in a process in which six megabases
of mouse immune gene loci were replaced, or &#147;humanized,&#148; with corresponding
human immune gene loci. </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> mice can be used to
generate efficiently fully human monoclonal antibodies to targets of therapeutic
interest. </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> and our entire </FONT><I><FONT face=serif size=2>VelociSuite</FONT></I><FONT face=serif size=2> offer the potential to
increase the speed and efficiency through which human monoclonal antibody
therapeutics may be discovered and validated, thereby improving the overall
efficiency of our early stage drug development activities. We are utilizing the
</FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2>
technology to produce our next generation of drug candidates for preclinical and
clinical development.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>23</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
</FONT><I><FONT face=serif size=2>VelociGene<SUP>&#174;</SUP></FONT></I><FONT face=serif size=2>
platform allows custom and precise manipulation of very large sequences of DNA
to produce highly customized alterations of a specified target gene, or genes,
and accelerates the production of knock-out and transgenic expression models
without using either positive/negative selection or isogenic DNA. In producing
knock-out models, a color or fluorescent marker may be substituted in place of
the actual gene sequence, allowing for high-resolution visualization of
precisely where the gene is active in the body, during normal body functioning,
as well as in disease processes. For the optimization of pre-clinical
development and toxicology programs, </FONT><I><FONT face=serif size=2>VelociGene</FONT></I><FONT face=serif size=2> offers the opportunity to
humanize targets by replacing the mouse gene with the human homolog. Thus,
</FONT><I><FONT face=serif size=2>VelociGene</FONT></I><FONT face=serif size=2>
allows scientists to rapidly identify the physical and biological effects of
deleting or over-expressing the target gene, as well as to characterize and test
potential therapeutic molecules.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
<I>VelociMouse<SUP>&#174;</SUP></I> technology platform allows for the direct and
immediate generation of genetically altered mice from embryonic stem cells (ES
cells), thereby avoiding the lengthy process involved in generating and breeding
knockout mice from chimeras. Mice generated through this method are normal and
healthy and exhibit a 100% germ-line transmission. Furthermore, the VelociMice
are suitable for direct phenotyping or other studies. We have also developed our
<I>VelociMab<SUP>TM</SUP></I> platform for the rapid screening of antibodies and
rapid generation of expression cell lines for our Traps and our
<I>VelocImmune<SUP>&#174;</SUP></I> human monoclonal antibodies.</FONT></P>
<P align=left><B><FONT face=serif size=2>Antibody Collaboration with
sanofi-aventis </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
November 2007, we and sanofi-aventis entered into a global, strategic
collaboration to discover, develop, and commercialize fully human monoclonal
antibodies. The collaboration is governed by a Discovery and Preclinical
Development Agreement and a License and Collaboration Agreement. We received a
non-refundable, up-front payment of $85.0 million from sanofi-aventis under the
discovery agreement. In addition, sanofi-aventis is funding research at
Regeneron to identify and validate potential drug discovery targets and develop
fully human monoclonal antibodies against these targets. Sanofi-aventis funded
approximately $75 million of research from the collaboration&#146;s inception through
December 31, 2008 and will fund up to $100 million per year in 2009 through
2012. Sanofi-aventis also has an option to extend the discovery program for up
to an additional three years for further antibody development and preclinical
activities. We will lead the design and conduct of research activities,
including target identification and validation, antibody development, research
and preclinical activities through filing of an Investigational New Drug
Application, toxicology studies, and manufacture of preclinical and clinical
supplies. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For each
drug candidate identified under the discovery agreement, sanofi-aventis has the
option to license rights to the candidate under the license agreement. If it
elects to do so, sanofi-aventis will co-develop the drug candidate with us
through product approval. Development costs will be shared between the
companies, with sanofi-aventis generally funding drug candidate development
costs up front. We are generally responsible for reimbursing sanofi-aventis for
half of the total development costs for all collaboration products from our
share of profits from commercialization of collaboration products to the extent
they are sufficient for this purpose. Sanofi-aventis will lead commercialization
activities for products developed under the license agreement, subject to our
right to co-promote such products. The parties will equally share profits and
losses from sales within the United States. The parties will share profits
outside the United States on a sliding scale based on sales starting at 65%
(sanofi-aventis)/35% (us) and ending at 55% (sanofi-aventis)/45% (us), and will
share losses outside the United States at 55% (sanofi-aventis)/45% (us). In
addition to profit sharing, we are entitled to receive up to $250 million in
sales milestone payments, with milestone payments commencing after aggregate
annual sales outside the United States exceed $1.0 billion on a rolling 12-month
basis. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In August
2008, we entered into an agreement with sanofi-aventis to use our
<I>VelociGene</I> platform to supply sanofi-aventis with genetically modified
mammalian models of gene function and disease. Sanofi-aventis will pay us a
minimum of $21.5 million for the term of the agreement, which extends through
December 2012, for knock-out and transgenic models of gene function for target
genes identified by sanofi-aventis. Sanofi-aventis will use these models for its
internal research programs that are outside of the scope of our antibody
collaboration. </FONT></P>
<P align=left><B><FONT face=serif size=2>License Agreement with AstraZeneca
</FONT></B><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In February 2007, we entered into a non-exclusive license agreement with
AstraZeneca UK Limited that allows AstraZeneca to utilize our </FONT><I><FONT face=serif size=2>VelocImmune<SUP>&#174;</SUP></FONT></I><FONT face=serif size=2> technology in
its internal research programs to discover human monoclonal antibodies. Under
the terms of the agreement, AstraZeneca made $20.0 million annual,
non-refundable payments to us in the first quarter of 2007, 2008, and 2009.
AstraZeneca is required to make up to three additional annual payments of $20.0
million, subject to its ability to terminate the agreement after making the next
additional payment. We are entitled to receive a mid-single-digit royalty on any
future sales of antibody products discovered by AstraZeneca using our <I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2>
technology.</FONT><B><FONT face=serif size=2> </FONT></B></FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>24</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif size=2>License Agreement with Astellas
</FONT></B><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In March
2007, we entered into a non-exclusive license agreement with Astellas Pharma
Inc. that allows Astellas to utilize our </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> technology in its internal
research programs to discover human monoclonal antibodies. Under the terms of
the agreement, Astellas made $20.0 million annual, non-refundable payments to us
in the second quarter of 2007, 2008, and 2009. Astellas is required to make up
to three additional annual payments of $20.0 million, subject to its ability to
terminate the agreement after making the next additional payment. We are
entitled to receive a mid-single-digit royalty on any future sales of antibody
products discovered by Astellas using our </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> technology.</FONT></P>
<P align=left><FONT face=serif size=2><STRONG>Academic </STRONG></FONT><FONT face=serif size=2><STRONG><EM>VelocImmune</EM></STRONG><SUP><FONT face=Arial>&#174;</FONT></SUP></FONT><FONT face=serif size=2><STRONG> Investigators&#146;
Program</STRONG></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
September 2008, we entered into an agreement that will provide researchers at
Columbia University Medical Center with access to our </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> technology platform. In
March 2009, we entered into a similar agreement with The University of Texas
Southwestern Medical Center at Dallas. Under the agreements, scientists at these
academic institutions will use </FONT><I><FONT face=serif size=2>VelocImmune</FONT></I><FONT face=serif size=2> mice to generate
antibodies against their research targets and will conduct research to discover
potential human therapeutics based on the antibodies. We have an exclusive
option to license the antibodies for development and commercialization as
therapeutic or diagnostic products and will pay to the appropriate institution a
low single-digit royalty on ensuing product sales. </FONT></P>
<P align=left><B><FONT face=serif size=2>National Institutes of Health
Grant</FONT></B><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
September 2006, we were awarded a five-year grant from the National Institutes
of Health (NIH) as part of the NIH&#146;s Knockout Mouse Project. The goal of the
Knockout Mouse Project is to build a comprehensive and broadly available
resource of knockout mice to accelerate the understanding of gene function and
human diseases. We are using our </FONT><I><FONT face=serif size=2>VelociGene<SUP>&#174;</SUP></FONT></I><FONT face=serif size=2> technology to
take aim at 3,500 of the most difficult genes to target and which are not
currently the focus of other large-scale knockout mouse programs. We also agreed
to grant a limited license to a consortium of research institutions, the other
major participants in the Knockout Mouse Project, to use components of our
</FONT><I><FONT face=serif size=2>VelociGene</FONT></I><FONT face=serif size=2>
technology in the Knockout Mouse Project. We are generating a collection of
targeting vectors and targeted mouse ES cells which can be used to produce
knockout mice. These materials are available to academic researchers without
charge. We will receive a fee for each targeted ES cell line or targeting
construct made by us or the research consortium and transferred to commercial
entities. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Under the
NIH grant, as amended, we are entitled to receive a minimum of $25.3 million
over the five-year period beginning September 2006, including $1.5 million to
optimize our existing C57BL/6 ES cell line and its proprietary growth medium,
both of which are being supplied to the research consortium for its use in the
Knockout Mouse Project. We have the right to use, for any purpose, all materials
generated by us and the research consortium.</FONT></P>
<P align=left><B><U><FONT face=serif size=2>Research
Programs</FONT></U></B><B><FONT face=serif size=2>: </FONT></B></P>
<P align=left><B><I><FONT face=serif size=2>Oncology and Angiogenesis
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In many
clinical settings, positively or negatively regulating blood vessel growth could
have important therapeutic benefits, as could the repair of damaged and leaky
vessels. VEGF was the first growth factor shown to be specific for blood
vessels, by virtue of having its receptor specifically expressed on blood vessel
cells. In 1994, we discovered a second family of angiogenic growth factors,
termed angiopoietins, and we have received patents covering members of this
family. Angiopoietins include naturally occurring positive and negative
regulators of angiogenesis, as described in numerous scientific manuscripts
published by our scientists and their collaborators. Angiopoietins are being
evaluated in preclinical research by us and our academic collaborators. Our
preclinical studies have revealed that VEGF and angiopoietins normally function
in a coordinated and collaborative manner during blood vessel growth.
Manipulation of both VEGF and angiopoietins seems to be of value in either
promoting or blocking vessel growth. We have research programs focusing on
several targets in the areas of oncology and angiogenesis. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>25</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Tumors
depend on the growth of new blood vessels (a process called &#147;angiogenesis&#148;) to
support their continued growth. Therapies that block tumor angiogenesis,
specifically those that block VEGF, the key initiator of tumor angiogenesis,
recently have been validated in human cancer patients. However, anti-VEGF
approaches do not work in all patients, and many tumors can become resistant to
such therapies.</FONT><I><FONT face=serif size=2> </FONT></I><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
December 21, 2006 issue of the journal </FONT><I><FONT face=serif size=2>Nature,</FONT></I><FONT face=serif size=2> we reported data from a
preclinical study demonstrating that blocking an important cell signaling
molecule, known as Delta-like ligand 4 (Dll4), inhibited the growth of
experimental tumors by interfering with their ability to produce a functional
blood supply. The inhibition of tumor growth was seen in a variety of tumor
types, including those that were resistant to blockade of VEGF, suggesting a
novel anti-angiogenesis therapeutic approach. A fully human monoclonal antibody
to Dll4 that was discovered using our </FONT><FONT face=serif size=2><EM>VelocImmune</EM><SUP><FONT face=Arial>&#174;</FONT></SUP></FONT><FONT face=serif size=2><EM> </EM></FONT><FONT face=serif size=2>technology is being
studied in a Phase 1 clinical trial in patients with advanced
malignancies.</FONT></P>
<P align=left><B><I><FONT face=serif size=2>Metabolic and Related Diseases
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Food
intake and metabolism are regulated by complex interactions between diverse
neural and hormonal signals that serve to maintain an optimal balance between
energy intake, storage, and utilization. The hypothalamus, a small area at the
base of the brain, is critically involved in integrating peripheral signals
which reflect nutritional status and neural outputs which regulate appetite,
food seeking behaviors, and energy expenditure. Metabolic disorders, such as
type 2 diabetes, reflect a dysregulation in the systems which ordinarily tightly
couple energy intake to energy expenditure. Our preclinical research program in
this area encompasses the study of peripheral (hormonal) regulators of food
intake and metabolism in health and disease. We have identified several targets
in these therapeutic areas and are evaluating lead monoclonal antibodies in
relevant preclinical models. </FONT></P>
<P align=left><B><I><FONT face=serif size=2>Muscle Diseases and Disorders
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Muscle
atrophy occurs in many neuromuscular diseases and also when muscle is unused, as
often occurs during prolonged hospital stays and during convalescence.
Currently, physicians have few options to treat subjects with muscle atrophy or
other muscle conditions which afflict millions of people globally. Thus, a
treatment that has beneficial effects on skeletal muscle could have significant
clinical benefit. Our muscle research program is currently focused on conducting
</FONT><I><FONT face=serif size=2>in vivo</FONT></I><FONT face=serif size=2> and
</FONT><I><FONT face=serif size=2>in vitro</FONT></I><FONT face=serif size=2>
experiments with the objective of demonstrating and further understanding the
molecular pathways involved in muscle atrophy and hypertrophy, and discovering
therapeutic candidates that can modulate these pathways. We have several
molecules in late stage research and are evaluating them for possible further
development. </FONT></P>
<P align=left><B><I><FONT face=serif size=2>Other Therapeutic Areas
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We also
have research programs focusing on ophthalmology, inflammatory and immune
diseases, bone and cartilage, pain, cardiovascular diseases, and infectious
diseases. </FONT></P>
<P align=left><B><FONT face=serif size=2>General </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Developing and commercializing new medicines entails significant risk and
expense. Since inception we have not generated any significant sales or profits
from the commercialization of ARCALYST<SUP>&#174;</SUP> (rilonacept) or any of our other product candidates. Before significant
revenues from the commercialization of ARCALYST or our other product candidates
can be realized, we (or our collaborators) must overcome a number of hurdles
which include successfully completing research and development and obtaining
regulatory approval from the FDA and regulatory authorities in other countries.
In addition, the biotechnology and pharmaceutical industries are rapidly
evolving and highly competitive, and new developments may render our products
and technologies uncompetitive or obsolete.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>26</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>From inception on January 8, 1988
through September 30, 2009, we had a cumulative loss of $904.6 million. In the
absence of significant revenues from the commercialization of ARCALYST or our
other product candidates or other sources, the amount, timing, nature, and
source of which cannot be predicted, our losses will continue as we conduct our
research and development activities. We expect to incur substantial losses over
the next several years as we continue the clinical development of VEGF Trap-Eye
and ARCALYST in other indications; advance new product candidates into clinical
development from our existing research programs utilizing our technology for
discovering fully human monoclonal antibodies; continue our research and
development programs; and commercialize additional product candidates that
receive regulatory approval, if any. Also, our activities may expand over time
and require additional resources, and we expect our operating losses to be
substantial over at least the next several years. Our losses may fluctuate from
quarter to quarter and will depend on, among other factors, the progress of our
research and development efforts, the timing of certain expenses, and the amount
and timing of payments that we receive from collaborators. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
planning, execution, and results of our clinical programs are significant
factors that can affect our operating and financial results. In our clinical
programs, key events to date in 2009 and plans over the next 12 months are as
follows: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="12%"><B><FONT face=serif size=2>Clinical Program</FONT></B>&nbsp;
    </TD>
    <TD align=left width="13%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><B><FONT face=serif size=2>2009 Events to Date</FONT></B>&nbsp;
    </TD>
    <TD align=left width="31%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><B><FONT face=serif size=2>2009-10 Plans (next 12
      months)</FONT></B>&nbsp; </TD>
    <TD align=left width="32%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="25%" colSpan=2><FONT face=serif size=2>ARCALYST<SUP>&#174;&nbsp;<BR></SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      (rilonacept;&nbsp;&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; also
      known&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as IL-1
Trap)</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="36%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI>
        <P><FONT face=serif size=2>Initiated patient enrollment in the Phase 3
        program evaluating ARCALYST in the prevention of gout flares associated
        with the initiation of urate-lowering drug therapy and in the treatment
        of acute gout attacks<BR>&nbsp;</FONT></P></LI></UL></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="37%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI><FONT face=serif size=2>Continue enrollment in the Phase 3 program in
        gout</FONT>
        <LI>Report initial data from Phase 3 gout program during the first half
        of 2010<BR></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="25%" colSpan=2><FONT face=serif size=2>Aflibercept</FONT>&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>(VEGF Trap
      &#150;</FONT>&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Oncology)</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="36%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI><FONT face=serif size=2>Initiated a Phase 2 1<SUP>st</SUP><FONT face=serif> line study in</FONT></FONT>&nbsp;<FONT face=serif size=2>metastatic colorectal cancer in</FONT>&nbsp;<FONT face=serif size=2>combination with chemotherapy</FONT>
        <LI><FONT face=serif size=2>Achieved more than 80%<FONT size=3>&nbsp;</FONT><FONT face=serif size=2>enrollment in each of the
        Phase 3</FONT><FONT size=3>&nbsp;</FONT><FONT face=serif size=2>studies</FONT></FONT>
        <LI><FONT face=serif size=2>Reported results of a Phase
        2</FONT>&nbsp;<FONT face=serif size=2>single-agent study in
        symptomatic</FONT>&nbsp;<FONT face=serif size=2>malignant ascites
        (SMA)</FONT>
        <LI><FONT face=serif size=2>Discontinued a Phase 3 study in<FONT size=3>&nbsp;</FONT><FONT face=serif size=2>metastatic pancreatic cancer
        in</FONT><FONT size=3>&nbsp;</FONT><FONT face=serif size=2>combination
        with chemotherapy</FONT></FONT> <BR>&nbsp;</LI></UL></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="37%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI><FONT face=serif size=2>Continue enrollment of the Phase 3 studies
        in colorectal cancer,</FONT>&nbsp;<FONT face=serif size=2>non-small cell
        lung cancer, and</FONT>&nbsp;<FONT face=serif size=2>prostate
        cancer</FONT>
        <LI><FONT face=serif size=2>During the second half of 2010,<FONT size=3>&nbsp;</FONT><FONT face=serif size=2>an Independent Data
        Monitoring</FONT><FONT size=3>&nbsp;</FONT><FONT face=serif size=2>Committee is expected to</FONT><FONT size=3>&nbsp;</FONT><FONT face=serif size=2>conduct an interim analysis of</FONT><FONT size=3>&nbsp;</FONT><FONT face=serif size=2>the Phase 3 study
        in</FONT><FONT size=3>&nbsp;</FONT><FONT face=serif size=2>colorectal
        cancer</FONT></FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="25%" colSpan=2>
      <P><FONT face=serif size=2>VEGF Trap-Eye&nbsp;<BR></FONT><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      (intravitreal<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    injection)</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="36%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI><FONT face=serif size=2>Completed enrollment of
        patients</FONT>&nbsp;<FONT face=serif size=2>in the Phase 3 wet AMD
        program</FONT>&nbsp;<FONT face=serif size=2>(VIEW 1 and VIEW 2)</FONT>
        <LI><FONT face=serif size=2>Completed enrollment of patients<FONT size=3>&nbsp;</FONT><FONT face=serif size=2>in the Phase 2 DME
        trial</FONT></FONT>
        <LI><FONT face=serif size=2><FONT face=serif size=2>Initiated a Phase 3
        CRVO program</FONT></FONT><FONT size=3>&nbsp;<BR>&nbsp;</FONT></LI></UL></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="37%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI><FONT face=serif size=2>Continue enrollment in Phase
        3</FONT>&nbsp;<FONT face=serif size=2>CRVO trials</FONT>
        <LI><FONT face=serif size=2>Report data from Phase 2 DME<FONT size=3>&nbsp;</FONT><FONT face=serif size=2>trial during the first half
        of 2010</FONT></FONT>
        <LI><FONT face=serif size=2>Report data from VIEW 1
        and</FONT>&nbsp;<FONT face=serif size=2>VIEW 2 trials in the
        fourth</FONT>&nbsp;<FONT face=serif size=2>quarter of
    2010</FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="25%" colSpan=2>
      <P><FONT face=serif size=2>Monoclonal<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT face=serif size=2>Antibodies</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="36%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI><FONT face=serif size=2>Initiated a Phase 1 trial
        for</FONT>&nbsp;<FONT face=serif size=2>REGN475 (anti-NGF) in
        healthy</FONT>&nbsp;<FONT face=serif size=2>volunteers</FONT>
        <LI><FONT face=serif size=2>Initiated a Phase 1 trial for
        REGN421(anti-Dll4) in oncology</FONT>
        <LI><FONT face=serif size=2>Initiated a dose ranging study for REGN475
        in osteoarthritis of the knee</FONT></LI></UL></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="37%" colSpan=2>
      <UL style="MARGIN-LEFT: 13pt">
        <LI><FONT face=serif size=2>Report data from a Phase 1 trial of REGN88
        (anti-IL-6R) in rheumatoid arthritis</FONT>
        <LI><FONT face=serif size=2>Initiate a dose-ranging study for REGN88 in
        rheumatoid arthritis</FONT>
        <LI><FONT face=serif size=2>Initiate additional Phase 2 trials for
        REGN475 in pain indications</FONT>
        <LI><FONT face=serif size=2>Report data from the study of REGN475 in
        osteoarthritis of the knee during the first half of 2010</FONT>
        <LI><FONT face=serif size=2>Advance additional antibody candidate(s)
        into clinical&nbsp;<FONT face=serif size=2>development</FONT></FONT></LI></UL></TD></TR></TABLE></DIV>
<P align=center><FONT face=serif size=2>27</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif size=2>Results of Operations</FONT></B></P>
<P align=left><B><I><FONT face=serif size=2>Three Months Ended September 30,
2009 and 2008 </FONT></I></B></P>
<P align=left><I><FONT face=serif size=2>Net Loss: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron
reported a net loss of $1.0 million, or $0.01 per share (basic and diluted), for
the third quarter of 2009 compared to a net loss of $19.1 million, or $0.24 per
share (basic and diluted), for the third quarter of 2008. The decrease in our
net loss was principally due to higher contract research and development revenue
in connection with our antibody collaboration with sanofi-aventis, and
receipt of a $20.0 million research progress payment from Bayer HealthCare,
partially offset by higher research and development expenses, as detailed
below.</FONT></P>
<P align=left><I><FONT face=serif size=2>Revenues: </FONT></I></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Revenues for the three months ended
September 30, 2009 and 2008 consist of the following: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="91%"><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="4%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0><FONT face=serif size=2>Contract research &amp; development revenue</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="4%" bgColor=#c0c0c0 colSpan=2></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Sanofi-aventis</FONT></TD>
    <TD align=right width="1%">&nbsp;</TD>
    <TD align=right width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="2%"><FONT face=serif size=2>68.5</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>42.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Bayer HealthCare</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>12.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>9.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Other</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>1.8</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>1.9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total contract research &amp; development
      revenue</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>82.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>52.9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%"><FONT face=serif size=2>Research progress
      payment</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>20.0</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0><FONT face=serif size=2>Technology licensing revenue</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>10.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>10.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%"><FONT face=serif size=2>Net product
    sales</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>5.0</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>2.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total revenue</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>117.5</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>65.6</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The contract research and development revenue we earn from sanofi-aventis, as
detailed below, consists primarily of reimbursement for research and development
expenses and partly of the recognition of revenue related to non-refundable
up-front payments of $105.0 million related to the aflibercept collaboration and
$85.0 million related to the antibody collaboration. </FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD noWrap align=left width="28%" ></TD>
    <TD align=left width="63%" >&nbsp;</TD>
    <TD align=left width="1%" ></TD>
    <TD noWrap align=center width="7%"  colSpan=5><STRONG>Three
      months ended</STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="28%"><B><FONT face=serif size=2>Sanofi-aventis Contract Research
      &amp; Development Revenue</FONT></B></TD>
    <TD align=left width="63%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>September 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" colSpan=2><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><FONT face=serif size=2></FONT><STRONG>2009</STRONG>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%"  colSpan=2>&nbsp; <STRONG>2008</STRONG>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Aflibercept:</FONT>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=center width="3%" bgColor=#c0c0c0 colSpan=2><B><FONT face=serif size=2></FONT></B></TD>
    <TD align=center width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=center width="3%" bgColor=#c0c0c0 colSpan=2><B><FONT face=serif size=2></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Regeneron expense reimbursement</FONT></TD>
    <TD align=right width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>7.0</FONT></TD>
    <TD align=right width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>7.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Recognition of deferred revenue related to up-front
    payments</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>2.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>2.1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total aflibercept</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>9.5</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>9.4</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Antibody:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Regeneron expense reimbursement</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>55.7</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>29.5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Recognition of deferred revenue related to up-front
    payment</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>2.6</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>2.6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Recognition of revenue related to </FONT><I><FONT face=serif size=2>VelociGene<SUP>&#174;</SUP></FONT></I><I><FONT face=serif size=2><SUP>
      </SUP></FONT></I><FONT face=serif size=2>agreement</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>0.7</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>0.5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif size=2>Total antibody</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>59.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>32.6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#ffffff colSpan=2><FONT face=serif size=2>Total sanofi-aventis contract research &amp; development
      revenue</FONT></TD>
    <TD align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>68.5</FONT></TD>
    <TD align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#ffffff><FONT face=serif size=2>42.0</FONT>
</TD></TR></TABLE>


<BR>
<P align=justify><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Sanofi-aventis&#146; reimbursement of Regeneron&#146;s aflibercept expenses decreased in
the third quarter of 2009, compared to the same period in 2008, primarily due to
lower costs related to internal research activities, partially offset by higher
costs related to manufacturing aflibercept clinical supplies. Recognition of
deferred revenue related to sanofi-aventis&#146; up-front aflibercept payments
increased in the third quarter of 2009 compared to the same period in 2008 due
to shortening the estimated performance period over which this deferred revenue
is being recognized, effective in the fourth quarter of 2008. As of September
30, 2009, $45.0 million of the original $105.0 million of up-front payments
related to aflibercept was deferred and will be recognized as revenue in future
periods.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2009, sanofi-aventis&#146; reimbursement of Regeneron&#146;s antibody
expenses consisted of $25.7 million under the discovery agreement and $30.0
million of development costs under the license agreement, compared to $24.1
million and $5.4 million, respectively, in the third quarter of 2008. The higher
reimbursement amounts in the third quarter of 2009 compared to the same period
in 2008 were due to an increase in our research activities conducted under the
discovery agreement and increases in our development activities for antibody
candidates, including REGN88, REGN421, and REGN475, under the license agreement.
</FONT></P>
<P align=center><FONT face=serif size=2>28</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Recognition of deferred revenue under the antibody collaboration related
to sanofi-aventis&#146; $85.0 million up-front payment. As of September 30, 2009,
$65.7 million of this up-front payment was deferred and will be recognized as
revenue in future periods. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
described above, in August 2008, we entered into a separate </FONT><I><FONT face=serif size=2>VelociGene<SUP>&#174;</SUP></FONT></I><FONT face=serif size=2> agreement with
sanofi-aventis. For the three months ended September 30, 2009, we recognized
$0.7 million of revenue related to this agreement. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
contract research and development revenue we earn from Bayer HealthCare, as
detailed below, consists of cost sharing of Regeneron VEGF Trap-Eye development
expenses and recognition of deferred revenue related to a non-refundable $75.0
million up-front payment and $20.0 million non-substantive milestone payment.
</FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="91%" colSpan=2></TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>Three months ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="27%"><B><FONT face=serif size=2>Bayer HealthCare Contract Research
      &amp; Development Revenue</FONT></B></TD>
    <TD align=left width="64%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>September 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" colSpan=2><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Cost-sharing of Regeneron VEGF Trap-Eye development
    expenses</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>9.7</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>5.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" colSpan=2><FONT face=serif size=2>Recognition
      of deferred revenue related to up-front and non-substantive milestone payments</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>2.5</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%"><FONT face=serif size=2>3.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="91%" bgColor=#c0c0c0 colSpan=2>&nbsp; &nbsp;<FONT face=serif size=2>Total Bayer HealthCare contract research &amp;
      development revenue</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>12.2</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>9.0</FONT></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2009, cost-sharing of Regeneron VEGF Trap-Eye development
expenses increased, compared to the same period in 2008, primarily due to higher
clinical development costs in connection with our VIEW 1 trial in wet AMD, Phase
2 trial in DME, and Phase 3 trial in CRVO. Recognition of deferred revenue
related to Bayer&#146;s up-front and milestone payments decreased in the third
quarter of 2009 compared to the same period in 2008 due to an extension of the
estimated performance period over which this deferred revenue is being
recognized, effective in the fourth quarter of 2008. As of September 30, 2009,
$59.3 million of the up-front licensing and non-substantive milestone payments was deferred and
will be recognized as revenue in future periods.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Other
contract research and development revenue in the third quarter of 2009 and 2008
includes $1.4 million and $1.2 million, respectively, in connection with our
five-year grant from the NIH, which we were awarded in September 2006 as part of
the NIH&#146;s Knockout Mouse Project. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In July
2009, we received a $20.0 million substantive milestone payment from Bayer
HealthCare in connection with the dosing of the first patient in a Phase 3 trial
of VEGF Trap-Eye in CRVO. The payment was recognized in revenues as a research
progress payment for the three months ended September 30, 2009.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with our </FONT><I><FONT face=serif size=2>VelocImmune<SUP>&#174;</SUP></FONT></I><FONT face=serif size=2> license
agreements with AstraZeneca and Astellas, each of the $20.0 million annual,
non-refundable payments are deferred upon receipt and recognized as revenue
ratably over approximately the ensuing year of each agreement. In the third
quarter of both 2009 and 2008, we recognized $10.0 million of technology
licensing revenue related to these agreements. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For the
three months ended September 30, 2009, we recognized as revenue $5.0 million of
ARCALYST<SUP><FONT face=serif>&#174;</FONT></SUP></FONT><FONT face=serif size=2>
(rilonacept) net product sales for which both the right of return no longer
exists and rebates can be reasonably estimated, compared to $2.7 million for the
same period in 2008. At September 30, 2009, deferred revenue related to ARCALYST
net product sales totaled $5.0 million. </FONT></P>
<P align=justify><I><FONT face=serif size=2>Expenses:</FONT></I><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total
operating expenses increased to $118.7 million in the third quarter of 2009 from
$83.5 million in the same period of 2008. Our average headcount increased to 998
in the third quarter of 2009 from 851 in the same period of 2008, principally as
a result of our expanding research and development activities that are primarily
attributable to the sanofi-aventis antibody collaboration.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>29</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Operating
expenses in the third quarter of 2009 and 2008 include a total of $7.5 million
and $8.2 million, respectively, of non-cash compensation expense related to
employee stock option and restricted stock awards (Non-cash Compensation
Expense), as detailed below: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2></TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="19%" colSpan=8><B><FONT face=serif size=2>For the three months ended September
      30, 2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2></TD>
    <TD align=left width="1%"></TD>
    <TD noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>Expenses before<BR>inclusion of Non-cash</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=center width="6%" colSpan=2><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD align=left width="75%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=center width="3%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="6%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="8%" colSpan=2><B><FONT face=serif size=2>Expenses
      as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="6%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=2><B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>100.8</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>4.6</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="7%" bgColor=#c0c0c0>&nbsp;<FONT face=serif size=2>105.4</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2><FONT face=serif size=2>Selling,
      general, and administrative</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>9.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>2.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="7%"><FONT face=serif size=2>12.8</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Cost of goods sold</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>0.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="7%" bgColor=#c0c0c0><FONT face=serif size=2>0.5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Total operating expenses</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT face=serif size=2>111.2</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%"><FONT face=serif size=2>7.5</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="7%">&nbsp;<FONT face=serif size=2>118.7</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=11>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="19%" colSpan=8><B><FONT face=serif size=2>For the three months ended September
      30, 2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2></TD>
    <TD align=left width="1%"></TD>
    <TD align=center width="3%" colSpan=2><B><FONT face=serif size=2>Expenses
      before<BR>inclusion of Non-cash</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="6%" colSpan=2><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="1%"></TD>
    <TD align=center width="7%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD align=left width="75%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=center width="3%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=center width="6%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=center width="8%" colSpan=2><B><FONT face=serif size=2>Expenses
      as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2>&nbsp; <B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="6%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="8%" colSpan=2>&nbsp; <B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>67.1</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>5.0</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="7%" bgColor=#c0c0c0><FONT face=serif size=2>72.1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2><FONT face=serif size=2>Selling,
      general, and administrative</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>7.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT face=serif size=2>3.2</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="7%"><FONT face=serif size=2>11.1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Cost of goods sold</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>0.3</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="7%" bgColor=#c0c0c0><FONT face=serif size=2>0.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Total operating expenses</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT face=serif size=2>75.3</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%"><FONT face=serif size=2>8.2</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="7%"><FONT face=serif size=2>83.5</FONT></TD></TR></TABLE>
</DIV><BR>
<P align=left><I><FONT face=serif size=2>Research and Development Expenses:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Research and
development expenses increased to $105.4 million in the third quarter of 2009
from $72.1 million in the same period of 2008. The following table summarizes
the major categories of our research and development expenses for the three
months ended September 30, 2009 and 2008: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="87%" colSpan=2></TD>
    <TD align=left width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>For the three months ended</FONT></B></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="10%"><FONT face=serif size=2><STRONG>Research and Development Expenses</STRONG></FONT></TD>
    <TD align=left width="77%" >&nbsp;</TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="7%" colSpan=5><B><FONT face=serif size=2>September 30,</FONT></B></TD>
    <TD align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" colSpan=2><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="3%" colSpan=2><B><FONT face=serif size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Payroll and benefits (1)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>24.5</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>22.5</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT>
    </TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>2.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" colSpan=2><FONT face=serif size=2>Clinical
      trial expenses</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>29.4</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>14.7</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="2%"><FONT face=serif size=2>14.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Clinical manufacturing costs (2)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>18.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>13.8</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>4.2</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" colSpan=2><FONT face=serif size=2>Research and
      preclinical development costs</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>11.1</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>8.7</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="2%"><FONT face=serif size=2>2.4</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Occupancy and other operating costs</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>10.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>8.8</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>1.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" colSpan=2><FONT face=serif size=2>Cost-sharing
      of Bayer HealthCare VEGF</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trap-Eye development
      expenses (3)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>3.6</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>8.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total research and
      development</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT face=serif size=2>105.4</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT face=serif size=2>72.1</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT face=serif size=2>33.3</FONT></TD></TR></TABLE>
</DIV><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face=serif size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face=serif size=2>Includes $3.9 million and $4.3
      million of Non-cash Compensation Expense for the three months ended
      September 30, 2009 and 2008, respectively.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=serif size=2>(2)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face=serif size=2>Represents the full cost of
      manufacturing drug for use in research, preclinical development, and
      clinical trials, including related payroll and benefits, Non-cash
      Compensation Expense, manufacturing materials and supplies, depreciation,
      and occupancy costs of our Rensselaer manufacturing facility. Includes
      $0.7 million of Non-cash Compensation Expense for both the three months
      ended September 30, 2009 and 2008.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=serif size=2>(3)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face=serif size=2>Under our collaboration with
      Bayer HealthCare, in periods when Bayer HealthCare incurs VEGF Trap-Eye
      development expenses, we also recognize, as additional research and
      development expense, the portion of Bayer HealthCare&#146;s VEGF Trap-Eye
      development expenses that we are obligated to reimburse. Bayer HealthCare
      provides us with estimated VEGF Trap-Eye development expenses for the most
      recent interim fiscal quarter. Bayer HealthCare&#146;s estimate is reconciled
      to its actual expenses for such quarter in the subsequent interim quarter
      and our portion of its VEGF Trap-Eye development expenses that we are
      obligated to reimburse is adjusted
accordingly.</FONT></P></TD></TR></TABLE>
<P align=center><FONT face=serif size=2>30</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Payroll
and benefits increased principally due to the increase in employee headcount, as
described above. Clinical trial expenses increased due primarily to higher costs
related to our clinical development programs for (i) VEGF Trap-Eye, including
our VIEW 1 trial in wet AMD, Phase 2 trial in DME, and recently initiated Phase
3 trial in CRVO, (ii) ARCALYST, related to our Phase 3 clinical development
program in gout, and (iii) monoclonal antibodies, primarily related to REGN475
for the treatment of pain. Clinical manufacturing costs increased due to higher
costs related to manufacturing clinical supplies of monoclonal antibodies.
Research and preclinical development costs increased primarily due to higher
costs associated with our antibody programs. Occupancy and other operating costs
increased principally in connection with our higher headcount and expanded
research and development activities. Cost-sharing of Bayer HealthCare&#146;s VEGF
Trap-Eye development expenses increased primarily due to higher costs in
connection with the VIEW 2 trial in wet AMD, which is being conducted by Bayer
HealthCare.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We budget
our research and development costs by expense category, rather than by project.
We also prepare estimates of research and development costs for projects in
clinical development, which include direct costs and allocations of certain
costs such as indirect labor, Non-cash Compensation Expense, and manufacturing
and other costs related to activities that benefit multiple projects, and, under
our collaboration with Bayer HealthCare, the portion of Bayer HealthCare&#146;s VEGF
Trap-Eye development expenses that we are obligated to reimburse. Our estimates
of research and development costs for clinical development programs are shown
below: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><B><FONT face=serif size=2></FONT></B>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="9%" colSpan=5><B><FONT face=serif size=2>For the three months ended</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><STRONG><FONT size=2>Project Costs</FONT></STRONG></TD>
    <TD noWrap align=left width="79%" >&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>September
      30,</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=center width="5%" colSpan=3><FONT size=+0>&nbsp;<STRONG><FONT size=2>Increase</FONT></STRONG> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2009</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2008</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>(Decrease)</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>ARCALYST<SUP>&#174; </SUP>(rilonacept)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>15.5</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>9.7</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>5.8</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>Aflibercept</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>6.1</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>6.6</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>(0.5</FONT></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>VEGF Trap-Eye</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>29.9</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>18.7</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>11.2</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>REGN88</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>10.0</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>5.4</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>4.6</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>REGN421 and REGN475</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>9.5</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>9.5</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>Other
      research programs &amp; unallocated costs</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>34.4</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>31.7</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT size=+0><FONT face=serif size=2>2.7</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total
      research and development expenses</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>105.4</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>72.1</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>33.3</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE>
</DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Drug
development and approval in the United States is a multi-step process regulated
by the FDA. The process begins with discovery and preclinical evaluation,
leading up to the submission of an IND to the FDA which, if successful, allows
the opportunity for study in humans, or clinical study, of the potential new
drug. Clinical development typically involves three phases of study: Phase 1, 2,
and 3. The most significant costs in clinical development are in Phase 3
clinical trials, as they tend to be the longest and largest studies in the drug
development process. Following successful completion of Phase 3 clinical trials
for a biological product, a biologics license application (or BLA) must be
submitted to, and accepted by, the FDA, and the FDA must approve the BLA prior
to commercialization of the drug. It is not uncommon for the FDA to request
additional data following its review of a BLA, which can significantly increase
the drug development timeline and expenses. We may elect either on our own, or
at the request of the FDA, to conduct further studies that are referred to as
Phase 3B and 4 studies. Phase 3B studies are initiated and either completed or
substantially completed while the BLA is under FDA review. These studies are
conducted under an IND. Phase 4 studies, also referred to as post-marketing
studies, are studies that are initiated and conducted after the FDA has approved
a product for marketing. In addition, as discovery research, preclinical
development, and clinical programs progress, opportunities to expand development
of drug candidates into new disease indications can emerge. We may elect to add
such new disease indications to our development efforts (with the approval of
our collaborator for joint development programs), thereby extending the period
in which we will be developing a product. For example, we, and our collaborators
where applicable, continue to explore further development of ARCALYST,
aflibercept, and VEGF Trap-Eye in different disease indications. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There are
numerous uncertainties associated with drug development, including uncertainties
related to safety and efficacy data from each phase of drug development,
uncertainties related to the enrollment and performance of clinical trials,
changes in regulatory requirements, changes in the competitive landscape
affecting a product candidate, and other risks and uncertainties described in
Part II, Item 1A, &#147;Risk Factors&#148; under &#147;Risks Related to ARCALYST<SUP>&#174;</SUP>
(rilonacept) and the Development of Our Product Candidates,&#148; &#147;Regulatory and
Litigation Risks,&#148; and &#147;Risks Related to Commercialization of Products.&#148; The
lengthy process of seeking FDA approvals, and subsequent compliance with
applicable statutes and regulations, require the expenditure of substantial
resources. Any failure by us to obtain, or delay in obtaining, regulatory
approvals could materially adversely affect our business.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>31</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For these
reasons and due to the variability in the costs necessary to develop a product
and the uncertainties related to future indications to be studied, the estimated
cost and scope of the projects, and our ultimate ability to obtain governmental
approval for commercialization, accurate and meaningful estimates of the total
cost to bring our product candidates to market are not available. Similarly, we
are currently unable to reasonably estimate if our product candidates will
generate material product revenues and net cash inflows. In 2008, we received
FDA approval for ARCALYST<SUP>&#174;</SUP> (rilonacept) for the treatment of CAPS, a group of rare, inherited
auto-inflammatory diseases that affect a very small group of people. We project
to ship approximately $20 million of ARCALYST to our U.S. distributors in 2009.
</FONT><I><FONT face=serif size=2></FONT></I></P>
<P align=justify><I><FONT face=serif size=2>Selling, General, and Administrative
Expenses: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Selling,
general, and administrative expenses increased to $12.8 million in the third
quarter of 2009 from $11.1 million in the same period of 2008 due primarily to
(i) higher compensation and facility-related expenses due primarily to increases
in administrative headcount to support our expanded research and development
activities, (ii) higher patent-related costs, (iii) higher professional fees
related to various corporate matters, and (iv) higher patient assistance costs
related to ARCALYST,. These increases were partially offset by lower market
research costs related to various programs and a decrease in recruitment costs
for administrative headcount.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Cost of Goods Sold: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2008, we began recognizing revenue and cost of goods sold from
product sales of ARCALYST. We began capitalizing inventory costs associated with
commercial supplies of ARCALYST subsequent to receipt of marketing approval from
the FDA in February 2008. Costs for manufacturing supplies of ARCALYST prior to
receipt of FDA approval were recognized as research and development expenses in
the period that the costs were incurred. Therefore, these costs are not being
included in cost of goods sold when revenue is recognized from the sale of those
supplies of ARCALYST. Cost of goods sold for the third quarter of 2009 was $0.5
million, compared to $0.3 million for the same period of 2008, and consisted
primarily of royalty and other period costs related to ARCALYST commercial
supplies. </FONT></P>
<P align=justify><I><FONT face=serif size=2>Other Income and Expense:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Investment income decreased to $0.9 million in the third quarter of 2009
from $3.7 million in the comparable quarter of 2008. The decrease in investment
income was due to lower yields on, and lower balances of, cash and marketable
securities in the first quarter of 2009 compared to the same quarter of 2008.
Interest expense decreased to $0.6 million in the third quarter of 2009 from
$1.8 million in the comparable quarter of 2008. Interest expense in 2009 was
attributable to the imputed interest portion of payments to our landlord,
commencing in the third quarter of 2009, to lease newly constructed laboratory
and office facilities in Tarrytown, New York. Interest expense in the third
quarter of 2008 related to $200.0 million of formerly outstanding 5.5%
Convertible Senior Subordinated Notes which we either repurchased or repaid in
full during 2008. During the second and third quarters of 2008, we repurchased a
total of $82.5 million in principal amount of these convertible notes for $83.3
million. In connection with the repurchases, we recognized a $7 thousand loss on
early extinguishment of debt in the third quarter of 2008.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Income Tax Expense</FONT></I><FONT face=serif size=2>:&nbsp;</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2008, we implemented a tax planning strategy which resulted in
the utilization of certain net operating loss carry-forwards for tax purposes
that would otherwise have expired over the next several years. As a result, we
incurred income tax expense of $3.1 million, which relates to U.S. Federal and
New York State alternative minimum tax and includes $0.2 million of interest and
penalties.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>32</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Nine Months Ended September 30,
2009 and 2008 </FONT></I></B></P>
<P align=justify><I><FONT face=serif size=2>Net Loss: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron
reported a net loss of $31.3 million, or $0.39 per share (basic and diluted),
for the first nine months of 2009 compared to a net loss of $49.6 million, or
$0.63 per share (basic and diluted), for the same period of 2008. The decrease
in our net loss was principally due to higher contract research and development
revenue in connection with our antibody collaboration with sanofi-aventis,
receipt of a $20.0 million research progress payment from Bayer HealthCare,
and higher ARCALYST<SUP>&#174;</SUP> (rilonacept) sales, partially offset by higher research and development
expenses, as detailed below.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Revenues: </FONT></I></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Revenues for the nine months ended
September 30, 2009 and 2008 consist of the following: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="70%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="89%"><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Contract research &amp; development revenue</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sanofi-aventis</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>178.9</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>116.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bayer HealthCare</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>34.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>28.2</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>5.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>5.4</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Total contract research &amp; development revenue</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>219.1</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>149.9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>Research progress
      payment</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>20.0</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Technology licensing revenue</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>30.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>30.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>Net product
    sales</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>13.4</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>2.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Total revenue</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>282.5</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>182.6</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The contract and research
development revenue we earn from sanofi-aventis, as detailed below, consists
primarily of reimbursement for research and development expenses and partly of
the recognition of revenue related to non-refundable up-front payments of $105.0
million related to the aflibercept collaboration and $85.0 million related to
the antibody collaboration. </FONT></P>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="89%" colSpan=2><FONT size=+0><B><FONT face=serif size=2></FONT></B></FONT>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>Nine months ended</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="10%"><FONT size=+0><B><FONT face=serif size=2>Sanofi-aventis
      Contract Research &amp; Development Revenue</FONT></B></FONT></TD>
    <TD align=left width="79%" >&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>September
      30,</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" colSpan=2><FONT size=+0><FONT face=serif size=2><STRONG><EM>(In millions)</EM></STRONG></FONT></FONT></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2009</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2008</FONT></B></FONT></TD></TR>
  <TR>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=2>Aflibercept:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#ffffff colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regeneron expense
      reimbursement</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>21.6</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>29.3</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recognition of
      deferred revenue related to up-front payments</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>7.4</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>6.2</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#ffffff colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Total aflibercept</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>29.0</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>35.5</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>Antibody:</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#ffffff colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regeneron expense
      reimbursement</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>139.8</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>72.4</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recognition of
      deferred revenue related to up-front payment</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>7.9</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>7.9</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#ffffff colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recognition of revenue related
      to <I>VelociGene<SUP>&#174;</SUP></I> agreement</FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>2.2</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>0.5</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Total antibody</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>149.9</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>80.8</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#ffffff colSpan=2><FONT size=+0><FONT face=serif size=2>Total sanofi-aventis contract research &amp; development
      revenue</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>178.9</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>116.3</FONT></FONT></TD></TR></TABLE>
<BR>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Sanofi-aventis&#146; reimbursement of
Regeneron&#146;s aflibercept expenses decreased in the first nine months of 2009,
compared to the same period in 2008, primarily due to lower costs related to
internal research activities and manufacturing aflibercept clinical supplies.
Recognition of deferred revenue related to sanofi-aventis&#146; up-front aflibercept
payments increased in the first nine months of 2009 compared to the same period
in 2008 due to shortening the estimated performance period over which this
deferred revenue is being recognized, effective in the fourth quarter of
2008.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
first nine months of 2009, sanofi-aventis&#146; reimbursement of Regeneron&#146;s antibody
expenses consisted of $76.7 million under the discovery agreement and $63.1
million of development costs under the license agreement, compared to $56.5
million and $15.9 million, respectively, in the first nine months of 2008. The
higher reimbursement amounts in the first nine months of 2009 compared to the
same period in 2008 were due to an increase in our research activities conducted
under the discovery agreement and increases in our development activities for
antibody candidates, including REGN88, REGN421, and REGN475, under the license
agreement. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>33</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
described above, in August 2008, we entered into a separate
<I>VelociGene<SUP>&#174;</SUP> </I>agreement with sanofi-aventis. For the nine months
ended September 30, 2009, we recognized $2.2 million of revenue related to this
agreement, compared to $0.5 million for the same period in 2008. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
contract research and development revenue we earn from Bayer HealthCare, as
detailed below, consists partly of cost sharing of Regeneron VEGF Trap-Eye
development expenses and partly of recognition of deferred revenue related to a
non-refundable $75.0 million up-front payment and $20.0 million non-substantive
milestone payment. </FONT></P>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="89%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>Nine months ended</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT size=+0><B><FONT face=serif size=2>Bayer HealthCare
      Contract Research &amp; Development Revenue</FONT></B></FONT></TD>
    <TD align=left width="88%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>September
      30,</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" colSpan=2><FONT size=+0><B><I><FONT face=serif size=2>(In millions)</FONT></I></B></FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2009</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2008</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>Cost-sharing of Regeneron VEGF Trap-Eye development
      expenses</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>27.5</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>18.3</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" colSpan=2><FONT size=+0><FONT face=serif size=2>Recognition of deferred revenue related to up-front and non-substantive milestone
      payments</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>7.4</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>9.9</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Total Bayer
      HealthCare contract research &amp; development revenue</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>34.9</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>28.2</FONT></FONT></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
first nine months of 2009, cost-sharing of Regeneron VEGF Trap-Eye development
expenses increased, compared to the same period in 2008, primarily due to higher
clinical development costs in connection with our VIEW 1 trial in wet AMD, Phase
2 trial in DME, and Phase 3 trial in CRVO. Recognition of deferred revenue
related to Bayer&#146;s up-front and non-substantive milestone payments decreased in the first nine
months of 2009 compared to the same period in 2008 due to an extension of the
estimated performance period over which this deferred revenue is being
recognized, effective in the fourth quarter of 2008.</FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Other contract research and
development revenue in the first nine months of 2009 and 2008 includes $4.4
million and $3.6 million, respectively, in connection with our five-year grant
from the NIH, which we were awarded in September 2006 as part of the NIH&#146;s
Knockout Mouse Project. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In July
2009, we received a $20.0 million substantive milestone payment from Bayer
HealthCare in connection with the dosing of the first patient in a Phase 3 trial
of VEGF Trap-Eye in CRVO. The payment was recognized in revenues as a research
progress payment for the nine months ended September 30, 2009.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with our <I>VelocImmune<SUP>&#174;</SUP></I> license agreements with
AstraZeneca and Astellas, each of the $20.0 million annual, non-refundable
payments are deferred upon receipt and recognized as revenue ratably over
approximately the ensuing year of each agreement. In the first nine months of
both 2009 and 2008, we recognized $30.0 million of technology licensing revenue
related to these agreements. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For the
nine months ended September 30, 2009, we recognized as revenue $13.4 million of
ARCALYST<SUP>&#174;</SUP> (rilonacept) net product sales for which both the right of
return no longer exists and rebates can be reasonably estimated, compared to
$2.7 million for the same period in 2008.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Expenses:</FONT></I><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total
operating expenses increased to $317.2 million in the first nine months of 2009
from $236.3 million in the same period of 2008. Our average headcount increased
to 967 in the first nine months of 2009 from 778 in the same period of 2008
principally as a result of our expanding research and development activities
that are primarily attributable to the sanofi-aventis antibody
collaboration.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>34</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Operating
expenses for the first nine months of 2009 and 2008 include a total of $22.6
million and $24.7 million, respectively, of Non-cash Compensation Expense, as
detailed below: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="85%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="14%" colSpan=8><B><FONT face=serif size=2>For the nine months ended September
      30, 2009</FONT></B></TD></TR>
  <TR>
    <TD align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><STRONG><FONT size=2>Expenses
      before</FONT></STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>inclusion of Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD align=left width="84%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Expenses as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>266.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>14.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>280.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT face=serif size=2>Selling,
      general, and administrative</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>27.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>8.6</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>35.9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Cost of goods sold</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1.3</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating
    expenses</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=2>294.6</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=2>22.6</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=2>317.2</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=11>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="14%" colSpan=8><B><FONT face=serif size=2>For the nine months ended September
      30, 2008</FONT></B></TD></TR>
  <TR>
    <TD align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><STRONG><FONT size=2>Expenses
      before</FONT></STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>inclusion of Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD align=left width="84%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Expenses as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>185.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>14.8</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>200.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT face=serif size=2>Selling,
      general, and administrative</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>25.8</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>9.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>35.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Cost of goods sold</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>0.3</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>0.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating
    expenses</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=2>211.6</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=2>24.7</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=2>236.3</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT face=serif size=2>Research and Development Expenses:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Research
and development expenses increased to $280.0 million in the first nine months of
2009 from $200.3 million in the same period of 2008. The following table
summarizes the major categories of our research and development expenses for the
nine months ended September 30, 2009 and 2008: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="85%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>For the nine months ended</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT size=+0><STRONG><FONT size=2>Research and Development
      Expenses</FONT></STRONG></FONT></TD>
    <TD align=left width="84%"><FONT size=+0></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>September
      30,</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT size=+0><B><I><FONT face=serif size=2>(In millions)</FONT></I></B></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2009</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2008</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>Increase</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>Payroll and benefits (1)</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>71.0</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>61.4</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>9.6</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT size=+0><FONT face=serif size=2>Clinical trial expenses</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>78.9</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>35.2</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>43.7</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>Clinical manufacturing costs (2)</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>46.0</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>40.3</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>5.7</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT size=+0><FONT face=serif size=2>Research and preclinical development costs</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>29.5</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>21.6</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>7.9</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>Occupancy and other operating costs</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>27.9</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>22.8</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>5.1</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" colSpan=2><FONT size=+0><FONT face=serif size=2>Cost-sharing of Bayer HealthCare VEGF</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#ffffff colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trap-Eye
      development expenses (3)</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>26.7</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>19.0</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT face=serif size=2>7.7</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="85%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total research and
      development</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>280.0</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>200.3</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>79.7</FONT></FONT></TD></TR></TABLE></DIV><BR>
<TABLE style="FONT-SIZE: 10pt; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face=serif size=2>(1)</FONT></TD>
    <TD noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD width="100%"><FONT face=serif size=2>Includes $11.8 million and $12.6
      million of Non-cash Compensation Expense for the nine months ended
      September 30, 2009 and 2008, respectively.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=serif size=2>(2)</FONT></TD>
    <TD noWrap></TD>
    <TD width="100%"><FONT face=serif size=2>Represents the full cost of
      manufacturing drug for use in research, preclinical development, and
      clinical trials, including related payroll and benefits, Non-cash
      Compensation Expense, manufacturing materials and supplies, depreciation,
      and occupancy costs of our Rensselaer manufacturing facility. Includes
      $2.2 million of Non-cash Compensation Expense for both the nine months
      ended September 30, 2009 and 2008.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=serif size=2>(3)</FONT></TD>
    <TD noWrap></TD>
    <TD width="100%"><FONT face=serif size=2>Under our collaboration with
      Bayer HealthCare, in periods when Bayer HealthCare incurs VEGF Trap-Eye
      development expenses, we also recognize, as additional research and
      development expense, the portion of Bayer HealthCare&#146;s VEGF Trap-Eye
      development expenses that we are obligated to reimburse. Bayer HealthCare
      provides us with estimated VEGF Trap-Eye development expenses for the most
      recent interim fiscal quarter. Bayer HealthCare&#146;s estimate is reconciled
      to its actual expenses for such quarter in the subsequent interim quarter
      and our portion of its VEGF Trap-Eye development expenses that we are
      obligated to reimburse is adjusted accordingly.</FONT></TD></TR></TABLE>
<P align=center><FONT face=serif size=2>35</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Payroll
and benefits increased principally due to the increase in employee headcount, as
described above. Clinical trial expenses increased due primarily to higher costs
related to our clinical development programs for (i) VEGF Trap-Eye, including
our VIEW 1 trial in wet AMD, Phase 2 trial in DME, and Phase 3 trial in CRVO,
(ii) ARCALYST, related to our Phase 3 clinical development program in gout, and
(iii) monoclonal antibodies, primarily related to REGN88 in rheumatoid arthritis
and REGN475 for the treatment of pain. Clinical manufacturing costs increased
due to higher costs related to manufacturing clinical supplies of ARCALYST and
monoclonal antibodies, partially offset by lower costs related to manufacturing
aflibercept clinical supplies. Research and preclinical development costs
increased primarily due to higher costs associated with our antibody programs.
Occupancy and other operating costs increased principally in connection with our
higher headcount and expanded research and development activities. Cost-sharing
of Bayer HealthCare&#146;s VEGF Trap-Eye development expenses increased primarily due
to higher costs in connection with the VIEW 2 trial in wet AMD, which is being
conducted by Bayer HealthCare.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We budget
our research and development costs by expense category, rather than by project.
We also prepare estimates of research and development costs for projects in
clinical development, which include direct costs and allocations of certain
costs such as indirect labor, Non-cash Compensation Expense, and manufacturing
and other costs related to activities that benefit multiple projects, and, under
our collaboration with Bayer HealthCare, the portion of Bayer HealthCare&#146;s VEGF
Trap-Eye development expenses that we are obligated to reimburse. Our estimates
of research and development costs for clinical development programs (including
ARCALYST for the treatment of CAPS prior to receipt of marketing approval from
the FDA in February 2008) are shown below: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="85%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>For the nine months ended</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT size=+0><B><FONT face=serif size=2>Project
      Costs</FONT></B></FONT></TD>
    <TD align=left width="81%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT size=+0><B><FONT face=serif size=2>September
      30,</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><FONT size=+0><STRONG><FONT size=2>Increase</FONT></STRONG></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT size=+0><B><I><FONT face=serif size=2>(In millions)</FONT></I></B></FONT></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2009</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>2008</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>(Decrease)</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP> (rilonacept)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>49.1</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>24.9</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>24.2</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT size=+0><FONT face=serif size=2>Aflibercept</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>17.7</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>25.4</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>(7.7</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>VEGF Trap-Eye</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>77.7</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>57.6</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>20.1</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT size=+0><FONT face=serif size=2>REGN88</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>27.5</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>14.7</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="5%"><FONT size=+0><FONT face=serif size=2>12.8</FONT></FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>REGN421 and REGN475</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>19.4</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>19.4</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT size=+0><FONT face=serif size=2>Other research programs &amp; unallocated costs</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>88.6</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>77.7</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="5%"><FONT size=+0><FONT face=serif size=2>10.9</FONT></FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total research and
      development expenses</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>280.0</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>200.3</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="5%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>79.7</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For the
reasons described above under &#147;Research and Development Expenses&#148; for the three
months ended September 30, 2009 and 2008, and due to the variability in the
costs necessary to develop a product and the uncertainties related to future
indications to be studied, the estimated cost and scope of the projects, and our
ultimate ability to obtain governmental approval for commercialization, accurate
and meaningful estimates of the total cost to bring our product candidates to
market are not available. Similarly, we are currently unable to reasonably
estimate if our product candidates will generate material product revenues and
net cash inflows. In 2008, we received FDA approval for ARCALYST for the
treatment of CAPS, a group of rare, inherited auto-inflammatory diseases that
affect a very small group of people. We project to ship approximately $20
million of ARCALYST to our U.S. distributors in 2009.</FONT><I><FONT face=serif size=2> </FONT></I></P>
<P align=justify><I><FONT face=serif size=2>Selling, General, and Administrative
Expenses: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Selling,
general, and administrative expenses increased slightly to $35.9 million from
$35.7 million for the first nine months of 2009 compared to 2008. In 2009, we
incurred (i) higher compensation expense and facility-related expenses, due
primarily to increases in administrative headcount to support our expanded
research and development activities, (ii) higher selling expenses and patient
assistance costs related to ARCALYST, and (iii) higher patent-related costs.
These increases were offset by (i) lower market research costs related to
various programs, (ii) a decrease in recruitment costs for administrative
headcount, and (iii) lower professional fees related to various corporate
matters.</FONT></P>
<P align=center><FONT face=serif size=2>36</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT face=serif size=2>Cost of Goods Sold: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2008, we began recognizing revenue and cost of goods sold from
product sales of ARCALYST<SUP>&#174;</SUP> (rilonacept). We began capitalizing inventory costs associated with
commercial supplies of ARCALYST subsequent to receipt of marketing approval from
the FDA in February 2008. Costs for manufacturing supplies of ARCALYST prior to
receipt of FDA approval were recognized as research and development expenses in
the period that the costs were incurred. Therefore, these costs are not included
in cost of goods sold when revenue is recognized from the sale of those supplies
of ARCALYST. Cost of goods sold for the first nine months of 2009 was $1.3
million, compared to $0.3 million for the same period in 2008, and consisted
primarily of royalty and other period costs related to ARCALYST commercial
supplies. </FONT></P>
<P align=justify><I><FONT face=serif size=2>Other Income and Expense:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Investment income decreased to $3.9 million in the first nine months of
2009 from $15.5 million in the comparable period of 2008. The decrease in
investment income was due to lower yields on, and lower balances of, cash and
marketable securities in the first nine months of 2009 compared to the same
period in 2008. Interest expense decreased to $0.6 million in the first nine
months of 2009 from $7.5 million in the comparable period of 2008. Interest
expense in 2009 was attributable to the imputed interest portion of the payments
to our landlord, commencing in the third quarter of 2009, to lease newly
constructed laboratory and office facilities in Tarrytown. Interest expense in
the first nine months of 2008 related to $200.0 million of formerly
outstanding 5.5% Convertible Senior Subordinated Notes which we either
repurchased or repaid in full during 2008. In the first nine months of 2008, we
repurchased a total of $82.5 million in principal amount of these convertible
notes for $83.3 million. In connection with the repurchases, we recognized a
$0.9 million loss on early extinguishment of debt, representing the premium paid
on the notes plus related unamortized debt issuance costs. </FONT></P>
<P align=justify><I><FONT face=serif size=2>Income Tax Expense</FONT></I><FONT face=serif size=2>: </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2008, we implemented a tax planning strategy which resulted in
the utilization of certain net operating loss carry-forwards for tax purposes
that would otherwise have expired over the next several years. As a result, we
incurred income tax expense of $3.1 million, which relates to U.S. Federal and
New York State alternative minimum tax and includes $0.2 million of interest and
penalties.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Revision of Previously Issued
Financial Statements</FONT></B><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
application of authoritative guidance issued by the Financial Accounting
Standards Board (FASB), under certain conditions, can result in the
capitalization on a lessee&#146;s books of a lessor&#146;s costs of constructing
facilities to be leased to the lessee. In mid-2009, we became aware that certain
of these conditions were applicable to our December 2006 lease, as amended, of
new laboratory and office facilities in Tarrytown, New York. As a result, we are
deemed, in substance, to be the owner of the landlord&#146;s buildings, and the
landlord&#146;s costs of constructing these new facilities were required to be
capitalized on our books as a non-cash transaction, offset by a corresponding
lease obligation on our balance sheet. In addition, the land element of the
lease should have been accounted for as an operating lease; therefore,
adjustments to non-cash rent expense previously recognized in connection with
these new facilities were also required. Lease payments on these facilities
commenced in August 2009.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
revised our previously issued financial statements to capitalize the landlord&#146;s
costs of constructing the new Tarrytown facilities which we are leasing and to
adjust our previously recognized rent expense in connection with these
facilities, as described above. These revisions primarily resulted in an
increase to property, plant, and equipment and a corresponding increase in
facility lease obligation (a long-term liability) at each balance sheet date. We
also revised our statements of operations and statements of cash flows to
reflect rent expense in connection with only the land element of our lease, with
a corresponding adjustment to other long-term liabilities. In addition, we
revised our statement of cash flows for the quarter ended March 31, 2009 to
reclassify, from an operating activity to a financing activity, a $5.2 million
reimbursement received from our landlord for tenant improvement costs we
incurred. Under FASB authoritative guidance, such payments that we receive from
our landlord are deemed to be a financing obligation.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>37</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
previously disclosed, the above described revisions consisted entirely of
non-cash adjustments. They had no impact on our business operations, existing
capital resources, or our ability to fund our operating needs, including the
preclinical and clinical development of our product candidates. The revisions
also had no impact on our previously reported net increases or decreases in cash
and cash equivalents in any period and, except for the </FONT><FONT face=serif size=2>quarter ended March 31, 2009 (as described above), had no impact on our
previously reported net cash flows from operating activities, investing
activities, and financing activities. In addition, these revisions had no impact
on our previously reported current assets, current liabilities, and operating
revenues. We have not amended previously issued financial statements because,
after considering both qualitative and quantitative factors, we determined that
the judgment of a reasonable person relying on our previously issued financial
statements would not have been changed or influenced by these
revisions.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to our balance
sheets as of the dates set forth below is as follows: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="75%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="100%" colSpan=13><B><FONT face=serif size=2>Balance
      Sheet Impact at December 31, 2007 and 2008, and March 31,
    2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><B><I><FONT face=serif size=2>(in
      millions)</FONT></I></B></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="5%" colSpan=3></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2007</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As originally
      reported</FONT></B></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>Property, plant, and
      equipment, net</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>58.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>87.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>109.8</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Total
      assets</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=13>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Other
      long-term liabilities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5.1</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>13.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>Total
    liabilities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>476.0</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>251.2</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>271.1</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=13>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(793.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(875.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(893.4</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>Total stockholders&#146;
      equity</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>460.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>418.8</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>410.3</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Total
      liabilities and stockholders&#146; equity</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=13>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As
      revised</FONT></B></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>Property, plant, and
      equipment, net</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>79.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>142.0</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%"><FONT face=serif size=2>164.6</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Total
      assets</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=13>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Facility lease obligation</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>21.6</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>54.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>60.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>Other long-term
      liabilities</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>0.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>2.4</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>3.2</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Total
      liabilities</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>498.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>302.7</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>321.1</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=13>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(794.1</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(873.3</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(888.7</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%"><FONT face=serif size=2>Total stockholders&#146;
      equity</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>459.4</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>421.5</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>415.1</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0><FONT face=serif size=2>Total
      liabilities and stockholders&#146; equity</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE></DIV>
<P align=center><FONT face=serif size=2>38</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to our
statements of operations and statement of cash flows for the period(s) set forth
below is as follows: </FONT></P>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR style="LINE-HEIGHT: 12pt" vAlign=bottom>
    <TD align=left width="100%" colSpan=25>
      <P align=justify><B><FONT face=serif size=2>Statements of Operations
      Impact for the three, six, and nine month periods ended March 31, June 30
      and September 30, 2008, the years ended December 31, 2007 and 2008, and
      the three months ended March 31, 2009</FONT></B></P></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="79%" colSpan=4><B><I><FONT face=serif size=2>(in
      millions, except per share data)</FONT></I></B></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>June 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>September 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=7><B><FONT face=serif size=2>December 31,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>2007</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As originally
      reported</FONT></B></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"><FONT face=serif size=2>Research and
      development expenses</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>61.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>127.8</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>201.7</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>201.6</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>278.0</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>82.1</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%" bgColor=#c0c0c0><FONT face=serif size=2>Selling, general, and administrative expenses</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>11.0</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>24.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>35.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>37.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>49.3</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>11.7</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"><FONT face=serif size=2>Total
expenses</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>72.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>152.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>237.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>239.5</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>328.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>94.2</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(11.6</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(30.1</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(51.2</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(105.6</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(82.7</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(17.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"><FONT face=serif size=2>Net loss per share,
      basic and diluted</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.15</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.38</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.65</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(1.59</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(1.05</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.22</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="75%"  bgColor=#ffffff>&nbsp; </TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="2%"  bgColor=#ffffff></TD>
    <TD align=right width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=right width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=right width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=right width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=right width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD>
    <TD align=right width="1%"  bgColor=#ffffff></TD>
    <TD align=left width="1%"  bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As
      revised</FONT></B></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"><FONT face=serif size=2>Research and
      development expenses</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>61.5</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>128.2</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>200.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>202.5</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>274.9</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>80.3</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%" bgColor=#c0c0c0><FONT face=serif size=2>Selling, general, and administrative expenses</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>11.1</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>24.6</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>35.7</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>37.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>48.9</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>11.4</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"><FONT face=serif size=2>Total
expenses</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="2%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>72.5</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>152.8</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>236.3</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>240.4</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>324.7</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="1%"><FONT face=serif size=2>92.1</FONT></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="2%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(11.8</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(30.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(49.6</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(106.5</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(79.1</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>(15.4</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="75%"><FONT face=serif size=2>Net loss per share,
      basic and diluted</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="2%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.15</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.39</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.63</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(1.61</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(1.00</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="1%"><FONT face=serif size=2>(0.19</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR></TABLE>


<BR>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="85%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="99%" colSpan=9><FONT size=+0><B><FONT face=serif size=2>Statement of Cash Flows Impact for the three months ended March 31,
      2009</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"><FONT size=+0><B><I><FONT face=serif size=2>(in
      millions)</FONT></I></B></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%"></TD>
    <TD align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>As Originally</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>Reported</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>As
      Revised</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>Net cash used in operating activities</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(10.2</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>(15.4</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"><FONT size=+0><FONT face=serif size=2>Net cash
      used in investing activities</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>(39.5</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>(39.5</FONT></FONT></TD>
    <TD align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>Net cash provided by financing activities</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>1.0</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>6.2</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net decrease in cash and cash
      equivalents</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT size=+0><FONT face=serif size=2>(48.7</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD>
    <TD align=right width="1%"><FONT size=+0>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%"><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT size=+0><FONT face=serif size=2>(48.7</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" align=left width="1%"><FONT size=+0><FONT face=serif size=2>)</FONT></FONT></TD></TR></TABLE>
</DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>These
revised amounts, as applicable, are reflected in this Quarterly Report on Form
10-Q for the period ended September 30, 2009, and will be included in our
Annual Report on Form 10-K for the year ended December 31, 2009 and our
Quarterly Report on Form 10-Q for the period ended March 31, 2010.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Liquidity and Capital
Resources</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Since our
inception in 1988, we have financed our operations primarily through offerings
of our equity securities, a private placement of convertible debt (which was
repurchased or repaid in 2008), purchases of our equity securities by our
collaborators, including sanofi-aventis, revenue earned under our past and
present research and development agreements, including our agreements with
sanofi-aventis and Bayer HealthCare, our past contract manufacturing agreements,
and our technology licensing agreements, ARCALYST<SUP>&#174;</SUP> (rilonacept) product revenue, and
investment income.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Nine months ended September 30,
2009 and 2008 </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At
September 30, 2009, we had $438.6 million in cash, cash equivalents, restricted
cash, and marketable securities compared with $527.5 million at December 31,
2008. In February 2009, we received a $20.0 million annual, non-refundable
payment in connection with our non-exclusive license agreement with AstraZeneca.
In May 2009, we received a $20.0 million annual, non-refundable payment in
connection with our non-exclusive license agreement with Astellas. In July 2009,
we received a $20.0 million milestone payment from Bayer HealthCare in
connection with the dosing of the first patient in a Phase 3 trial of VEGF
Trap-Eye in CRVO.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>39</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT face=serif size=2>Cash Used in Operations:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
used in operations was $25.8 million in the first nine months of 2009 compared
to $53.2 million in the first nine months of 2008. Our net losses of $31.3
million in the first nine months of 2009 and $49.6 million in the first nine
months of 2008 included $22.6 million and $24.7 million, respectively, of
Non-cash Compensation Expense.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At
September 30, 2009, accounts receivable increased by $32.6 million, compared to
end-of-year 2008, primarily due to a higher receivable balance related to our
antibody collaboration with sanofi-aventis. Also, our deferred revenue balances
at September 30, 2009 decreased by $11.4 million, compared to end-of-year 2008,
primarily due to the amortization of previously received deferred payments under
our collaborations with sanofi-</FONT><FONT face=serif size=2>aventis and Bayer
HealthCare. This decrease was partly offset by the receipt of the $20.0 million
payments from AstraZeneca and Astella, as described above, which were deferred
and are being recognized ratably over the ensuing year. At September 30, 2009,
accounts payable, accrued expenses, and other liabilities increased by $18.0
million compared to end-of-year 2008. The increase was due primarily to higher
liabilities for clinical trial and payroll-related costs, partially offset by a
$7.0 million decrease in the cost-sharing payment due to Bayer HealthCare at
September 30, 2009 compared to December 31, 2008 in connection with the
companies&#146; VEGF Trap-Eye collaboration.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At
September 30, 2008, accounts receivable increased by $23.9 million, compared to
end-of-year 2007, primarily due to a higher receivable balance related to our
antibody collaboration with sanofi-aventis. Also, our deferred revenue balances
at September 30, 2008 decreased by $10.1 million, compared to end-of-year 2007,
primarily due to the amortization of previously received deferred payments under
our collaborations with sanofi-aventis and Bayer HealthCare. This decrease was
partly offset by (i) the receipt of $20.0 million payments from AstraZeneca in
February 2008 and Astellas in June 2008, which were deferred and recognized
ratably over the ensuing year, and (ii) deferral of $3.8 million of ARCALYST<SUP>&#174;</SUP> (rilonacept) net
product sales at September 30, 2008.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Cash Provided by (Used in) Investing
Activities: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
provided by investing activities was $19.3 million in the first nine months of
2009 compared to net cash used in investing activities of $53.9 million in the
same period of 2008, due primarily to a decrease in purchases of marketable
securities net of sales or maturities. In the first nine months of 2009, sales
or maturities of marketable securities exceeded purchases by $94.3 million,
whereas in the first nine months of 2008, purchases of marketable securities
exceeded sales or maturities by $34.7 million. In addition, cash used for
capital expenditures totaled $75.0 million in the first nine months of 2009,
primarily for tenant improvements and related costs in connection with our new
leased facilities in Tarrytown. </FONT></P>
<P align=justify><I><FONT face=serif size=2>Cash Provided by (Used in) Financing
Activities: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
provided by financing activities was $9.0 million in the first nine months of
2009 compared to net cash used in financing activities of $77.1 million in the
same period in 2008. In the first nine months of 2009, we received a $5.2
million reimbursement of tenant improvements from our landlord in connection
with our new Tarrytown facilities, which we are deemed to own in accordance with
FASB authoritative guidance. In the first nine months of 2008, we
repurchased $82.5 million in principal amount of our convertible senior
subordinated notes for $83.3 million. In addition, proceeds from issuances of
Common Stock in connection with exercises of employee stock options were $4.6
million and $6.2 million in the first nine months of 2009 and 2008,
respectively.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Fair Value of Marketable
Securities: </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At
September 30, 2009 and December 31, 2008, we held marketable securities whose
aggregate fair value totaled $186.7 million and $278.0 million, respectively.
The composition of our portfolio of marketable securities on these dates was as
follows: </FONT></P>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="81%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=4><FONT size=+0><B><FONT face=serif size=2>September 30,
      2009</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=4><FONT size=+0><B><FONT face=serif size=2>December 31,
      2008</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT size=+0><B><FONT face=serif size=2>Investment
      type</FONT></B></FONT></TD>
    <TD align=left width="80%">&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>Fair
      Value</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><FONT size=+0><B><FONT face=serif size=2>Percent</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT face=serif size=2>Fair
      Value</FONT></B></FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><FONT size=+0><B><FONT face=serif size=2>Percent</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>U.S. Treasury securities</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>80.5</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>43%</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>113.9</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>41%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" colSpan=2><FONT size=+0><FONT face=serif size=2>U.S. government agency securities</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>24.9</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>13%</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>58.3</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>21%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>U.S. government-guaranteed corporate
    bonds</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>49.1</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>26%</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>29.8</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>11%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" colSpan=2><FONT size=+0><FONT face=serif size=2>U.S. government guaranteed collateralized mortgage
      obligations</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>4.8</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>3%</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>17.4</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>6%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>Corporate bonds</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>16.1</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>9%</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>37.1</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>13%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" colSpan=2><FONT size=+0><FONT face=serif size=2>Mortgage-backed securities</FONT></FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>4.2</FONT></FONT></TD>
    <TD align=right width="1%">&nbsp;</TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>2%</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>10.0</FONT></FONT></TD>
    <TD align=right width="1%">&nbsp;</TD>
    <TD align=right width="3%"><FONT size=+0><FONT face=serif size=2>4%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>Other asset-backed securities</FONT></FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>7.8</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>3%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" colSpan=2><FONT size=+0><FONT face=serif size=2>Other</FONT></FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>7.1</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>4%</FONT></FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>3.7</FONT></FONT></TD>
    <TD align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT size=+0><FONT face=serif size=2>1%</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total marketable
      securities</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>186.7</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>100%</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>278.0</FONT></FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>100%</FONT></FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>40</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, at September 30, 2009 and December 31, 2008, we had $251.9 million and
$249.5 million, respectively, of cash, cash equivalents, and restricted cash,
primarily held in money market funds that invest in U.S. government securities.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the first nine months of 2009, as marketable securities in our portfolio matured
or paid down, we purchased primarily U.S. Treasury securities, U.S. government
agency obligations, and U.S. government-guaranteed debt. This shift toward higher
quality securities, which we initiated in 2008, continues to reduce the risk
profile, as well as the overall yield, of our portfolio. In particular, we
continue to reduce the proportion of asset-backed securities and corporate bonds
in our portfolio.</FONT><B><FONT face=serif size=2> </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Capital
Expenditures:</FONT></I></B><B><I><FONT face=serif size=2> </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our cash
expenditures for property, plant, and equipment totaled $75.0 million and $19.1
million for the first nine months of 2009 and 2008, respectively. During the
remainder of 2009, we expect to incur approximately $10 to $15 million in
capital expenditures, primarily in connection with expanding our Rensselaer, New
York manufacturing facilities and tenant improvements at our new leased
Tarrytown facilities, which will be funded by our existing capital resources. In
October 2009, we received $16.9 million from our landlord as partial
reimbursement of tenant improvement costs we incurred in Tarrytown. An
additional $33 million is reimbursable at our option at any time through June
2010 under the terms of our Tarrytown lease.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Amendment to Lease &#150; Tarrytown,
New York Facilities: </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
currently lease approximately 248,000 square feet of laboratory and office
facilities in Tarrytown, New York. In December 2006, we entered into a new lease
agreement (as amended in October 2007 and September 2008) to lease approximately
348,000 square feet of laboratory and office space at our current Tarrytown
location, including approximately 230,000 square feet in newly constructed
facilities that were completed during the third quarter of 2009. The term of the
lease commenced effective June 2008 and will expire in June 2024. In April 2009,
we amended the lease agreement to increase the amount of space we will lease to
approximately 389,500 square feet. As amended, the lease contains early
termination options on approximately 159,500 square feet of space. Other terms
and conditions, as previously described in our Annual Report on Form 10-K for
the year ended December 31, 2008, remain unchanged. In connection with the lease
amendment, in April 2009, we terminated a sublease for 16,200 square feet of
space in Tarrytown, New York. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Facility Lease
Obligation:</FONT></I></B><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
described above, in connection with the application of FASB authoritative
guidance to our lease of office and laboratory facilities constructed in
Tarrytown, New York by our landlord, we capitalized the landlord&#146;s costs of
constructing the new facilities, which totaled $58.2 million as of September 30,
2009, and recognized a corresponding facility lease obligation of $58.2 million.
We also recognized, as an additional facility lease obligation, a $5.2 million
reimbursement received from our landlord for tenant improvement costs that we
incurred since, under FASB authoritative guidance, such payments that we receive
from our landlord are deemed to be a financing obligation. Monthly lease
payments on these facilities are allocated between the land element of the lease
(which is accounted for as an operating lease) and the facility lease
obligation, based on the estimated relative fair values of the land and
buildings. The imputed interest rate applicable to the facility lease obligation
is approximately 11%. The new facilities were placed in service in September
2009. For the three and nine months ended September 30, 2009, we recognized $0.6
million of interest expense in connection with the facility lease obligation in
our statement of operations. At September 30, 2009, the facility lease
obligation balance was $62.6 million. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Funding Requirements:
</FONT></I></B><B><I><FONT face=serif size=2></FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
to continue to incur substantial funding requirements primarily for research and
development activities (including preclinical and clinical testing). Before
taking into account reimbursements from collaborators, we currently anticipate
that approximately 50-60% of our expenditures for 2009 will be directed toward
the preclinical and clinical development of product candidates, including
ARCALYST<SUP>&#174;</SUP> (rilonacept), aflibercept, VEGF Trap-Eye, and monoclonal
antibodies (including REGN88, REGN421, and REGN475); approximately 20-30% of our
expenditures for 2009 will be applied to our basic research and early
preclinical activities and the remainder of our expenditures for 2009 will be
used for the continued development of our novel technology platforms, capital
expenditures, and general corporate purposes.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>41</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
currently anticipate that in 2009 sales of ARCALYST<SUP>&#174;</SUP> (rilonacept) for the treatment of CAPS
will not materially enhance or otherwise materially impact our cash flows.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the April 2009 amendment to our lease agreement for facilities
in Tarrytown, New York, as described above, our total estimated future minimum
noncancelable lease commitments, previously disclosed in our Annual Report on
Form 10-K for the year ended December 31, 2008, will increase (i) from $9.1
million to $9.4 million for the year ending December 31, 2009, (ii) from $26.8
million to $29.2 million for the two-year period beginning January 1, 2010,
(iii) from $27.2 million to $28.8 million for the two-year period beginning
January 1, 2012, and (iv) from $167.0 million to $182.5 million for the
eleven-year period beginning January 1, 2014.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
amount we need to fund operations will depend on various factors, including the
status of competitive products, the success of our research and development
programs, the potential future need to expand our professional and support staff
and facilities, the status of patents and other intellectual property rights,
the delay or failure of a clinical trial of any of our potential drug
candidates, and the continuation, extent, and success of our collaborations with
sanofi-aventis and Bayer HealthCare. Clinical trial costs are dependent, among
other things, on the size and duration of trials, fees charged for services
provided by clinical trial investigators and other third parties, the costs for
manufacturing the product candidate for use in the trials, and for supplies,
laboratory tests, and other expenses. The amount of funding that will be
required for our clinical programs depends upon the results of our research and
preclinical programs and early-stage clinical trials, regulatory requirements,
the duration and results of clinical trials underway and of additional clinical
trials that we decide to initiate, and the various factors that affect the cost
of each trial as described above. Currently, we are required to remit royalties
on product sales of ARCALYST for the treatment of CAPS.
In the future, if we are able to successfully develop, market, and sell ARCALYST
for other indications or certain of our product candidates, we may be required
to pay royalties or otherwise share the profits generated on such sales in
connection with our collaboration and licensing agreements. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
that expenses related to the filing, prosecution, defense, and enforcement of
patents and other intellectual property will continue to be
substantial.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
believe that our existing capital resources, including funding we are entitled
to receive under our collaboration agreements, will enable us to meet operating
needs through at least 2012. However, this is a forward-looking statement based
on our current operating plan, and there may be a change in projected revenues
or expenses that would lead to our capital being consumed significantly before
such time. If there is insufficient capital to fund all of our planned
operations and activities, we would expect to prioritize available capital to
fund selected preclinical and clinical development programs.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Other
than a $1.6 million letter of credit issued to our landlord in connection with
our lease for facilities in Tarrytown, New York, as described above, we have no
off-balance sheet arrangements. In addition, we do not guarantee the obligations
of any other entity. As of September 30, 2009, we had no established banking
arrangements through which we could obtain short-term financing or a line of
credit. In the event we need additional financing for the operation of our
business, we will consider collaborative arrangements and additional public or
private financing, including additional equity financing. Factors influencing
the availability of additional financing include our progress in product
development, investor perception of our prospects, and the general condition of
the financial markets. We may not be able to secure the necessary funding
through new collaborative arrangements or additional public or private
offerings. If we cannot raise adequate funds to satisfy our capital
requirements, we may have to delay, scale-back, or eliminate certain of our
research and development activities or future operations. This could materially
harm our business.</FONT><I><FONT face=serif size=2> </FONT></I></P>
<P align=justify><B><FONT face=serif size=2>Future Impact of Recently Issued
Accounting Standards </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
October 2009, the FASB amended its authoritative guidance on
multiple-deliverable revenue arrangements. The amended guidance provides greater
ability to separate and allocate arrangement consideration in a multiple element
revenue arrangement by requiring the use of estimated selling price to allocate
arrangement consideration, thereby eliminating the use of the residual method of
allocation. The amended guidance also requires expanded qualitative and
quantitative disclosures surrounding multiple deliverable revenue arrangements.
This guidance may be applied retrospectively or prospectively for new or
materially modified arrangements. We are required to adopt this amended guidance
effective for the fiscal year beginning January 1, 2011, although earlier
adoption is permitted. We are currently evaluating the impact that this guidance
will have on our financial statements. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>42</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>ITEM 3. QUANTITATIVE AND QUALITATIVE
DISCLOSURE ABOUT MARKET RISK </FONT></B></P>
<P align=justify><I><FONT face=serif size=2>Interest Rate Risk:</FONT></I><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
earnings and cash flows are subject to fluctuations due to changes in interest
rates primarily from our investment of available cash balances in investment
grade corporate, asset-backed, and U.S. government securities. We do not believe
we are materially exposed to changes in interest rates. Under our current
policies, we do not use interest rate derivative instruments to manage exposure
to interest rate changes. We estimated that a one percent unfavorable change in
interest rates would result in approximately a $0.9 million and $1.7 million
decrease in the fair value of our investment portfolio at September 30, 2009 and
2008, respectively.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Credit Quality Risk:</FONT></I><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
an investment policy that includes guidelines on acceptable investment
securities, minimum credit quality, maturity parameters, and concentration and
diversification. Nonetheless, deterioration of the credit quality of an
investment security subsequent to purchase may subject us to the risk of not
being able to recover the full principal value of the security. We have
recognized other-than-temporary impairment charges related to certain marketable
securities of $5.9 million, $2.5 million and $0.1 million in 2007, 2008, and the
first nine months of 2009, respectively.</FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The current economic environment,
the deterioration in the credit quality of some of the issuers of securities
that we hold, and the recent volatility of securities markets increase the risk
that there could be further declines in the market value of marketable
securities in our investment portfolio and that such declines could result in
charges against income in future periods for other-than-temporary impairments,
and such amounts could be material. </FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 4. CONTROLS AND PROCEDURES
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
management, with the participation of our chief executive officer and chief
financial officer, conducted an evaluation of the effectiveness of our
disclosure controls and procedures (as such term is defined in Rules 13a-15(e)
and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;)), as of the end of the period covered by this report. Based on
this evaluation, our chief executive officer and chief financial officer each
concluded that, as of the end of such period, our disclosure controls and
procedures were effective in ensuring that information required to be disclosed
by us in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized, and reported within the time periods specified in
applicable rules and forms of the Securities and Exchange Commission, and is
accumulated and communicated to our management, including our chief executive
officer and chief financial officer, as appropriate to allow timely decisions
regarding required disclosure. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There has
been no change in our internal control over financial reporting (as such term is
defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the
quarter ended September 30, 2009 that has materially affected, or is reasonably
likely to materially affect, our internal control over financial
reporting.</FONT><B><I><FONT face=serif size=2> </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>PART II. OTHER INFORMATION
</FONT></B></P>
<P align=justify><B><FONT face=serif size=2>ITEM 1. LEGAL
PROCEEDINGS</FONT></B><B><I><FONT face=serif size=2> </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From time
to time, we are a party to legal proceedings in the course of our business. We
do not expect any such current legal proceedings to have a material adverse
effect on our business or financial condition.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>43</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>ITEM 1A. RISK FACTORS
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
operate in an environment that involves a number of significant risks and
uncertainties. We caution you to read the following risk factors, which have
affected, and/or in the future could affect, our business, operating results,
financial condition, and cash flows. The risks described below include
forward-looking statements, and actual events and our actual results may differ
substantially from those discussed in these forward-looking statements.
Additional risks and uncertainties not currently known to us or that we
currently deem immaterial may also impair our business operations. Furthermore,
additional risks and uncertainties are described under other captions in this
report and should be considered by our investors.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Financial
Results and Need for Additional Financing</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We have had a history of
operating losses and we may never achieve profitability. If we continue to incur
operating losses, we may be unable to continue our operations.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From
inception on January 8, 1988 through September 30, 2009, we had a cumulative
loss of $904.6 million. If we continue to incur operating losses and fail to
become a profitable company, we may be unable to continue our operations. In the
absence of substantial revenue from the sale of products or other sources, the
amount, timing, nature or source of which cannot be predicted, our losses will
continue as we conduct our research and development activities.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>We may need additional funding in
the future, which may not be available to us, and which may force us to delay,
reduce or eliminate our product development programs or commercialization
efforts. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We will
need to expend substantial resources for research and development, including
costs associated with clinical testing of our product candidates. We believe our
existing capital resources, including funding we are entitled to receive under
our collaboration agreements, will enable us to meet operating needs through at
least 2012; however, one or more of our collaboration agreements may terminate,
our projected revenue may decrease, or our expenses may increase and that would
lead to our capital being consumed significantly before such time. We may
require additional financing in the future and we may not be able to raise such
additional funds. If we are able to obtain additional financing through the sale
of equity or convertible debt securities, such sales may be dilutive to our
shareholders. Debt financing arrangements may require us to pledge certain
assets or enter into covenants that would restrict our business activities or
our ability to incur further indebtedness and may contain other terms that are
not favorable to our shareholders. If we are unable to raise sufficient funds to
complete the development of our product candidates, we may face delay, reduction
or elimination of our research and development programs or preclinical or
clinical trials, in which case our business, financial condition or results of
operations may be materially harmed.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>The value of our investment
portfolio, which includes cash, cash equivalents, and marketable securities, is
influenced by varying economic and market conditions. A decrease in the value of
an asset in our investment portfolio or a default by the issuer may result in
our inability to recover the principal we invested and/or a recognition of a
loss charged against income. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As of
September 30, 2009, cash, cash equivalents, restricted cash, and marketable
securities totaled $438.6 million and represented 59% of our total assets. We
have invested available cash balances primarily in money market funds and U.S.
Treasury, U.S. government agency, corporate, and to a lesser extent,
asset-backed securities. We consider assets classified as marketable securities
to be &#147;available-for-sale,&#148; as defined by FASB authoritative guidance.
Marketable securities totaled $186.7 million at September 30, 2009, are carried
at fair value, and the unrealized gains and losses are included in other
accumulated comprehensive income (loss) as a separate component of stockholders&#146;
equity. If the decline in the value of a security in our investment portfolio is
deemed to be other-than-temporary, we write down the security to its current
fair value and recognize a loss which may be fully charged against income. For
example, we recognized other-than-temporary impairment charges related to
certain marketable securities of $5.9 million, $2.5 million and $0.1 million in
2007, 2008, and the first nine months of 2009, respectively. The current
economic environment, the deterioration in the credit quality of some of the
issuers of securities that we hold, and the recent volatility of securities
markets increase the risk that we may not recover the principal we invested
and/or there may be further declines in the market value of securities in our
investment portfolio. As a result, we may incur additional charges against
income in future periods for other-than-temporary impairments or realized losses
upon a security&#146;s sale or maturity, and such amounts may be material.</FONT></P>
<P align=center><FONT face=serif size=2>44</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Risks Related to
ARCALYST<SUP>&#174;</SUP> (rilonacept) and the Development of Our Product Candidates
</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Successful development of any of
our product candidates is highly uncertain. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Only a
small minority of all research and development programs ultimately result in
commercially successful drugs. Even if clinical trials demonstrate safety and
effectiveness of any of our product candidates for a specific disease and the
necessary regulatory approvals are obtained, the commercial success of any of
our product candidates will depend upon their acceptance by patients, the
medical community, and third-party payers and on our partners&#146; ability to
successfully manufacture and commercialize our product candidates. Our product
candidates are delivered either by intravenous infusion or by intravitreal or
subcutaneous injections, which are generally less well received by patients than
tablet or capsule delivery. If our products are not successfully commercialized,
we will not be able to recover the significant investment we have made in
developing such products and our business would be severely harmed.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
testing aflibercept, VEGF Trap-Eye, and ARCALYST in a
number of late-stage clinical trials. Clinical trials may not demonstrate
statistically sufficient effectiveness and safety to obtain the requisite
regulatory approvals for these product candidates. In a number of instances, we
have terminated the development of product candidates due to a lack of or modest
effectiveness.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is in Phase 3 clinical trials in combination with standard
chemotherapy regimens for the treatment of 2<SUP>nd</SUP> line metastatic
colorectal cancer, 1<SUP>st</SUP> line androgen independent prostate cancer, and
2<SUP>nd</SUP> line metastatic non-small cell lung cancer. Aflibercept may not
demonstrate the required safety or efficacy to support an application for
approval in any of these indications. We do not have proof of concept data from
early-stage, double-blind, controlled clinical trials that aflibercept will be
safe or effective in any of these cancer settings. In September 2009, we
announced the discontinuation of a Phase 3 clinical trial that evaluated
aflibercept plus gemcitabine versus placebo plus gemcitabine for the first-line
treatment of metastatic pancreatic cancer after an Independent Data Monitoring
Committee for the trial determined that the addition of aflibercept to
gemcitabine would be unable to demonstrate a statistically significant
improvement in the primary endpoint of overall survival compared to placebo plus
gemcitabine.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
testing VEGF Trap-Eye in Phase 3 trials for the treatment of wet AMD and the
treatment of Central Retinal Vein Occlusion (CRVO). Although we reported
positive Phase 2 trial results with VEGF Trap-Eye in wet AMD, based on a limited
number of patients, the results from the larger Phase 3 trials may not
demonstrate that VEGF Trap-Eye is safe and effective or compares favorably to
Lucentis<SUP>&#174;</SUP> (ranibizumab injection), marketed by Genentech, Inc. A
number of other potential new drugs and biologics which showed promising results
in initial clinical trials subsequently failed to establish sufficient safety
and efficacy data to obtain necessary regulatory approvals. VEGF Trap-Eye has
not been previously studied in CRVO.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>ARCALYST
is in Phase 3 clinical trials for two different gout indications &#150; the
prevention of gout flares in patients initiating urate-lowering drug therapy and
acute gout. We do not have proof of concept data from Phase 2 clinical trials
that ARCALYST will be safe or effective in the acute gout setting. Although we
reported positive Phase 2 proof of concept data from a small number of patients
initiating urate-lowering drug therapy, there is a risk that the results of the
larger Phase 3 trials of ARCALYST in patients initiating urate-lowering drug
therapy will differ from the previously reported Phase 2 trial. A number of
potential new drugs and biologics which showed promising results in initial
clinical trials subsequently failed to establish sufficient safety and efficacy
data to obtain necessary regulatory approvals. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
studying our antibody candidates in a wide variety of indications in early stage
clinical trials. Many of these trials are exploratory studies designed to
evaluate the safety profile of these compounds and to identify what diseases and
uses, if any, are best suited for these product candidates. These early stage
product candidates may not demonstrate the requisite efficacy and/or safety
profile to support continued development for some or all of the indications that
are being, or are planned to be, studied.</FONT></P>
<P align=center><FONT face=serif size=2>45</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Clinical trials required for our
product candidates are expensive and time-consuming, and their outcome is highly
uncertain. If any of our drug trials are delayed or yield unfavorable results,
we will have to delay or may be unable to obtain regulatory approval for our
product candidates. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We must
conduct extensive testing of our product candidates before we can obtain
regulatory approval to market and sell them. We need to conduct both preclinical
animal testing and human clinical trials. Conducting these trials is a lengthy,
time-consuming, and expensive process. These tests and trials may not achieve
favorable results for many reasons, including, among others, failure of the
product candidate to demonstrate safety or efficacy, the development of serious
or life-threatening adverse events (or side effects) caused by or connected with
exposure to the product candidate, difficulty in enrolling and maintaining
subjects in the clinical trial, lack of sufficient supplies of the product
candidate or comparator drug, and the failure of clinical investigators, trial
monitors and other consultants, or trial subjects to comply with the trial plan
or protocol. A clinical trial may fail because it did not include a sufficient
number of patients to detect the endpoint being measured or reach statistical
significance. A clinical trial may also fail because the dose(s) of the
investigational drug included in the trial were either too low or too high to
determine the optimal effect of the investigational drug in the disease
setting.</FONT></P>

<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Many of
our clinical trials are conducted  under the oversight of  Independent  Data
Monitoring  Committees (or IDMCs).  These independent  oversight bodies are made
up of external experts who review the progress of ongoing clinical trials,
including  available safety and efficacy  data,  and make  recommendations
concerning  a trial's  continuation, modification,  or  termination  based on
interim,  unblinded  data.  Any of our ongoing   clinical  trials  may  be
discontinued  or  amended  in  response  to recommendations  made by responsible
IDMCs based on their review of such interim trial  results.  For  example,  in
September  2009,  a Phase 3 trial  that  was evaluating aflibercept as a
1<SUP>st</SUP> line treatment for metastic pancreatic cancer in combination with
gemcitabine was discontinued at the  recommendation of an IDMC after a planned
analysis of interim  efficacy  data  determined  that the trial would not meet
its efficacy endpoint. The recommended  termination of any of our ongoing
late-stage clinical trials by an IDMC could harm the future development of our
product candidate(s) and our business may be materially harmed.</FONT></P>

<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We will
need to reevaluate any drug candidate that does not test favorably and either
conduct new trials, which are expensive and time consuming, or abandon the drug
development program. Even if we obtain positive results from preclinical or
clinical trials, we may not achieve the same success in future trials. Many
companies in the biopharmaceutical industry, including Regeneron, have suffered
significant setbacks in clinical trials, even after promising results have been
obtained in earlier trials. The failure of clinical trials to demonstrate safety
and effectiveness for the desired indication(s) could harm the development of
our product candidate(s), and our business, financial condition, and results of
operations may be materially harmed. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Serious complications or side
effects have occurred, and may continue to occur, in connection with the use of
our approved product and in clinical trials of some of our product candidates
which could cause our regulatory approval to be revoked or otherwise negatively
affected or lead to delay or discontinuation of development of our product
candidates which could severely harm our business.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the conduct of clinical trials, patients report changes in their health,
including illnesses, injuries, and discomforts, to their study doctor. Often, it
is not possible to determine whether or not the drug candidate being studied
caused these conditions. Various illnesses, injuries, and discomforts have been
reported from time-to-time during clinical trials of our product candidates. It
is possible as we test our drug candidates in larger, longer, and more extensive
clinical programs, illnesses, injuries, and discomforts that were observed in
earlier trials, as well as conditions that did not occur or went undetected in
smaller previous trials, will be reported by patients. Many times, side effects
are only detectable after investigational drugs are tested in large scale, Phase
3 clinical trials or, in some cases, after they are made available to patients
after approval. If additional clinical experience indicates that any of our
product candidates has many side effects or causes serious or life-threatening
side effects, the development of the product candidate may fail or be delayed,
which would severely harm our business.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept (VEGF Trap) is being studied for the potential treatment of
certain types of cancer and our VEGF Trap-Eye candidate is being studied in
diseases of the eye. There are many potential safety concerns associated with
significant blockade of vascular endothelial growth factor, or VEGF, that may
limit our ability to successfully develop aflibercept and VEGF Trap-Eye. These
serious and potentially life-threatening risks, based on clinical and
preclinical experience of VEGF inhibitors, include bleeding, intestinal
perforation, hypertension, proteinuria, congestive heart failure, heart attack,
and stroke. In addition, patients given infusions of any protein, including VEGF
Trap delivered through intravenous administration, may develop severe
hypersensitivity reactions or infusion reactions. Other VEGF blockers have
reported side effects that became evident only after large scale trials or after
marketing approval and large number of patients were treated. These and other
complications or side effects could harm the development of aflibercept for the
treatment of cancer or VEGF Trap-Eye for the treatment of diseases of the
eye.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
tested ARCALYST<SUP>&#174;</SUP> (rilonacept) in only a small number of patients. As more patients begin to
use our product and as we test it in new disease settings, new risks and side
effects associated with ARCALYST may be discovered, and risks previously viewed
as inconsequential could be determined to be significant. Like cytokine
antagonists such as Kineret<SUP>&#174;</SUP> (anakinra), marketed by Biovitrum,
Enbrel<SUP>&#174;</SUP> (etanercept), marketed by Amgen Inc. and Wyeth
Pharmaceuticals, Inc., and Remicade<SUP>&#174;</SUP> (infliximab) marketed by
Centocor Ortho Biotech, Inc., ARCALYST affects the immune defense system of the
body by blocking some of its functions. Therefore, ARCALYST may interfere with
the body&#146;s ability to fight infections. Treatment with Kineret, a medication
that works through the inhibition of IL-1, has been associated with an increased
risk of serious infections, and serious, life threatening infections have been
reported in patients taking ARCALYST. These or other complications or side
effects could cause regulatory authorities to revoke approvals of ARCALYST.
Alternatively, we may be required to conduct additional clinical trials, make
changes in the labeling of our product, or limit or abandon our efforts to
develop ARCALYST in new disease settings. These side effects may also result in
a reduction, or even the elimination, of sales of ARCALYST in approved
indications.</FONT></P>
<P align=center><FONT face=serif size=2>46</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP> (rilonacept)
and our product candidates in development are recombinant proteins that could
cause an immune response, resulting in the creation of harmful or neutralizing
antibodies against the therapeutic protein. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by
our product candidates, the administration of recombinant proteins frequently
causes an immune response, resulting in the creation of antibodies against the
therapeutic protein. The antibodies can have no effect or can totally neutralize
the effectiveness of the protein, or require that higher doses be used to obtain
a therapeutic effect. In some cases, the antibody can cross react with the
patient&#146;s own proteins, resulting in an &#147;auto-immune&#148; type disease. Whether
antibodies will be created can often not be predicted from preclinical or
clinical experiments, and their detection or appearance is often delayed, so
that there can be no assurance that neutralizing antibodies will not be detected
at a later date, in some cases even after pivotal clinical trials have been
completed. Antibodies directed against the receptor domains of rilonacept were
detected in patients with CAPS after treatment with ARCALYST. Nineteen of 55
subjects (35%) who received ARCALYST for at least 6 weeks tested positive for
treatment-emerging binding antibodies on at least one occasion. To date, no side
effects related to antibodies were observed in these subjects and there were no
observed effects on drug efficacy or drug levels. It is possible that as we
continue to test aflibercept and VEGF Trap-Eye with more sensitive assays in
different patient populations and larger clinical trials, we will find that
subjects given aflibercept and VEGF Trap-Eye develop antibodies to these product
candidates, and may also experience side effects related to the antibodies,
which could adversely impact the development of such candidates. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>We may be unable to formulate or
manufacture our product candidates in a way that is suitable for clinical or
commercial use. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Changes
in product formulations and manufacturing processes may be required as product
candidates progress in clinical development and are ultimately commercialized.
If we are unable to develop suitable product formulations or manufacturing
processes to support large scale clinical testing of our product candidates,
including aflibercept, VEGF Trap-Eye, and our antibody candidates, we may be
unable to supply necessary materials for our clinical trials, which would delay
the development of our product candidates. Similarly, if we are unable to supply
sufficient quantities of our product or develop product formulations suitable
for commercial use, we will not be able to successfully commercialize our
product candidates.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Intellectual
Property </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we cannot protect the
confidentiality of our trade secrets or our patents are insufficient to protect
our proprietary rights, our business and competitive position will be harmed.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
business requires using sensitive and proprietary technology and other
information that we protect as trade secrets. We seek to prevent improper
disclosure of these trade secrets through confidentiality agreements. If our
trade secrets are improperly exposed, either by our own employees or our
collaborators, it would help our competitors and adversely affect our business.
We will be able to protect our proprietary rights from unauthorized use by third
parties only to the extent that our rights are covered by valid and enforceable
patents or are effectively maintained as trade secrets. The patent position of
biotechnology companies involves complex legal and factual questions and,
therefore, enforceability cannot be predicted with certainty. Our patents may be
challenged, invalidated, or circumvented. Patent applications filed outside the
United States may be challenged by third parties who file an opposition. Such
opposition proceedings are increasingly common in the European Union and are
costly to defend. We have patent applications that are being opposed and it is
likely that we will need to defend additional patent applications in the future.
Our patent rights may not provide us with a proprietary position or competitive
advantages against competitors. Furthermore, even if the outcome is favorable to
us, the enforcement of our intellectual property rights can be extremely
expensive and time consuming.</FONT></P>
<P align=center><FONT face=serif size=2>47</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>We may be restricted in our
development and/or commercialization activities by, and could be subject to
damage awards if we are found to have infringed, third party patents or other
proprietary rights. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
commercial success depends significantly on our ability to operate without
infringing the patents and other proprietary rights of third parties. Other
parties may allege that they have blocking patents to our products in clinical
development, either because they claim to hold proprietary rights to the
composition of a product or the way it is manufactured or used. Moreover, other
parties may allege that they have blocking patents to antibody products made
using our <I>VelocImmune</I><SUP>&#174;</SUP> technology, either because of the way
the antibodies are discovered or produced or because of a proprietary position
covering an antibody or the antibody&#146;s target.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of patents and pending applications owned by Genentech that claim certain
chimeric VEGF receptor compositions. Although we do not believe that aflibercept
or VEGF Trap-Eye infringes any valid claim in these patents or patent
applications, Genentech could initiate a lawsuit for patent infringement and
assert that its patents are valid and cover aflibercept or VEGF Trap-Eye.
Genentech may be motivated to initiate such a lawsuit at some point in an effort
to impair our ability to develop and sell aflibercept or VEGF Trap-Eye, which
represent potential competitive threats to Genentech&#146;s VEGF-binding products and
product candidates. An adverse determination by a court in any such potential
patent litigation would likely materially harm our business by requiring us to
seek a license, which may not be available, or resulting in our inability to
manufacture, develop, and sell aflibercept or VEGF Trap-Eye or in a damage
award.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of patents and pending applications owned by Roche that claim antibodies
to the interleukin-6 receptor and methods of treating rheumatoid arthritis with
such antibodies. We are developing REGN88, an antibody to the interleukin-6
receptor, for the treatment of rheumatoid arthritis. Although we do not believe
that REGN88 infringes any valid claim in these patents or patent applications,
Roche could initiate a lawsuit for patent infringement and assert its patents
are valid and cover REGN88.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of a U.S. patent jointly owned by Genentech and City of Hope relating to
the production of recombinant antibodies in host cells. We currently produce our
antibody product candidates using recombinant antibodies from host cells and may
choose to produce additional antibody product candidates in this manner. Neither
ARCALYST<SUP>&#174;</SUP> (rilonacept), aflibercept, nor VEGF Trap-Eye are
recombinant antibodies. If any of our antibody product candidates are produced
in a manner subject to valid claims in the Genentech patent, then we may need to
obtain a license from Genentech, should one be available. Genentech has licensed
this patent to several different companies under confidential license
agreements. If we desire a license for any of our antibody product candidates
and are unable to obtain a license on commercially reasonable terms or at all,
we may be restricted in our ability to use Genentech&#146;s techniques to make
recombinant antibodies in or to import them into the United States.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Further,
we are aware of a number of other third party patent applications that, if
granted, with claims as currently drafted, may cover our current or planned
activities. We cannot assure you that our products and/or actions in
manufacturing and selling our product candidates will not infringe such patents.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Any
patent holders could sue us for damages and seek to prevent us from
manufacturing, selling, or developing our drug candidates, and a court may find
that we are infringing validly issued patents of third parties. In the event
that the manufacture, use, or sale of any of our clinical candidates infringes
on the patents or violates other proprietary rights of third parties, we may be
prevented from pursuing product development, manufacturing, and
commercialization of our drugs and may be required to pay costly damages. Such a
result may materially harm our business, financial condition, and results of
operations. Legal disputes are likely to be costly and time consuming to
defend.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We seek
to obtain licenses to patents when, in our judgment, such licenses are needed.
If any licenses are required, we may not be able to obtain such licenses on
commercially reasonable terms, if at all. The failure to obtain any such license
could prevent us from developing or commercializing any one or more of our
product candidates, which could severely harm our business. </FONT></P>
<P align=center><FONT face=serif size=2>48</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Regulatory and Litigation Risks
</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we do not obtain regulatory
approval for our product candidates, we will not be able to market or sell them.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We cannot
sell or market products without regulatory approval. If we do not obtain and
maintain regulatory approval for our product candidates, including ARCALYST<SUP>&#174;</SUP> (rilonacept) for
the treatment of diseases other than CAPS, the value of our company and our
results of operations will be harmed. In the United States, we must obtain and
maintain approval from the United States Food and Drug Administration (FDA) for
each drug we intend to sell. Obtaining FDA approval is typically a lengthy and
expensive process, and approval is highly uncertain. Foreign governments also
regulate drugs distributed in their country and approval in any country is
likely to be a lengthy and expensive process, and approval is highly uncertain.
Except for the FDA approval of ARCALYST and the EMEA approval of rilonacept for
the treatment of CAPS, none of our product candidates has ever received
regulatory approval to be marketed and sold in the United States or any other
country. We may never receive regulatory approval for any of our product
candidates.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The FDA
enforces good clinical practices and other regulations through periodic
inspections of trial sponsors, clinical research organizations (CROs), principal
investigators, and trial sites. If we or any of the third parties conducting our
clinical studies are determined to have failed to fully comply with Good
Clinical Practice regulations (GCPs), the study protocol or applicable
regulations, the clinical data generated in our studies may be deemed
unreliable. This could result in non-approval of our product candidates by the
FDA, or we or the FDA may decide to conduct additional audits or require
additional clinical studies, which would delay our development programs and
substantially harm our business.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Before
approving a new drug or biologic product, the FDA requires that the facilities
at which the product will be manufactured be in compliance with current Good
Manufacturing Practices, or cGMP requirements. Manufacturing product candidates
in compliance with these regulatory requirements is complex, time-consuming, and
expensive. To be successful, our products must be manufactured for development,
following approval, in commercial quantities, in compliance with regulatory
requirements, and at competitive costs. If we or any of our product
collaborators or third-party manufacturers, product packagers, or labelers are
unable to maintain regulatory compliance, the FDA can impose regulatory
sanctions, including, among other things, refusal to approve a pending
application for a new drug or biologic product, or revocation of a pre-existing
approval. As a result, our business, financial condition, and results of
operations may be materially harmed. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to the FDA and other regulatory agency regulations in the United
States, we are subject to a variety of foreign regulatory requirements governing
human clinical trials, manufacturing, marketing and approval of drugs, and
commercial sale and distribution of drugs in foreign countries. The foreign
regulatory approval process includes all of the risks associated with FDA
approval as well as country specific regulations. Whether or not we obtain FDA
approval for a product in the United States, we must obtain approval by the
comparable regulatory authorities of foreign countries before we can commence
clinical trials or marketing of rilonacept or any of our product candidates in
those countries. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If we fail to meet the stringent
requirements of governmental regulation in the manufacture of our marketed
product and clinical candidates, we could incur substantial remedial costs,
delays in the development of our clinical candidates, and a reduction in sales.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
our third party providers are required to maintain compliance with current Good
Manufacturing Practice, or cGMP, and are subject to inspections by the FDA or
comparable agencies in other jurisdictions to confirm such compliance. Changes
of suppliers or modifications of methods of manufacturing may require amending
our application to the FDA and acceptance of the change by the FDA prior to
release of product. Because we produce multiple product candidates at our
facility in Rensselaer, New York, there are increased risks associated with cGMP
compliance. Our inability, or the inability of our third party service
providers, to demonstrate ongoing cGMP compliance could require us to engage in
lengthy and expensive remediation efforts, withdraw or recall product, halt or
interrupt clinical trials, and/or interrupt commercial supply of our marketed
product. Any delay, interruption or other issues that arise in the manufacture,
fill-finish, packaging, or storage of our product candidates as a result of a
failure of our facilities or the facilities or operations of third parties to
pass any regulatory agency inspection or maintain cGMP compliance could
significantly impair our ability to develop and commercialize our products. Any
finding of non-compliance could increase our costs, cause us to delay the
development of our product candidates, and cause us to lose revenue from our
marketed product.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>49</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>If the testing or use of our
products harms people, we could be subject to costly and damaging product
liability claims.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
testing, manufacturing, marketing, and sale of drugs for use in people expose us
to product liability risk. Any informed consent or waivers obtained from people
who sign up for our clinical trials may not protect us from liability or the
cost of litigation. We may be subject to claims by CAPS patients who use
ARCALYST that they have been injured by a side effect associated with the drug.
Our product liability insurance may not cover all potential liabilities or may
not completely cover any liability arising from any such litigation. Moreover,
we may not have access to liability insurance or be able to maintain our
insurance on acceptable terms.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If we market and sell
ARCALYST<SUP>&#174;</SUP> (rilonacept) in a way that violates federal or state fraud
and abuse laws, we may be subject to civil or criminal penalties.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to FDA and related regulatory requirements, we are subject to health
care &#147;fraud and abuse&#148; laws, such as the federal False Claims Act, the
anti-kickback provisions of the federal Social Security Act, and other state and
federal laws and regulations. Federal and state anti-kickback laws prohibit,
among other things, knowingly and willfully offering, paying, soliciting or
receiving remuneration to induce, or in return for, purchasing, leasing,
ordering or arranging for the purchase, lease or order of any health care item
or service reimbursable under Medicare, Medicaid, or other federally or state
financed health care programs.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Federal
false claims laws prohibit any person from knowingly presenting, or causing to
be presented, a false claim for payment to the federal government, or knowingly
making, or causing to be made, a false statement to get a false claim paid.
Pharmaceutical companies have been prosecuted under these laws for a variety of
alleged promotional and marketing activities, such as allegedly providing free
product to customers with the expectation that the customers would bill federal
programs for the product; reporting to pricing services inflated average
wholesale prices that were then used by federal programs to set reimbursement
rates; engaging in promotion for uses that the FDA has not approved, or
off-label uses, that caused claims to be submitted to Medicaid for non-covered
off-label uses; and submitting inflated best price information to the Medicaid
Rebate program. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
majority of states also have statutes or regulations similar to the federal
anti-kickback law and false claims laws, which apply to items and services
reimbursed under Medicaid and other state programs, or, in several states, apply
regardless of the payer. Sanctions under these federal and state laws may
include civil monetary penalties, exclusion of a manufacturer&#146;s products from
reimbursement under government programs, criminal fines, and imprisonment.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Even if
we are not determined to have violated these laws, government investigations
into these issues typically require the expenditure of significant resources and
generate negative publicity, which would also harm our financial condition.
Because of the breadth of these laws and the narrowness of the safe harbors, it
is possible that some of our business activities could be subject to challenge
under one or more of such laws. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In recent
years, several states and localities, including California, the District of
Columbia, Massachusetts, Maine, Minnesota, Nevada, New Mexico, Vermont, and West
Virginia, have enacted legislation requiring pharmaceutical companies to
establish marketing compliance programs, and file periodic reports with the
state or make periodic public disclosures on sales, marketing, pricing, clinical
trials, and other activities. Similar legislation is being considered in other
states and also at the federal level. Many of these requirements are new and uncertain, and the penalties for
failure to comply with these requirements are unclear. Nonetheless, if we are
found not to be in full compliance with these laws, we could face enforcement
action and fines and other penalties, and could receive adverse publicity.
</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Our operations may involve
hazardous materials and are subject to environmental, health, and safety laws
and regulations. We may incur substantial liability arising from our activities
involving the use of hazardous materials. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As a
biopharmaceutical company with significant manufacturing operations, we are
subject to extensive environmental, health, and safety laws and regulations,
including those governing the use of hazardous materials. Our research and
development and manufacturing activities involve the controlled use of
chemicals, viruses, radioactive compounds, and other hazardous materials. The
cost of compliance with environmental, health, and safety regulations is
substantial. If an accident involving these materials or an environmental
discharge were to occur, we could be held liable for any resulting damages, or
face regulatory actions, which could exceed our resources or insurance
coverage.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>50</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Changes in the securities laws
and regulations have increased, and are likely to continue to increase, our
costs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Sarbanes-Oxley Act of 2002, which became law in July 2002, has required changes
in some of our corporate governance, securities disclosure, and compliance
practices. In response to the requirements of that Act, the SEC and the NASDAQ
Stock Market have promulgated rules and listing standards covering a variety of
subjects. Compliance with these rules and listing standards has increased our
legal costs, and significantly increased our accounting and auditing costs, and
we expect these costs to continue. These developments may make it more difficult
and more expensive for us to obtain directors&#146; and officers&#146; liability
insurance. Likewise, these developments may make it more difficult for us to
attract and retain qualified members of our board of directors, particularly
independent directors, or qualified executive officers.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>In future years, if we are unable
to conclude that our internal control over financial reporting is effective, the
market value of our Common Stock could be adversely affected.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
directed by Section 404 of the Sarbanes-Oxley Act of 2002, the SEC adopted rules
requiring public companies to include a report of management on the Company&#146;s
internal control over financial reporting in their annual reports on Form 10-K
that contains an assessment by management of the effectiveness of our internal
control over financial reporting. In addition, the independent registered public
accounting firm auditing our financial statements must attest to and report on
the effectiveness of our internal control over financial reporting. Our
independent registered public accounting firm provided us with an unqualified
report as to the effectiveness of our internal control over financial reporting
as of December 31, 2008, which report is included in our Annual Report on Form
10-K for the fiscal year ended December 31, 2008. However, we cannot assure you
that management or our independent registered public accounting firm will be
able to provide such an unqualified report as of future year-ends. In this
event, investors could lose confidence in the reliability of our financial
statements, which could result in a decrease in the market value of our Common
Stock. In addition, if it is determined that deficiencies in the design or
operation of internal controls exist and that they are reasonably likely to
adversely affect our ability to record, process, summarize, and report financial
information, we would likely incur additional costs to remediate these
deficiencies and the costs of such remediation could be material. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Changes in laws and regulations
affecting the healthcare industry could adversely affect our business.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>All
aspects of our business, including research and development, manufacturing,
marketing, pricing, sales, litigation, and intellectual property rights, are
subject to extensive legislation and regulation. Changes in applicable federal
and state laws and agency regulations could have a material adverse effect on
our business. These include:</FONT></P>
<UL style="FONT-SIZE: 10pt">
  <LI>changes in the FDA and foreign regulatory processes for new therapeutics
  that may delay or prevent the approval of any of our current or future product
  candidates;
  <LI>new laws, regulations, or judicial decisions related to healthcare
  availability or the payment for healthcare products and services, including
  prescription drugs, that would make it more difficult for us to market and
  sell products once they are approved by the FDA or foreign regulatory
  agencies; and
  <LI>changes in FDA and foreign regulations that may require additional safety
  monitoring prior to or after the introduction of new products to market, which
  could materially increase our costs of doing business.
  <LI>changes in FDA and foreign current Good Manufacturing Practice, or cGMPs,
  that make it more difficult for us to manufacture our marketed product and
  clinical candidates in accordance with cGMPs.</LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
enactment in the United States of the Medicare Prescription Drug Improvement and
Modernization Act of 2003 and current pending legislation which would ease the
entry of competing follow-on biologics into the marketplace are examples of
changes and possible changes in laws that could adversely affect our business.
</FONT></P>
<P align=center><FONT face=serif size=2>51</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Reliance on
Third Parties </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If our antibody collaboration
with sanofi-aventis is terminated, our business operations and our ability to
discover, develop, manufacture, and commercialize our pipeline of product
candidates in the time expected, or at all, would be materially harmed.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on the funding from sanofi-aventis to support our target discovery and
antibody research and development programs. Sanofi-aventis has committed to pay
up to $400 million between 2009 and 2012 to fund our efforts to identify and
validate drug discovery targets and pre-clinically develop fully human
monoclonal antibodies against such targets. In addition, sanofi-aventis funds
almost all of the development expenses incurred by both companies in connection
with the clinical development of antibodies that sanofi-aventis elects to
co-develop with us. We rely on sanofi-aventis to fund these activities. In
addition, with respect to those antibodies that sanofi-aventis elects to
co-develop with us, such as REGN88, REGN421, and REGN475, we rely on
sanofi-aventis to lead much of the clinical development efforts and assist with
obtaining regulatory approval, particularly outside the United States. We also
rely on sanofi-aventis to lead the commercialization efforts to support all of
the antibody products that are co-developed by sanofi-aventis and us. If
sanofi-aventis does not elect to co-develop the antibodies that we discover or
opts-out of their development, we would be required to fund and oversee on our
own the clinical trials, any regulatory responsibilities, and the ensuing
commercialization efforts to support our antibody products. If sanofi-aventis
terminates the antibody collaboration or fails to comply with its payment
obligations thereunder, our business, financial condition, and results of
operations would be materially harmed. We would be required to either expend
substantially more resources than we have anticipated to support our research
and development efforts, which could require us to seek additional funding that
might not be available on favorable terms or at all, or materially cut back on
such activities. While we cannot assure you that any of the antibodies from this
collaboration will ever be successfully developed and commercialized, if
sanofi-aventis does not perform its obligations with respect to antibodies that
it elects to co-develop, our ability to develop, manufacture, and commercialize
these antibody product candidates will be significantly adversely
affected.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If our collaboration with
sanofi-aventis for aflibercept (VEGF Trap) is terminated, or sanofi-aventis
materially breaches its obligations thereunder, our business operations and
financial condition, and our ability to develop, manufacture, and commercialize
aflibercept in the time expected, or at all, would be materially harmed.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on sanofi-aventis to lead much of the development of aflibercept.
Sanofi-aventis funds all of the development expenses incurred by both companies
in connection with the aflibercept program. If the aflibercept program
continues, we will rely on sanofi-aventis to assist with funding the aflibercept
program, provide commercial manufacturing capacity, enroll and monitor clinical
trials, obtain regulatory approval, particularly outside the United States, and
lead the commercialization of aflibercept. While we cannot assure you that
aflibercept will ever be successfully developed and commercialized, if
sanofi-aventis does not perform its obligations in a timely manner, or at all,
our ability to develop, manufacture, and commercialize aflibercept in cancer
indications will be significantly adversely affected. Sanofi-aventis has the
right to terminate its collaboration agreement with us at any time upon twelve
months advance notice. If sanofi-aventis were to terminate its collaboration
agreement with us, we would not have the resources or skills to replace those of
our partner, which could require us to seek additional funding that might not be
available on favorable terms or at all, and could cause significant delays in
the development and/or manufacture of aflibercept and result in substantial
additional costs to us. We have limited commercial capabilities and would have
to develop or outsource these capabilities. Termination of the sanofi-aventis
collaboration agreement for aflibercept would create substantial new and
additional risks to the successful development and commercialization of
aflibercept. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If our collaboration with Bayer
HealthCare for VEGF Trap-Eye is terminated, or Bayer HealthCare materially
breaches its obligations thereunder, our business, operations and financial
condition, and our ability to develop and commercialize VEGF Trap-Eye in the
time expected, or at all, would be materially harmed. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on Bayer HealthCare to assist with the development of VEGF Trap-Eye.
Under our agreement with them, Bayer HealthCare is required to fund
approximately half of the development expenses incurred by both companies in
connection with the global VEGF Trap-Eye development program. If the VEGF
Trap-Eye program continues, we will rely on Bayer HealthCare to assist with
funding the VEGF Trap-Eye development program, lead the development of VEGF
Trap-Eye outside the United States, obtain regulatory approval outside the
United States, and provide all sales, marketing, and commercial support for the
product outside the United States. In particular, Bayer HealthCare has
responsibility for selling VEGF Trap-Eye outside the United States using its
sales force. While we cannot assure you that VEGF Trap-Eye will ever be
successfully developed and commercialized, if Bayer HealthCare does not perform
its obligations in a timely manner, or at all, our ability to develop,
manufacture, and commercialize VEGF Trap-Eye outside the United States will be
significantly adversely affected. Bayer HealthCare has the right to terminate
its collaboration agreement with us at any time upon six or twelve months
advance notice, depending on the circumstances giving rise to termination. If
Bayer HealthCare were to terminate its collaboration agreement with us, we would
not have the resources or skills to replace those of our partner, which could
require us to seek additional funding that might not be available on favorable
terms or at all, and could cause significant delays in the development and/or
commercialization of VEGF Trap-Eye outside the United States and result in
substantial additional costs to us. We have limited commercial capabilities and
would have to develop or outsource these capabilities outside the United States.
Termination of the Bayer HealthCare collaboration agreement would create
substantial new and additional risks to the successful development and
commercialization of VEGF Trap-Eye.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>52</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Our collaborators and service
providers may fail to perform adequately in their efforts to support the
development, manufacture, and commercialization of ARCALYST<SUP>&#174;</SUP>
(rilonacept) and our drug candidates. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We depend
upon third-party collaborators, including sanofi-aventis, Bayer HealthCare, and
service providers such as clinical research organizations, outside testing
laboratories, clinical investigator sites, and third-party manufacturers and
product packagers and labelers, to assist us in the manufacture and preclinical
and clinical development of our product candidates. If any of our existing
collaborators or service providers breaches or terminates its agreement with us
or does not perform its development or manufacturing services under an agreement
in a timely manner or in compliance with applicable Good Manufacturing Practices
(GMPs) or good clinical practices, we could experience additional costs, delays,
and difficulties in the manufacture or development or in obtaining approval by
regulatory authorities for our product candidates.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
on third party service providers to support the distribution of ARCALYST and
many other related activities in connection with the commercialization of
ARCALYST for the treatment of CAPS. We cannot be certain that these third
parties will perform adequately. If these service providers do not perform their
services adequately, our efforts to market and sell ARCALYST for the treatment
of CAPS will not be successful.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to the Manufacture of
Our Product Candidates </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We have limited manufacturing
capacity, which could inhibit our ability to successfully develop or
commercialize our drugs. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
manufacturing facility is likely to be inadequate to produce sufficient
quantities of product for commercial sale. We intend to rely on our corporate
collaborators, as well as contract manufacturers, to produce the large
quantities of drug material needed for commercialization of our products. We
rely entirely on third-party manufacturers for filling and finishing services.
We will have to depend on these manufacturers to deliver material on a timely
basis and to comply with regulatory requirements. If we are unable to supply
sufficient material on acceptable terms, or if we should encounter delays or
difficulties in our relationships with our corporate collaborators or contract
manufacturers, our business, financial condition, and results of operations may
be materially harmed. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We must
expand our own manufacturing capacity to support the planned growth of our
clinical pipeline. Moreover, we may expand our manufacturing capacity to support
commercial production of active pharmaceutical ingredients, or API, for our
product candidates. This will require substantial additional expenditures, and
we will need to hire and train significant numbers of employees and managerial
personnel to staff our facility. Start-up costs can be large and scale-up
entails significant risks related to process development and manufacturing
yields. We may be unable to develop manufacturing facilities that are sufficient
to produce drug material for clinical trials or commercial use. This may delay
our clinical development plans and interfere with our efforts to commercialize
our products. In addition, we may be unable to secure adequate filling and
finishing services to support our products. As a result, our business, financial
condition, and results of operations may be materially harmed. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We may be
unable to obtain key raw materials and supplies for the manufacture of ARCALYST
and our product candidates. In addition, we may face difficulties in developing
or acquiring production technology and managerial personnel to manufacture
sufficient quantities of our product candidates at reasonable costs and in
compliance with applicable quality assurance and environmental regulations and
governmental permitting requirements. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>53</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>If any of our clinical programs
are discontinued, we may face costs related to the unused capacity at our
manufacturing facilities. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
large-scale manufacturing operations in Rensselaer, New York. We use our
facilities to produce bulk product for clinical and preclinical candidates for
ourselves and our collaborations. If our clinical candidates are discontinued,
we will have to absorb one hundred percent of related overhead costs and
inefficiencies. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Third-party supply failures,
business interruptions, or natural disasters affecting our manufacturing
facilities in Rensselaer, New York could adversely affect our ability to supply
our products. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
manufacture all of our bulk drug materials for ARCALYST<SUP>&#174;</SUP> (rilonacept)
and our product candidates at our manufacturing facilities in Rensselaer, New
York. We would be unable to supply our product requirements if we were to cease
production due to regulatory requirements or action, business interruptions,
labor shortages or disputes, contaminations, fire, natural disasters, or other
problems at the facilities. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Certain
raw materials necessary for manufacturing and formulation of ARCALYST and our
product candidates are provided by single-source unaffiliated third-party
suppliers. In addition, we rely on certain third parties to perform filling,
finishing, distribution, and other services related to the manufacture of our
products. We would be unable to obtain these raw materials or services for an
indeterminate period of time if any of these third-parties were to cease or
interrupt production or otherwise fail to supply these materials, products, or
services to us for any reason, including due to regulatory requirements or
action, adverse financial developments at or affecting the supplier, failure by
the supplier to comply with GMPs, business interruptions, or labor shortages or
disputes. This, in turn, could materially and adversely affect our ability to
manufacture or supply ARCALYST or our product candidates for use in clinical
trials, which could materially and adversely affect our business and future
prospects. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Also,
certain of the raw materials required in the manufacturing and the formulation
of our clinical candidates may be derived from biological sources, including
mammalian tissues, bovine serum, and human serum albumin. There are certain
European regulatory restrictions on using these biological source materials. If
we are required to substitute for these sources to comply with European
regulatory requirements, our clinical development activities may be delayed or
interrupted. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Commercialization
of Products </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we are unable to establish
sales, marketing, and distribution capabilities, or enter into agreements with
third parties to do so, we will be unable to successfully market and sell future
products. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
marketing and selling ARCALYST for the treatment of CAPS ourselves in the United
States, primarily through third party service providers. We have no sales or
distribution personnel in the United States and have only a small staff with
commercial capabilities. We currently have no sales, marketing, commercial, or
distribution capabilities outside the United States. If we are unable to obtain
those capabilities, either by developing our own organizations or entering into
agreements with service providers, even if our current or future product
candidates receive marketing approval, we will not be able to successfully sell
those products. In that event, we will not be able to generate significant
revenue, even if our product candidates are approved. We cannot guarantee that
we will be able to hire the qualified sales and marketing personnel we need or
that we will be able to enter into marketing or distribution agreements with
third-party providers on acceptable terms, if at all. Under the terms of our
collaboration agreement with sanofi-aventis, we currently rely on sanofi-aventis
for sales, marketing, and distribution of aflibercept in cancer indications,
should it be approved in the future by regulatory authorities for marketing. We
will have to rely on a third party or devote significant resources to develop
our own sales, marketing, and distribution capabilities for our other product
candidates, including VEGF Trap-Eye in the United States, and we may be
unsuccessful in developing our own sales, marketing, and distribution
organization. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>54</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>There may be too few patients
with CAPS to profitably commercialize ARCALYST<SUP>&#174;</SUP> (rilonacept) in this
indication.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our only
approved product is ARCALYST for the treatment of CAPS, a group of rare,
inherited auto-inflammatory diseases. These rare diseases affect a very small
group of people. The incidence of CAPS has been reported to be approximately 1 in
1,000,000 people in the United States. Although the incidence rate of CAPS in
Europe has not been reported, it is known to be a rare set of diseases. In June
2009, Novartis received marketing approval from the FDA for its IL-1 antibody
product for the treatment of CAPS. In October 2009 we received European
marketing authorization for rilonacept for CAPS and Novartis received European
marketing authorization for its IL-1 antibody product for the treatment of CAPS.
Given the very rare nature of the disease and the competition from Novartis&#146;
IL-1 antibody product, we may be unable to profitably commercialize ARCALYST in
this indication. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Even if our product candidates
are approved for marketing, their commercial success is highly uncertain because
our competitors have received approval for products with a similar mechanism of
action, and competitors may get to the marketplace with better or lower cost
drugs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There is
substantial competition in the biotechnology and pharmaceutical industries from
pharmaceutical, biotechnology, and chemical companies. Many of our competitors
have substantially greater research, preclinical and clinical product
development and manufacturing capabilities, and financial, marketing, and human
resources than we do. Our smaller competitors may also enhance their competitive
position if they acquire or discover patentable inventions, form collaborative
arrangements, or merge with large pharmaceutical companies. Even if we achieve
product commercialization, our competitors have achieved, and may continue to
achieve, product commercialization before our products are approved for
marketing and sale.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Genentech
has an approved VEGF antagonist, Avastin<SUP>&#174;</SUP> (bevacizumab), on the
market for treating certain cancers and many different pharmaceutical and
biotechnology companies are working to develop competing VEGF antagonists,
including Novartis, Amgen, Imclone/Eli Lilly, Pfizer, AstraZeneca, and
GlaxoSmithKline plc. Many of these molecules are farther along in development
than aflibercept and may offer competitive advantages over our
molecule.</FONT><B><FONT face=serif size=2> </FONT></B><FONT face=serif size=2>Each of Pfizer and Onyx Pharmaceuticals, (together with its partner Bayer
HealthCare) has received approval from the FDA to market and sell an oral
medication that targets tumor cell growth and new vasculature formation that
fuels the growth of tumors. The marketing approvals for Genentech&#146;s VEGF
antagonist, Avastin, and their extensive, ongoing clinical development plan for
Avastin in other cancer indications, make it more difficult for us to enroll
patients in clinical trials to support aflibercept and to obtain regulatory
approval of aflibercept in these cancer settings. This may delay or impair our
ability to successfully develop and commercialize aflibercept. In addition, even
if aflibercept is ever approved for sale for the treatment of certain cancers,
it will be difficult for our drug to compete against Avastin and the FDA
approved kinase inhibitors, because doctors and patients will have significant
experience using these medicines. In addition, an oral medication may be
considerably less expensive for patients than a biologic medication, providing a
competitive advantage to companies that market such products. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
market for eye disease products is also very competitive. Novartis and Genentech
are collaborating on the commercialization and further development of a VEGF
antibody fragment, Lucentis<SUP>&#174;</SUP> (ranibizumab injection), marketed by
Genentech, Inc., for the treatment of age-related macular degeneration (wet AMD)
and other eye indications. Lucentis was approved by the FDA in June 2006 for the
treatment of wet AMD. Many other companies are working on the development of
product candidates for the potential treatment of wet AMD and DME that act by
blocking VEGF, VEGF receptors, and through the use of small interfering
ribonucleic acids (siRNAs) that modulate gene expression. In addition,
ophthalmologists are using off-label a third-party repackaged version of
Genentech&#146;s approved VEGF antagonist, Avastin<SUP>&#174;</SUP> (bevacizumab), with
success for the treatment of wet AMD. The National Eye Institute is conducting a
Phase 3 trial comparing Lucentis to Avastin in the treatment of wet AMD. The
marketing approval of Lucentis and the potential off-label use of Avastin make
it more difficult for us to enroll patients in our clinical trials and
successfully develop VEGF Trap-Eye. Even if VEGF Trap-Eye is ever approved for
sale for the treatment of eye diseases, it may be difficult for our drug to
compete against Lucentis, because doctors and patients will have significant
experience using this medicine. Moreover, the relatively low cost of therapy
with Avastin in patients with wet AMD presents a further competitive challenge
in this indication.</FONT><FONT face=serif> </FONT><FONT face=serif size=2>While
we believe that aflibercept would not be well tolerated if administered directly
to the eye, if aflibercept is ever approved for the treatment of certain
cancers, there is a risk that third parties will attempt to repackage
aflibercept for use and sale for the treatment of wet AMD and other diseases of
the eye, which would present a potential low-cost competitive threat to the VEGF
Trap-Eye if it is ever approved for sale. </FONT></P>
<P align=center><FONT face=serif size=2>55</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
availability of highly effective FDA approved TNF-antagonists such as
Enbrel<SUP>&#174;</SUP> (etanercept), marketed by Amgen Inc. and Wyeth
Pharmaceuticals, Inc., Remicade<SUP>&#174;</SUP> (infliximab), marketed by Centocor
Ortho Biotech, Inc., Humira<SUP>&#174;</SUP> (adalimumab), marketed by Abbott
Laboratories, and Simponi<SUP>TM</SUP> (golimumab), marketed by Centocor Ortho
Biotech, Inc., and the IL-1 receptor antagonist Kineret<SUP>&#174;</SUP> (anakinra)
marketed by Biovitrum, and other marketed therapies makes it more difficult to
successfully develop and commercialize ARCALYST<SUP>&#174;</SUP> (rilonacept). This
is one of the reasons we discontinued the development of ARCALYST in adult
rheumatoid arthritis. In addition, even if ARCALYST is ever approved for sale in
indications where TNF-antagonists are approved, it will be difficult for our
drug to compete against these FDA approved TNF-antagonists because doctors and
patients will have significant experience using these effective medicines.
Moreover, in such indications these approved therapeutics may offer competitive
advantages over ARCALYST, such as requiring fewer injections.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There are
both small molecules and antibodies in development by other companies that are
designed to block the synthesis of interleukin-1 or inhibit the signaling of
interleukin-1. For example, Eli Lilly, Xoma, and Novartis are each developing
antibodies to interleukin-1 and Amgen is developing an antibody to the
interleukin-1 receptor. Novartis received marketing approval for its IL-1
antibody for the treatment of CAPS from the FDA in June 2009 and from the
European Medicines Agency in October 2009. Novartis is also developing its IL-1
antibody in gout and other inflammatory diseases. Novartis&#146; IL-1 antibody and
these other drug candidates could offer competitive advantages over ARCALYST.
For example, Novartis&#146; IL-1 antibody is dosed once every eight weeks compared to
the once-weekly dosing regimen for ARCALYST. The successful development of these
competing molecules could impair our ability to successfully commercialize
ARCALYST.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
plans to develop ARCALYST for the treatment of certain gout indications. As
noted above, Novartis is testing its IL-1 antibody in gout. Novartis&#146; product
candidate is dosed less frequently for the treatment of CAPS and may be
perceived as offering competitive advantages over ARCALYST in gout by some
physicians, which would make it difficult for us to successfully commercialize
ARCALYST in that disease.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Currently, inexpensive, oral therapies such as analgesics and other
non-steroidal anti-inflammatory drugs are used as the standard of care to treat
the symptoms of these gout diseases. These established, inexpensive, orally
delivered drugs may make it difficult for us to successfully commercialize
ARCALYST in these diseases. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>The successful commercialization
of ARCALYST</FONT></I></B><FONT face=serif size=2><B><SUP>&#174;</SUP></B></FONT><B><I><FONT face=serif size=2> (rilonacept) and
our product candidates will depend on obtaining coverage and reimbursement for
use of these products from third-party payers and these payers may not agree to
cover or reimburse for use of our products. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
product candidates, if commercialized, may be significantly more expensive than
traditional drug treatments. For example, we have announced plans to initiate a
Phase 3 program studying the use of ARCALYST for the treatment of certain gout
indications. Patients suffering from these gout indications are currently
treated with inexpensive therapies, including non-steroidal anti-inflammatory
drugs. These existing treatment options are likely to be considerably less
expensive and may be preferable to a biologic medication for some patients. Our
future revenues and profitability will be adversely affected if United States
and foreign governmental, private third-party insurers and payers, and other
third-party payers, including Medicare and Medicaid, do not agree to defray or
reimburse the cost of our products to the patients. If these entities refuse to
provide coverage and reimbursement with respect to our products or provide an
insufficient level of coverage and reimbursement, our products may be too costly
for many patients to afford them, and physicians may not prescribe them. Many
third-party payers cover only selected drugs, making drugs that are not
preferred by such payer more expensive for patients, and require prior
authorization or failure on another type of treatment before covering a
particular drug. Payers may especially impose these obstacles to coverage on
higher-priced drugs, as our product candidates are likely to be.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We market
and sell ARCALYST in the United States for the
treatment of a group of rare genetic disorders called CAPS. We recently received
European Union marketing authorization for rilonacept for the treatment of CAPS.
There may be too few patients with CAPS to profitably commercialize ARCALYST.
Physicians may not prescribe ARCALYST, and CAPS patients may not be able to
afford ARCALYST, if third party payers do not agree to reimburse the cost of
ARCALYST therapy and this would adversely affect our ability to commercialize
ARCALYST profitably.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to potential restrictions on coverage, the amount of reimbursement for
our products may also reduce our profitability. In the United States, there have
been, and we expect will continue to be, actions and proposals to control and
reduce healthcare costs. Government and other third-party payers are challenging
the prices charged for <FONT face=serif size=2>healthcare products and
increasingly limiting, and attempting to limit, both coverage and level of
reimbursement for prescription drugs.&nbsp;</FONT></FONT></P>
<P align=center><FONT face=serif size=2>56</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Since
ARCALYST and our product candidates in clinical development will likely be too
expensive for most patients to afford without health insurance coverage, if our
products are unable to obtain adequate coverage and reimbursement by third-party
payers our ability to successfully commercialize our product candidates may be
adversely impacted. Any limitation on the use of our products or any decrease in
the price of our products will have a material adverse effect on our ability to
achieve profitability. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
certain foreign countries, pricing, coverage, and level of reimbursement of
prescription drugs are subject to governmental control, and we may be unable to
negotiate coverage, pricing, and reimbursement on terms that are favorable to
us. In some foreign countries, the proposed pricing for a drug must be approved
before it may be lawfully marketed. The requirements governing drug pricing vary
widely from country to country. For example, the European Union provides options
for its member states to restrict the range of medicinal products for which
their national health insurance systems provide reimbursement and to control the
prices of medicinal products for human use. A member state may approve a
specific price for the medicinal product or it may instead adopt a system of
direct or indirect controls on the profitability of the company placing the
medicinal product on the market. Our results of operations may suffer if we are
unable to market our products in foreign countries or if coverage and
reimbursement for our products in foreign countries is limited. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Risk Related to Employees
</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We are dependent on our key
personnel and if we cannot recruit and retain leaders in our research,
development, manufacturing, and commercial organizations, our business will be
harmed. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
highly dependent on certain of our executive officers. If we are not able to
retain any of these persons or our Chairman, our business may suffer. In
particular, we depend on the services of P. Roy Vagelos, M.D., the Chairman of
our board of directors, Leonard Schleifer, M.D., Ph.D., our President and Chief
Executive Officer, George D. Yancopoulos, M.D., Ph.D., our Executive Vice
President, Chief Scientific Officer and President, Regeneron Research
Laboratories, and Neil Stahl, Ph.D., our Senior Vice President, Research and
Development Sciences. There is intense competition in the biotechnology industry
for qualified scientists and managerial personnel in the development,
manufacture, and commercialization of drugs. We may not be able to continue to
attract and retain the qualified personnel necessary for developing our
business. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Common Stock
</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Our stock price is extremely
volatile. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There has
been significant volatility in our stock price and generally in the market
prices of biotechnology companies&#146; securities. Various factors and events may
have a significant impact on the market price of our Common Stock. These factors
include, by way of example: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>progress, delays, or adverse results in clinical
  trials;</FONT>
  <LI><FONT face=serif size=2>announcement of technological innovations or
  product candidates by us or competitors;</FONT>
  <LI><FONT face=serif size=2>fluctuations in our operating results;</FONT>
  <LI><FONT face=serif size=2>third party claims that our products or
  technologies infringe their patents;</FONT>
  <LI><FONT face=serif size=2>public concern as to the safety or effectiveness
  of ARCALYST<SUP>&#174;</SUP> (rilonacept) or any of our product candidates;</FONT>
  <LI><FONT face=serif size=2>developments in our relationship with
  collaborative partners;</FONT>
  <LI><FONT face=serif size=2>developments in the biotechnology industry or in
  government regulation of healthcare;</FONT>
  <LI><FONT face=serif size=2>large sales of our common stock by our executive
  officers, directors, or significant shareholders;</FONT>
  <LI><FONT face=serif size=2>arrivals and departures of key personnel;
  and</FONT>
  <LI><FONT face=serif size=2>general market conditions.</FONT></LI></UL>
<P align=center><FONT face=serif size=2>57</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
trading price of our Common Stock has been, and could continue to be, subject to
wide fluctuations in response to these and other factors, including the sale or
attempted sale of a large amount of our Common Stock in the market. Broad market
fluctuations may also adversely affect the market price of our Common Stock.
</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Future sales of our Common Stock
by our significant shareholders or us may depress our stock price and impair our
ability to raise funds in new share offerings. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>A small
number of our shareholders beneficially own a substantial amount of our Common
Stock. As of September 30, 2009, our five largest shareholders beneficially
owned 42.0% of our outstanding shares of Common Stock, assuming, in the case of
our Leonard S. Schleifer, M.D. Ph.D., our Chief Executive Officer, the
conversion of his Class A Stock into Common Stock and the exercise of all
options held by him which are exercisable within 60 days of September 30, 2009.
As of September 30, 2009, sanofi-aventis beneficially owned 14,799,552 shares of
Common Stock, representing approximately 18.9% of the shares of Common Stock
then outstanding. Under our investor agreement with sanofi-aventis,
sanofi-aventis may not sell these shares until December 20, 2012 except under
limited circumstances and subject to earlier termination of these restrictions
upon the occurrence of certain events. Notwithstanding these restrictions, if
sanofi-aventis, or our other significant shareholders or we, sell substantial
amounts of our Common Stock in the public market, or the perception that such
sales may occur exists, the market price of our Common Stock could fall. Sales
of Common Stock by our significant shareholders, including sanofi-aventis, also
might make it more difficult for us to raise funds by selling equity or
equity-related securities in the future at a time and price that we deem
appropriate. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Our existing shareholders may be
able to exert significant influence over matters requiring shareholder approval.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Holders
of Class A Stock, who are generally the shareholders who purchased their stock
from us before our initial public offering, are entitled to ten votes per share,
while holders of Common Stock are entitled to one vote per share. As of
September 30, 2009, holders of Class A Stock held 22.3% of the combined voting
power of all shares of Common Stock and Class A Stock then outstanding, plus any
voting power associated with any shares of Common Stock beneficially owned by
such Class A Stock holders. These shareholders, if acting together, would be in
a position to significantly influence the election of our directors and to
effect or prevent certain corporate transactions that require majority or
supermajority approval of the combined classes, including mergers and other
business combinations. This may result in us taking corporate actions that you
may not consider to be in your best interest and may affect the price of our
Common Stock. As of September 30, 2009: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>our current executive officers and directors
  beneficially owned 13.2% of our outstanding shares of Common Stock, assuming
  conversion of their Class A Stock into Common Stock and the exercise of all
  options held by such persons which are exercisable within 60 days of September
  30, 2009, and 28.0% of the combined voting power of our outstanding shares of
  Common Stock and Class A Stock, assuming the exercise of all options held by
  such persons which are exercisable within 60 days of September 30, 2009;
  and</FONT>
  <LI><FONT face=serif size=2>our five largest shareholders beneficially owned
  42.0% of our outstanding shares of Common Stock, assuming, in the case of
  Leonard S. Schleifer, M.D., Ph.D. our Chief Executive Officer, the conversion
  of his Class A Stock into Common Stock and the exercise of all options held by
  him which are exercisable within 60 days of September 30, 2009. In addition,
  these five shareholders held 48.8% of the combined voting power of our
  outstanding shares of Common Stock and Class A Stock, assuming the exercise of
  all options held by our Chief Executive Officer which are exercisable within
  60 days of September 30, 2009.</FONT> </LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Pursuant
to an investor agreement, sanofi-aventis has agreed to vote its shares, at
sanofi-aventis&#146; election, either as recommended by our board of directors or
proportionally with the votes cast by our other shareholders, except with
respect to certain change of control transactions, liquidation or dissolution,
stock issuances equal to or exceeding 10% of the then outstanding shares or
voting rights of Common Stock and Class A Stock, and new equity compensation
plans or amendments if not materially consistent with our historical equity
compensation practices.</FONT></P>
<P align=center><FONT face=serif size=2>58</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>The anti-takeover effects of
provisions of our charter, by-laws, and of New York corporate law and the
contractual &#147;standstill&#148; provisions in our investor agreement with
sanofi-aventis, could deter, delay, or prevent an acquisition or other &#147;change
in control&#148; of us and could adversely affect the price of our Common Stock.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
amended and restated certificate of incorporation, our by-laws, and the New York
Business Corporation Law contain various provisions that could have the effect
of delaying or preventing a change in control of our company or our management
that shareholders may consider favorable or beneficial. Some of these provisions
could discourage proxy contests and make it more difficult for you and other
shareholders to elect directors and take other corporate actions. These
provisions could also limit the price that investors might be willing to pay in
the future for shares of our Common Stock. These provisions include: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>authorization to issue &#147;blank check&#148; preferred
  stock, which is preferred stock that can be created and issued by the board of
  directors without prior shareholder approval, with rights senior to those of
  our common shareholders;</FONT>
  <LI><FONT face=serif size=2>a staggered board of directors, so that it would
  take three successive annual meetings to replace all of our directors; </FONT>
  <LI><FONT face=serif size=2>a requirement that removal of directors may only
  be effected for cause and only upon the affirmative vote of at least eighty
  percent (80%) of the outstanding shares entitled to vote for directors, as
  well as a requirement that any vacancy on the board of directors may be filled
  only by the remaining directors;</FONT>
  <LI><FONT face=serif size=2>any action required or permitted to be taken at
  any meeting of shareholders may be taken without a meeting, only if, prior to
  such action, all of our shareholders consent, the effect of which is to
  require that shareholder action may only be taken at a duly convened
  meeting;</FONT>
  <LI><FONT face=serif size=2>any shareholder seeking to bring business before
  an annual meeting of shareholders must provide timely notice of this intention
  in writing and meet various other requirements; and</FONT>
  <LI><FONT face=serif size=2>under the New York Business Corporation Law, in
  addition to certain restrictions which may apply to &#147;business combinations&#148;
  involving the Company and an &#147;interested shareholder&#148;, a plan of merger or
  consolidation of the Company must be approved by two-thirds of the votes of
  all outstanding shares entitled to vote thereon. See the risk factor
  immediately above captioned </FONT><I><FONT face=serif size=2>&#147;Our existing
  shareholders may be able to exert significant influence over matters requiring
  shareholder approval.&#148;</FONT></I></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Until the
later of the fifth anniversaries of the expiration or earlier termination of our
antibody collaboration agreements with sanofi-aventis or our aflibercept
collaboration with sanofi-aventis, sanofi-aventis will be bound by certain
"standstill" provisions, which contractually prohibit sanofi-aventis from
acquiring more than certain specified percentages of our Class A Stock and
Common Stock (taken together) or otherwise seeking to obtain control of the
Company.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, we have a Change in Control Severance Plan and our Chief Executive
Officer has an employment agreement that provides severance benefits in the
event our officers are terminated as a result of a change in control of the
Company. Many of our stock options issued under our Amended and Restated 2000
Long-Term Incentive Plan may become fully vested in connection with a &#147;change in
control&#148; of our company, as defined in the plan. </FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 6. EXHIBITS </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=5><FONT face=serif size=2>(a)</FONT> <FONT face=serif size=2>Exhibits</FONT></TD></TR>
  <TR>
    <TD width="1%"></TD>
    <TD width="98%" colSpan=5>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"><B><FONT face=serif size=2>Exhibit</FONT></B></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="94%" colSpan=3></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face=serif size=2>Number</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" colSpan=2><B><FONT face=serif size=2>Description</FONT></B> </TD>
    <TD noWrap align=left width="92%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="3%"><FONT face=serif size=2>31.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD noWrap align=left width="93%" colSpan=2>&nbsp; <FONT face=serif size=2>Certification of CEO pursuant to Rule 13a-14(a) under the
      Securities Exchange Act of 1934.<FONT size=3></FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"><FONT face=serif size=2>31.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD noWrap align=left width="93%" colSpan=2>&nbsp; <FONT size=2>Certification of CFO pursuant to Rule 13a-14(a) under the
      Securities Exchange Act of 1934.</FONT><FONT size=3></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="3%"><FONT face=serif size=2>32</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</FONT></TD>
    <TD noWrap align=left width="93%" colSpan=2>&nbsp; <FONT face=serif size=2>Certification of CEO and CFO pursuant to 18 U.S.C. Section
      1350.</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>59</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=center><B><U><FONT face=serif size=2>SIGNATURE</FONT></U></B><FONT face=serif size=2> </FONT></P>
<P align=justify><FONT face=serif size=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face=serif size=2>Regeneron Pharmaceuticals, Inc.</FONT> </TD></TR>
  <TR>
    <TD width="99%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"><FONT face=serif size=2>Date: November
      3, 2009</FONT> </TD>
    <TD noWrap align=left width="2%"><FONT face=serif size=2>By:<FONT size=3>&nbsp;</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="11%"><FONT size=2>/s/ M</FONT><FONT face=serif size=1>URRAY
      </FONT><FONT face=serif size=2>A. G</FONT><FONT face=serif size=1>OLDBERG</FONT> </TD>
    <TD noWrap align=left width="37%">&nbsp;</TD></TR>
  <TR>
    <TD width="99%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face=serif size=2>Murray
      A. Goldberg</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face=serif size=2>Senior
      Vice President, Finance &amp; Administration,</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face=serif size=2>Chief
      Financial Officer, Treasurer, and</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face=serif size=2>Assistant Secretary</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face=serif size=2>(Principal Financial Officer and</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face=serif size=2>Duly
      Authorized Officer)</FONT> </TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>60</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
